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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Historical Use of Hypothermia for Cancer
In the November 1982 issue of the Jour
nal (pages 603 to 608) Dresnik and col
leagues described the use of /type/lhermia
to treat malignant neoplasms and review
ed the history of “ fever therapy” for this
purpose, which dates back to about 1866.
During the same period, other in
vestigators, starting with Bennett in 1849,
explored the use of /rypothermia to treat
malignant neoplasms. In 1851, Arnott
published his book “On the Treatment of
Cancer, by the Regulated Application of
an Anaesthetic Temperature” .1 The first
attempts with modern methods to induce
local or systemic cooling for therapeutic
purposes were also applied to cancer and
were undertaken in Philadelphia between
1936 and 1940.1-5 While engaged in ex
perimental work on induced and acciden
tal hypothermia,6'8 1 studied the relevant
papers, although my experiments were
not related to cancer.
The basic observation that stimulated
Temple Fay to explore hypothermia for
cancer was that segments of the body with
a relatively low (34.4°C) surface tempera
ture, such as the extremities, rarely har
bour metastases.9 Recognizing “ that
temperature has a direct influence on
growth in all forms of cellular life” , he
postulated that the growth of cancer cells
might be influenced by cooling below
34.4°C. He differentiated between
“ refrigeration” — local cooling of the
malignant cells — and “ hibernation” —
total body cooling. His series consisted of
66 patients who underwent 169 episodes
of general cooling and 83 who received
local refrigeration for a total of 2807
days.1
General body cooling to a rectal
temperature of 31.1° to 32.2°C was in
duced and maintained for several days
with variable effects;2 it was recom
mended primarily for palliation, as
periods of hibernation were followed by
lessening of pain.3 Histologic evidence
following local cooling to 4.4° to 10.0°C
was more convincing because it
demonstrated degenerative changes in the
tumours, with complete necrosis in some
and even local disappearance, but rarely
before 120 hours of cooling.3 No impor

tant cell changes were noted in the sur
rounding non-neoplastic tissues.
The method was also used in other cen
tres, for example, Toronto, where
Richards “ cooled a number of patients
with cancer after Dr. Fay’s method ” .10
Although Fay wondered which par
ticular temperatures encouraged the
growth of cancer cells and which, if any,
delayed their growth or even destroyed
them,5 there is no evidence that he ever
explored the use of hyperthermia. A clue
may be found in another paper by Smith
and Fay11 in which they introduced the
following working hypothesis, referring
to a physical spectrum of wavelengths:
there is a stimulation zone (0.1 to 100 n,
heat energy, infrared, solar radiation,
visible light) and an inhibition zone,
primarily in the shorter wavelengths (1 to
0.000001 n, ultraviolet, roentgen rays, 7
rays); to produce selective inhibitory or
destructive effects, it is necessary to sub
tract the activating agents, such as heat,
hence the beneficial effects of cooling. In
accordance with this hypothesis, there
was no indication to try hyperthermia.
Fay and his colleagues deserve full
credit for their pioneering work on induc
ed general and local hypothermia. They
introduced new techniques that appear to
have been successful. Why then was their
work discontinued? In several papers
there are references to criticism express
ed by colleagues and nurses, but the
primary reason was that in 1941 Fay join
ed the Civil Air Patrol stationed in Long
Island and later gave the hypothermia
equipment to Charles Bailey in Phila
delphia and Claude Beck in Cleveland for
their work related to cardiac surgery.1
After the war, Fay turned to another field
— cerebral palsy.
However, this is not the complete story.
Fay presented a paper on human
refrigeration before the Third Interna
tional Cancer Congress held in Atlantic
City, NJ, in September 1939. The
manuscript was sent to Belgium for
publication but was intercepted by the
Germans who “ became familiar with the
technique of refrigeration and used it ex
perimentally in the concentration camps,

especially Dachau, without preparatory
treatment of patients or anesthesia. It
became an infamous procedure. . ,” .1
Fay explained his reaction to me: “ I
realize how great the hypothermia poten
tials were; I also realize that its benefits
could be set back fifty years by associa
tion with the brutal use of such a basic
factor by the public” (Fay T: Personal
communication, 1961).
The tragedy of seeing his methods
abused in this way12 may well explain
why Fay did not resume his work on
hypothermia after the war. During the
past 40 years temperature factors in the
treatment of cancer have not attracted
much attention and Fay’s work is refer
red to primarily in connection with induc
ed hypothermia rather than cancer. With
the renewed interest in hyperthermia,
perhaps the concept of the “ optimal
temperature for cancer growth” should
be further investigated. If the optimal
temperature is close to body temperature,
a much larger differential could be induc
ed by hypothermia, than by /rvperthermia.
Since Fay carried out his clinical in
vestigations, induced hypothermia has
become a routine procedure and some of
the problems encountered by the pioneers
in Philadelphia almost 50 years ago have
been solved.
W . Z lN G G , MD, M S C , FRCSfC]

Chief,
Division of surgical research,
The Research Institute,
The Hospital for Sick Children,
Toronto, Ont.
The work on hypothermia was carried out
in the surgical research laboratories, Univer
sity of Manitoba, Winnipeg (1958 to 1964) and
in the Research Institute, the Hospital for Sick
Children, Toronto (1964 to 1972), with the sup
port of the Defence Research Board of
Canada.
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Role of the Porcine Bioprosthesis in
Cardiac Valve Replacement
In the conclusions to their paper in this
issue (page 160), Janusz and associates
appear to favour use of the porcine
bioprosthesis in cardiac valve replace
ment, although they are careful to state
“ the question of which type of pros
thesis . . . remains unanswered.” While
their experience is gratifying, exclusive use
of the porcine valve is questionable. It is
very difficult to compare the performance
of one valve type to that of another due
to the variable manner of reporting
results, the different criteria for defining
various complications, the lack of com
parable data, the discrepancy in time
periods during which the valves are com
pared and technical changes and advances
that have been made. In spite of the dif
ficulties, some attempt must be made to
evaluate performance, and the usual fac
tors that are studied are hemodynamics,
durability and incidence of endocarditis
and thromboembolism.
Porcine valves are silent and not known
to cause hemolysis, but their hemo
dynamic performance was not originally
ideal; they were shown postoperatively to
have a mean diastolic gradient of 6 mm
Hg across the mitral prosthesis and peak
systolic gradients averaging 18 mm Hg
across the aortic prosthesis.1 This gra
dient, which was due to a septal muscle
bar on the right coronary cusp, presented
a problem particularly in the smaller-sized
valves. The newer modified prosthesis
replaces the right cusp with a non
coronary cusp and considerably improves
the hem odynam ic characteristics.
However, replacement of the cusp in
creases the cost of the valve and may
decrease its durability.
With the porcine valve, the frequency
of nonfatal embolism in patients without
anticoagulation is as low as for the best
mechanical valves available in patients
with anticoagulation and is comparable
to that for other bioprostheses. In the aor
tic position, the annual incidence per pa
tient is 0.5% to 3%. The advantage that
98

the porcine valve has over the mechanical
valve is that anticoagulants are not
routinely required for valves placed in the
aortic position, and the attendant mor
bidity and mortality of anticoagulation
are avoided. Bioprostheses in the mitral
position are associated with a higher in
cidence of thromboembolic events, 1.5%
to 6% of patients per year. This incidence
approaches 0% in patients who are in
sinus rhythm and rises to 6% in those pa
tients in atrial fibrillation or with large left
atria. The higher risk patients represent
approximately 50% of those who receive
biologic mitral valves and they therefore
require long-term anticoagulant therapy.
Although patients with bioprostheses
have the advantage over those with
mechanical valves of not requiring routine
anticoagulant therapy, there is concern
about the long-term durability of the
bioprostheses. The annual rate of struc
tural failure is 1% to 2% per patient.
Primary valve dysfunction from tissue
fatigue and wear in the form of leaflet
tear or perforation has been reported in
explanted valves in both the long and
short term. Janusz and colleagues report
only two cases of primary valve failure
in 316 valves from their patient popu
lation of 287. The valves appear to be
susceptible to structural changes with col
lagen degeneration and cusp calcification,
particularly in children and patients on
hemodialysis for renal failure. Magilligan
and associates2 reported that the in
cidence of Hancock valve failure has not
increased linearly, as expected, as the
number of valves at risk and length of im
plantation have increased. Rather, they
noted a decreased incidence and ascrib
ed it to improvement in valve manufac
ture. Hancock Laboratories have in
troduced a new “ anticalcification treat
ment” (T-6) in the valve production pro
cess that they believe has reduced the pro
blem of valve failure due to deposition of
calcium. However, only studies of the
new valve over time will support this.

Infective endocarditis at the prosthetic
valve site remains an uncommon but
serious complication. The incidence does
not appear to favour one valve site over
another and the usual infective agent is
streptococcus. The annual incidence is
1% to 2% per patient for porcine valves
and is comparable to that for mechanical
valves. The Hancock valve is easier to
sterilize than mechanical prostheses and
appears to be more resistant to bacteremia
in the early postoperative period. When
it is challenged with bacteria it also ap
pears to be more durable than other tissue
valves.
There is no one valve that is superior
to all others; each prosthesis presents its
own problems. At the University of Ot
tawa Cardiac Unit, we use the gluteraldehyde-treated pericardial valve for the
aortic and mitral positions in patients
with normal left atria who are not in
fibrillation, because of their superior
hemodynamics. Patients with giant left
atria or chronic atrial fibrillation, or both,
who require anticoagulant therapy should
have a mechanical valve because of its
superior durability. Young patients ap
pear best suited to a low-profile me
chanical valve. The choice of prosthesis
must be made after careful consideration
of the valve characteristics, clinical situa
tion and anatomic factors. Careful fol
low-up and reporting of all patients are
essential until the situation is clarified.
W .J. K e o n ,

m d , frcs [c ]

Member,
Editorial Board
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Is TPN obsolete?
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No, not really.
There will always be
some patients who
require TPN.
However, for the majority
of patients, those with
a functioning gut, there
is a preferred alternative.
Vivonex® HN, total
enteral nutrition, is that !
preferred alternative.
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Vivonex HN is as effective,
and is safer, easier to handle
and is less expensive, j
Equally effective
“ It is probable that the nitrogen and body
weight preservation provided by enteral
hyperalimentation equals or exceeds that
demonstrated for total parenteral nutrition
in postoperative patients.” 1

Safer
Vivonex HN reduces the risk of catheter
sepsis or embolism.

Easier to handle
With Vivonex HN, aseptic handling is
not as stringent as in TPN. This reduces
physician and staff time needed for
nutritional care.

Substantially less expensive
The cost of Vivonex HN is less than half
that of TPN.

For more information on indications and
precautions of Vivonex HN, please contact
your Norwich Eaton representative or write:
NORWICH EATON
PARIS, ONTARIO N3L 3T8
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Abortions Escape
Statistical Evaluation

To the editors.—Scientific accuracy and
respectability call for standardization of
terms in evaluating results.
Biologic variants prevent medicine
from being an exact science, so why do
we persist in fabricating basic terms that
are interpreted and used differently by
physicians in different specialties? For ex
ample, let’s analyse the term “mortality”.
A recent paper by Turley and col
leagues1 reported a successful technique
for cardiothoracic surgical repairs of the
fetus in utero. Their operations were per
formed in lambs from 90 to 120 days’
gestation. When analysing results they
referred to their fetuses as “survivors”.
In contrast, another recent paper by Mar
tin and Gelfand (Can J Surg 1982; 25:
641-3) reported the results of middle
trimester human abortions for sociologic
reasons. The ages of the fetuses ranged
from 13 to more than 21 weeks. Obvious
ly none survived. The authors reported an
incidence of 0.07% in maternal mortali
ty, but fetal mortality was ignored. If we
analyse Martin’s patients (abortions) by
Turley’s criteria, then we must auto
matically accept a 50% mortality (all
fetuses) plus the reported maternal mor
tality and morbidity. If so, it is barely
conceivable to accept a procedure (abor
tion) with such an unacceptable mortali
ty for a disease (“pregnancy”) that will
resolve spontaneously (delivery) with a
negligible one.
Since a further step in science is to draw
conclusions from known facts it would
not be difficult for a researcher to con
clude that expectant therapy is mandatory
if the aim is survival. If the above analysis
is not true, we should evaluate Turley’s
results by Martin’s standards — they
would be happy to see their survival rate
substantially improved (no fetuses died,
since what is not alive cannot die) or
should we say they operated on nonliving
structures that were born several weeks
later? In that case, they should not be call
ed survivors. If we don’t accept this argu
ment then we have to agree that animal
fetuses should be considered alive while
human fetuses should not. And again,
what is the scientific explanation for this?

Putting aside whatever bias I may have,
I shall continue to honour my Hip
pocratic oath to respect all life from
conception.
Carlos Del Campo, md, frcsic]
Department of cardiovascular surgery,
Victoria General Hospital,
Halifax, NS B3H 2Y9
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Eliminating Infection
of Fabric Grafts
7o the editors.—At the 1982 meeting of
the Royal College of Physicians and
Surgeons of Canada in Quebec City, I
was particularly interested in the presen
tations of the Canadian Society for
Vascular Surgery. Several excellent papers
were given concerning the trials, tribula
tions and mortality associated with in
fected fabric grafts, particularly those ot
the aortoiliofemoral variety.
The following describes a simple (but
messy) method of greatly reducing such
catastrophes, a method that in my ex
perience with nearly 200 such operations
resulted in only one infected graft.
During World War II, all battle
casualties operated on at our no. 6 casual
ty clearing station had contaminated or
infected wounds. After debridement and
removal of foreign bodies (such as metal,
battle dress and fragments) we routinely
irrigated the wound with 500 to 1000 ml
of normal saline. After the war I con
tinued to do this in every surgical opera
tion, be it the gallbladder bed in a
cholecystectomy, a gastrectomy, her
niotomy or the multiple incisions and tun
nels of a vein stripping. The incision of
an abdominal operation was also irrigated
layer by layer during closure.
This technique is especially indicated in
vascular surgery using fabric grafts. In an
aortoiliac (femoral) graft the bed in which
the graft lies and the tunnels for the iliac
section are extensively irrigated. When the
retroperitoneum is closed over the aortic
portion, the tip of the bulb syringe is in

serted through any small opening and fur
ther solution squirted in to remain there.
We used neomycin made up to a 1%
solution with normal saline; 1000 ml of
solution was used for a major procedure
and 500 ml for a minor. The femoral in
cisions for an aortofemoral bypass
received special attention as sterility in
these incisions, so close to the genitalia,
is questionable.
The method is messy; the drapes
become saturated and the operating-room
floor wet. The anesthetist will be very
strict about sucking out the excess spill
in the pelvis and abdominal gutters due
to the depressing effect on respiration of
the neomycin. You also become un
popular with the nurses and orderlies.
The use of this technique is just plain
common sense but does not seem to be
used by the majority of surgeons, either
general or vascular. Perhaps this letter
will lead to a revival of an old technique
that can reduce or eliminate the distress
ing problems created by an infected
prosthesis.
Josephus C. Luke, md, facs, frcs,
FRCS[C]

Ocean East Resort Club,
867 S. Atlantic Ave.,
Orrt^nd Beach, Fla. 32074

/ The Two-Step Management
of Breast Cancer
To the editors.—Dr. Devitt’s editorial
“The two-step management of breast
cancer” (Can J Surg 1982; 25; 475) rai
ses a number of points with which I disa
gree. Alternative approaches will be
presented.
Most breast biopsies are done for
benign disease (although with particular
attention to detail it is possible to im
prove the ratio of benign to malignant
biopsies ).‘ It is therefore inappropriate
to schedule the majority of patients for
possible definitive therapeutic breast
surgery (i.e., a biopsy followed by possi
ble modified radical mastectomy or
limited resection with axillary node exci
sion) when it is unlikely that this will be
necessary. Such a step causes unnecessary
anxiety for the patient and wastes
valuable scheduled operating room time.

VOLUME 26, NO. 2, MARCH 1983 / THE CANADIAN JOURNAL OF SURGERY

101

When the clinical examination, fineneedle aspiration and mammography,
where indicated, suggest that the lesion
is benign, we advise the patient that her
breast lump is probably benign but should
be excised because it is a solid mass. She
is scheduled for excision only. In less than
5% o f such cases will the tumour prove
to be malignant.
W hen there is doubt about the clinical
diagnosis, or the needle aspirate or mammographic findings are equivocal, we still
schedule the patient for biopsy only. This
situation usually arises in women with
clinically ill-defined but dominant masses.
On fine-needle aspiration they may be
solid or only partially cystic. In other in
stances mammography will indicate an
area of increased density or some distor
tion of the parenchymal architecture,
usually not palpable, in which an area of
hidden carcinoma cannot be excluded.
Patients with these lesions are scheduled
for excisional biopsy with needle localiza
tion. The lesions are malignant in about
10% of cases. Discussion of a possible
mastectomy and consent for the opera
tion will, therefore, not be necessary in
90% of such patients.
When mammography shows a cluster
of microcalcifications (usually five or
more) requiring needle localization and
specimen roentgenography, we never plan
for more than a biopsy, as the diagnosis
is often not possible until permanent sec
tions have been made. Because of their
small size, a frozen section may destroy
the lesion or distort the architectural
detail.
When carcinoma is probable on the
basis of clinical findings or a positive fineneedle aspirate, with or without a posi
tive mammogram, we tell the patient that
although a biopsy and frozen section will
be done (to eliminate any possible error
and to obtain material for receptor analy
sis), the diagnosis is almost certain to be
carcinoma, and we discuss the options for
definitive therapy. Whether the patient
will have a modified radical mastectomy
or a limited resection, it is better techni
cally to perform it as a one-step proce
dure and it avoids the need for a second
anesthetic. In these circumstances, most
of our patients opt for a one-stage pro
cedure. Only 10% request a two-stage
procedure so that they can have further
time to think about it — probably hoping
I am wrong!
There is still a widespread feeling that
when a woman is thought to have breast
cancer, the condition is an emergency and
surgery must be done immediately. This
is to some extent the basis for Devitt’s
statement that a women is seldom emo
tionally capable of making a rational deci
sion. There is no scientific evidence to
justify such advice, which may cause such
fear that the woman cannot make a deci
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sion, and runs from one consultant to
another until she is told what she wants
to hear. It precludes rational discussion,
so that even if she wants another opinion,
which is her right, she fears that the delay
may be self-destructive. There is no
evidence that a delay of even a few weeks
makes any difference, particularly when
a clinical cancer has been present for some
years before it is discovered.
It is time surgeons stopped advocating
unnecessary haste, which is not based on
scientific fact or experience, and in most
instances is done to accommodate the
surgeon’s schedule rather than the pa
tient’s needs.
A l a n A . B a s s e t t , m d , f r c s [c ], f a c s

Director,
Breast treatment unit,
Mount Sinai Hospital,
Toronto, Ont.
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To the editors.—Dr. Bassett and Drs.
Mueller (Can J Surg 1982; 25: 475-6) and
Wright (Can J Surg 1983; 26: 9) state
that, while trying to be sensitive to their
patients’ needs, they cannot discuss con
siderately, kindly and informatively, at
the time of the initial consultation, the
management that they recommend for the
patient with breast cancer. Apparently
this is because they are unable to diagnose
confidently the nature of the problem
without biopsy and, therefore, relatively
indiscriminately, perform surgical breast
biopsies, thus generating anxiety in the
patient. They are quite right not to
threaten a woman with a mutilating
operation that she does not need. But it
is far worse to threaten her with a
frightening disease that she does not have
— and benign breast biopsy does that.
In 1972 ways were described1 of
discriminating between breast lesions that
were likely to be cancerous and those that
were not. It was suggested that surgeons
should find cancer in at least 40% of
biopsies. With increasing acceptance of,
and experience with, needle biopsy and
mammography, surgeons should now be
finding cancer in two thirds of their
surgical biopsies. Included among the
other one third of biopsies will be the ob
vious fibroadenomas and duct papillo
mas. This is achievable. In a 1979 audit
of breast surgery at the Ottawa Civic
Hospital a majority of the surgeons found
breast cancer in 75% or more of breast
biopsy specimens. Canadian women need
not be subjected to a lower standard. In
discriminate biopsy is no more acceptable
than indiscriminate mastectomy. Sur
geons who cannot make a confident ofcontinued on page III
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Marvin J. Lopez , md, frcsicj*

Controversy in the Surgical Management of Melanoma
In more than one half of cases of
melanoma the disease is not controlled.
Treatment of the disease should be
based on a clear understanding of its
biology and natural history. This paper
presents an overview of the controversial
issues in the management of primary
melanoma and suggests an acceptable
approach.
The author recommends: (a) excisional
biopsy where anatomically feasible for
adequate histologic assessment, (b) wide
excision of the tumour including the
deep fascia, (c) en bloc in-continuity
dissection for lesions close to the
regional lymph nodes and (d) selective
elective lymphadenectomy for clinical
stage I melanoma and other groups, bas
ed on Clark's level of invasion and
Breslow’s thickness of the lesion, its
location, histologic factors and the pa
tient's medical and socioeconomic
background.
Dans plus de la moitie des cas de melanome, la maladie ne peut etre maitrisee.
Le traitement de cette maladie devrait
reposer sur une bonne connaissance de
sa biologie et de son histoire naturelle.
Cet article donne un apercu des controverses entourant le traitement primaire
du melanome et propose un abord
acceptable.
L'auteur recommande: a) une biopsieexerese quand il n'y a pas de contrainte
anatomique, de facon a permettre une
evaluation histologique adequate, b) une
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excision large de la tumeur incluant le
fascia profond, c) une dissection mono
bloc en continuite pour les lesions proches des ganglions lymphatiques regionaux et d) une lymphadenectomie selec
tive differee pour les melanomes de
stade I et autres groupes. Le choix
repose sur la determination du niveau
d'envahissement de Clark et de I'epaisseur de la lesion de Breslow, sur la loca
lisation de la lesion, les facteurs histologiques ainsi que sur les antecedents
medicaux et socio-economiques du
patient.

Although melanoma accounts for only
1% to 3% of all malignant tumours, ex
cluding other primary skin neoplasms, its
management presents a problem of great
magnitude because the disease is uncon
trolled in more than one half of patients.
The American Cancer Society projected
for 1982 14 800 new patients with
melanoma and 6900 deaths from this
tum our.1
History reveals that the “ black fatal
tumours” , as they were described in the
17th century, were as feared then as they
are today. Pemberton,2 in 1858, is said
have first described wide excision the
as best local treatment. The wellknown publications by Hutchison and
Paget in the latter half of the 19th cen
tury contributed important knowledge of
the m orphology o f moles and
melanomas. Early in this century, data
began to accumulate on melanoma
treated largely by an aggressive surgical
attack upon the primary lesion and
regional nodes. The publications by Eve
in 19033 and Pringle in 19084 were classic
examples. Pack and colleagues5 in 1952
published a review of 1190 cases, the
largest series, collected between 1917 and
1950. Their conclusions, which favoured
radical treatment, had a major impact for
years. In spite of the early popularity of
elective lym phadenectom y, several
investigators6’7 contended that routine
removal of nodes to eliminate drainage
was of no value, but none had the data

and methods to prove these contentions.
In an elegant mathematical analysis, Polk
and Linn8 wrote “ although analysis of
several patients and primary tumor
characteristics did not allow confident
prediction of lymph node outcome,
overall prognosis could be anticipated by
a system of discriminant scores. Utiliza
tion of such scores may facilitate selec
tive lymphadenectomy and add another
dimension to specification and instruction
of sound clinical judgment” . The con
troversy continues today.
During the last 15 years, there has been
a great advance in our knowledge of
melanoma as a result of studies on the
biology, classification, staging and risk
factors in melanoma and from randomiz
ed clinical trials. Geographic variables are
also important in interpreting data on
melanoma. For example, sex ratios,
histologic types and other variables that
influence prognosis differ when data from
North America are compared with those
from other countries,9,10 and co n 
siderable controversy has resulted from
attempts to compare data from European
countries with those from other countries.
To compound the confusion, data on
melanoma published before 1969 are dif
ficult to compare to recent data. In 1969,
Clark and colleagues11 described the
depth of dermal invasion and in 1975
Breslow12 related tumour thickness to
prognosis. These two major contributions
have become standards in the histologic
review of primary melanoma and have in
fluenced the extent of surgical therapy.
The prim ary m anagem ent o f
melanoma is surgical; however, the op
timal surgical approach to the various
aspects of initial management has long
been and still is controversial, primarily
because of the unique biologic behaviour
of this disease. Abundant support for
seemingly contradictory approaches can
be found in the literature. Some have
formed their bases of management from
review of the experience at a single institu
tion and from retrospective nonrandomized trials; there are few prospective
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studies. A detailed knowledge of this con
flicting evidence will help to develop a
uniform , rational approach that is based
on current understanding of the biologic
behaviour of melanoma. There are a
number of excellent reviews of the
biologic and pathologic features and
modern management of melanoma.1115
The purpose of this review is to present
concisely the conflicting evidence and to
suggest an acceptable approach, a com
promise between the radical and conser
vative concepts as they appear in North
American surgery today.
Excisional or Incisional Biopsy?

Few articles stress the importance of
the biopsy in diagnosing melanoma.
Although there are no randomized con
trolled studies to show whether incisional
biopsy leads to a higher incidence of local
recurrence, excision of the lesion with
a d eq u a te m argins, where this is
anatomically acceptable, is the biopsy
method of choice. Excisional biopsy of
a lesion in the trunk with primary closure
is a simple task and wider excision can be
accomplished later using a split-thickness
skin graft when the diagnosis is con
firmed. A pigmented nevus located in cer
tain areas of the face may be difficult to
excise without a reconstructive operation.
Re-excision would entail sacrifice of nor
mal tissues in all directions from the
previous incision, resulting in unnecessary
tissue loss. In general, if excision of the
primary lesion requires a skin graft for
closure and re-excision would mean loss
of the previous graft and adjacent
m arg in s, an incisional biopsy is
acceptable.
The advantage of an excisional over an
incisional biopsy rests not only in the
diminished risk of local recurrence, but
also in the availability of the entire lesion
for histologic assessment. Indeed, the
histologic type, the dermal depth of
penetration and the thickness of the le
sion not only have important prognostic
implications, but also may influence the
extent of surgical attack on the primary
site and regional nodes. Moreover, other
histologic findings such as polypoid
growth patterns, microscopic satellites in
the reticular dermis and subcutaneous
tissues and microscopic ulceration are im
portant prognostic indicators.16' 18 These
features can best be determined in an in
tact specimen. The excisional biopsy
should be performed with a “ no touch
technique” , discarding the instruments
needed for the excision and obtaining
closure with a new set of instruments,
thus avoiding the risk of tumour implan
tation. The incision should be placed in
the long axis of the extremity or in such
a manner as to avoid sacrificing an ex
cessive amount of tissue when wide exci
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sion is to be performed subsequently.
Electron microscopic examination should
be carried out if available.
Wide Excision

Melanoma cannot be treated by rigid
rules. The extent of the excision depends
on factors that affect prognosis, such as
histologic type, configuration and local
extent, microscopic features, level of
penetration and thickness of maximal in
vasion. Excision of normal tissue for 5 cm
in all directions from the lesion, when ad
vocated for all melanomas, can have a
devastating cosmetic and functional effect
in certain areas. Whether excision of less
than 5 cm from the lesion has a notable
effect on local recurrence rate or survival
is a question that has troubled surgeons
for many years. Several studies5'6,19 have
stressed the importance of “ wide
margins” , while others have pointed out
that the recurrence rate depends upon the
thickness and level of penetration rather
than the extent of excision alone.20'23
Olsen24 showed no difference in the
recurrence rate, regardless of the extent
of resection, although the same study
showed an increase in nodal metastases
as a result of narrow excision. A 6% in
cidence of local recurrence was found
after wide or narrow excisions. Cascinelli
and associates21 found that the size of
the resection margins had no influence on
survival. Although they could not con
clude that local recurrence rate is unaf
fected by the extent of excision, it appears
that the frequency of local recurrence is
related more to tumour thickness. In their
review of 593 patients with stage I disease
collected from the WHO collaborating
centres for the study of melanoma, local
recurrence was the first sign of relapse in
4.2% and increased from 1.1% to 5%
with increase in thickness. This study con
firms previous reports by Balch and
colleagues22 who had no local recur
rences in 36 patients with lesions less than
0.76 mm thick. There was local recur
rence in 8 of 287 patients (3%), all of
whom had level IV and V lesions with a
median thickness of 4 mm. Breslow12
also reported four recurrences in 41 pa
tients, all in lesions more than 0.76 mm
thick. In a later report, Breslow and
Macht25 reviewed 62 melanomas less
than 0.76 mm thick with resection rang
ing from 0.10 to 5.15 cm from the lesion.
None had recurrence. On the basis of
their findings, they suggested a conser
vative approach for “ thin” lesions.
Most investigators agree that the single
most important factor affecting local
recurrence is the thickness of the lesion,
but most opinions are based on retrospec
tive analyses. A well-controlled, ran
domized, prospective, clinical trial with
long-term follow-up, taking into account

all histologic parameters that are known
to affect prognosis, is needed to clarify
the relation of size and extent of excision
to local recurrence and survival. Balch
and associates22 suggested that a 2-cm
margin is correct for thin melanomas.
Most surgeons are convinced that wide
excision (3 to 5 cm from the lesion) is
necessary in all melanomas where such ex
cision is anatomically acceptable. An
understanding of the natural history of
the different histologic types is necessary
for a sound approach to the surgical at
tack on these lesions. Ideally, the surgeon
should review the slides with the pathol
ogist.
Preservation or Excision
of Underlying Fascia?

The literature appears clearly to sup
port excision of the underlying fascia in
most melanomas.22'30 In 1966, Olsen24
observed that metastases to regional
nodes developed in 14 of 31 patients
(45%) in whom the fascia had been
removed, but in only 5 of 36 patients
(14%) in whom the fascia had been left
intact; the local recurrence rate was not
affected. On the basis of this study, it was
concluded that the presence of the intact
fascia reduces the risk of spread after
surgical intervention. This study lacked
concurrent controls and the recurrence
rates were extremely high, possibly due
to patient selection. This concept has not
gained popular support in N orth
America.26,27 In a recent review of ex
perience at the M.D. Anderson Hospital
and Tumor Institute, Kenady and
associates31 found no significant dif
ference in recurrence between patients in
whom the underlying fascia was preserved
and those in whom it was excised. This
study was also retrospective and without
concurrent controls. The surgeon dealing
with melanoma is painfully aware of in
stances of local recurrence when the depth
of excision is adequate. This is particular
ly applicable to nodular melanomas,
which grow deeper than other histologic
types. In certain areas, such as the head,
neck, hands and feet, the fascial planes
are not uniform and the overlying sub
cutaneous tissues are rather thin. In these
cases, the fascia should always be ex
cised.24
Prophylactic or Therapeutic
Lymphadenectomy? - the Facts

Perhaps the height of the controversy
over the surgical m anagement of
melanoma concerns the management of
the regional nodes. There is no disagree
ment about the indication for lym
phadenectomy when the regional nodes
are clinically infiltrated. Without doubt,
survival is better in patients without nodal
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involvement.18,22'32'34 Fortner and
associates32 found a 5-year survival of
23.3% among 167 patients with positive
nodes compared with 78.7% among pa
tients with negative nodes. Furthermore,
the prognosis of melanoma for patients
with microscopic nodal metastases is
worse than for those with no nodal
metastases.2635 The arguments centre on
the following questions:
• Does the excision of nodes that are
clinically free of melanoma but
histologically contain tumour justify the
morbidity involved in removing the nodes
that are clinically and histologically free
of melanoma?
• Does prophylactic lymphadenectomy
(removal of clinically free nodes that may
have microscopic invasion) as opposed to
therapeutic lymphadenectomy (removal
of clinically evident metastases) improve
survival?
The proponents of prophylactic
regional node disssection have based their
arguments on the observation that 20%
to 25% of patients who present with
clinical stage I melanoma have
microscopic lymph-node metastases and,
therefore, local excision means in
complete treatm ent. Balch and
colleagues22 have shown that the risk of
nodal metastases was notably higher
(57%) for melanomas more than 1.5 mm
thick. Moreover, several studies have in
dicated an improvement in survival when
prophylactic lymphadenectomy is
performed.9'12’17’22’26’32'33,35’36 Among the
proponents of prophylactic lymphadenec
tomy are those who believe it should be
performed routinely,29,37'39 whereas
others recommend it only in certain highrisk groups.22’26’30,35’36 The Clark and
Breslow classifications have played an im
portant role in changing policy from
routine to qualified indications for
lymph-node dissection. Risk factors that
adversely affect prognosis in melanoma
include sex (more in men), primary
tumour location, nodularity stratum of
invasion, thickness, microscopic ulcera
tion, microscopic satellite formation,
polypoid nature, mitotic rate and lym
phocytic response.
The current advocates of elective
regional node dissection suggest that in
Clark’s level I or II lesions, or melanoma
less than 0.76 mm thick, prophylactic
lymphadenectomy should be avoided
because the incidence of metastases is low
and the postoperative morbidity high.
Treatment of regional nodes in level II le
sions, between 0.76 and 1.50 mm thick,
remains controversial.12 Patients with
level III, IV or V lesions, 1.50 mm or
thicker, should be subjected to lym
phadenectomy because the benefits of
survival, local control and proper staging
outweigh the disadvantages. Balch and
colleagues22 justified immediate regional

lymphadenectomy for lesions 1.50 to 3.99
mm thick because of the important dif
ference in 5-year survival (83% versus
37%). Holmes and colleagues35 found
that patients with lesions in Clark’s levels
III to V had an incidence of regional
lymph-node metastases ranging from
29% to 58%. The relation between
regional lymph-node metastases and
Clark’s level of invasion observed in their
study was consistent with previous
reports.12,36 Breslow12 found that pro
phylactic lymph-node dissection doubled
the rate of survival for patients with le
sions thicker than 1.50 mm but had no
effect on those with thinner lesions.
Wanebo and associates36 found that of
patients with level III melanoma who had
elective node dissection, 93% were
disease-free at 5 years compared with
66% of those who had wide excision on
ly. At 10 years this difference was more
pronounced but was not statistically
significant. Regional lymphadenectomy
in level III lesions, less than 0.76 mm
thick, remains controversial and manage
ment of the regional lymph nodes in these
cases should include considerations of
other histologic factors and location.
The opponents of elective lym
phadenectomy contend that 75% to 80%
of regional lymph-node dissections are
unnecessary and expose a large number
of patients to appreciable morbidity,
especially from groin dissections.
Moreover, several studies have concluded
that survival in patients with prophylactically or therapeutically treated nodal
regions is the same.10’23,28’40’41 In a pro
spective, randomized, multicentre study
of 553 patients and in a more recent up
date of their data, Veronesi and
associates28,40'41 from the WHO
melanoma group have cast serious doubt
on the efficacy of immediate node dissec
tion. The survival of the two groups was
essentially the same at 5 and 10 years. Sim
and coworkers,23 in a prospective, ran
domized study, concluded that elective
node dissection is not beneficial in the
management of melanoma. Observed
5-year survival curves for each of three
treatment groups were essentially the
same. Treatment was (a) lymphadenec
tomy when clinical involvement became
evident, (b) regional node dissection per
formed approximately 3 months after the
primary treatment and (c) regional lym
phadenectomy at the time of excision of
the primary lesion. These are two major
studies that do not base their conclusions
on retrospective analyses. Publications on
nonrandomized trials that oppose lym
phadenectomy are also available.742,43
Cade42 noted a 5-year survival of 69% in
those treated by immediate lymph-node
dissection and 65% in those who had no
initial node dissection; there was no
statistical difference. Block and

Hartwell43 also concluded that wide
resection was adequate treatment.
According to Moore and Gerner7 there
was no disadvantage to therapeutic dissec
tions if they were performed as soon as
lymph-node involvement was detected. It
is clear that within the voluminous
literature on this subject, little informa
tion is based on clinical evidence that
stands the scrutiny of a good study.
Elective Lymphadenectomy? - Discussion

A policy of routine elective lym
phadenectomy is no longer justified.
Clark’s levels I and II lesions and lesions
less than 0.76 mm thick rarely metastasize
and the morbidity and cost outweigh the
very limited gains. With few
exceptions,1226 publications in favour of
prophylactic lymph-node dissections are
retrospective; none are randomized.
These studies also lack controls. The
limitations of these studies are such that
strong scientific data are lacking and,
consequently, the studies do not meet pre
sent standards of critical scrutiny.
However, the enormous body of data ac
cumulated on retrospective analyses, writ
ten by surgeons who are highly respected
in this field, cannot be disregarded
or invalidated on the basis of statis
tical arguments alone. Indeed, there
is an erroneous tendency to disregard
what is not randomized and pros
pectively studied, but to accept ran
domized reports without scrutiny. The
two randomized studies that oppose
prophylactic lymphadenectomy also are
subject to valid and serious criticism. As
pointed out by Goldsmith,9 studies by
the the WHO melanoma group28,40’41
contained an unusually high pro
portion of female patients, who are
known to have a better prognosis. In the
WHO study, the nodular variety, the
most virulent type of melanoma, had a
prognosis comparable to the superficial
spreading variety. Various groups of pa
tients showed apparent benefit from elec
tive node dissection. These groups in
cluded men, patients with lesions 11 to 20
mm in diameter, those with upper ex
tremity melanomas, those with Clark’s
level IV lesions and patients with
melanomas 1.6 to 4.5 mm thick. Clark’s
level V lesions, prognostically poor, were
not evaluated. Geographic variables may
have played a role in producing poor
results from elective node dissections.
Similarly, the paper by Sim and associ
ates23 reported the results of a randomiz
ed trial of 173 patients; this study can be
criticized. Sixty-five percent of the pa
tients were women and more than 50%
of the melanomas were of the superficial
spreading variety. Both of these factors
are associated with a good prognosis.
Samples were too small. Furthermore,
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From cells
to organ systems...

Solu-MedroP
protects against
the inroads of
shock and improves
the patient’s
chance for survival*

Inadequate tissue perfusion, which
occurs during shock, changes the
metabolic function of vital organs,
leading to multiple organ failure.
Particularly insidious is the effect
on the lung. Polysaccharides
released in shock cause chaotic
activation of complement. This
affects granulocytes, which
migrate to the lung, plug the
pulmonary microvasculature, and
trigger the release of toxic oxygen
radicals that damage the
epithelium and permit capillary
leakage. The result is the acute
adult respiratory distress
syndrome (ARDS).

• Pharmacologic doses of SoluMedrol Sterile Powder (methylprednisolone sodium succinate)
given early in the course of the
illness can be lifesaving.
• In the lungs of patients with sep
tic and hemorrhagic shock, such
doses have reduced the perme- „
ability defect and increased sur
vival rates.14
• Solu-Medrol inhibits complementinduced granulocyte aggregation
and formation of leukostatic
plugs, decreases arteriovenous
-<
shunting, and increases oxygen
consumption.56
*adjunctively with standard methods o f
combating shock
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Dosage

Timing

• In early or impending shock, a
pharmacologic dose of 30 mg/kg
Solu-Medrol intravenously over
a period o f 10 to 20 minutes
• Additional doses at four-hour
intervals until patient’s condition
has stabilized (up to 48-72 hours)

Immediate stabilization of the pa
tient with respiratory support,
fluids and vasoactive drugs is of
primary concern. Solu-Medrol
may tip the balance toward
survival.7,8
• Early treatment with steroid
appeared to be “ a critically
important prerequisite for
successful recovery” of animals
subjected to experimental
shock.9,10
• Large doses of Solu-Medrol did
not depress phagocytic activity
or delay time of recovery in
dogs or baboons.
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Solu-Medrol
protects the chain
o f organ systems in shock
Sterile

Solu-Medrol
(methylprednisolone sodium succinate)
Action:

Solu-Medrol, like other corticosteroids, exerts its action by its
anti-inflammatory effect.
Indications and Clinical Uses:

Intravenous administration of Solu-Medrol is indicated in situa
tions in which a rapid and intense hormonal effect is required.
Shock:

In severe shock adjunctive use of intravenous methylpredni
solone sodium succinate (Solu-Medrol) may aid in achieving
hemodynamic restoration. Corticoid therapy should not replace
standard methods of combating shock, but present evidence
indicates that concurrent use of large doses of corticoids with
other measures may improve survival rates. In particular, large
pharmacological doses of Solu-Medrol have been proven useful
in bacteremic or endotoxin shock, hemorrhagic shock, traumatic
shock, and cardiogenic shock.

protein intake. In patients with diabetes mellitus, Solu-Medrol
may increase insulin requirements during the period o f adminis
tration. Ecchymotic manifestations, while noted only rarely
during the clinical evaluation o f Medrol may occur. Excessive
loss of potassium is not likely to be induced by effective mainte
nance doses of Medrol. If such reactions are serious or distres
sing to the patient, reduction in dosage or discontinuance of
corticoid therapy may be indicated. While a retardant effect on
wound healing is seldom encountered, except in high doses, it
should be a matter of consideration when Solu-Medrol is ad
ministered in conjunction with surgery.
Symptoms and Treatment of Overdosage:

Single large doses of Solu-Medrol do not have any apparent
toxic effect and require no specific therapy. Continuous over
dosage would require careful gradual reduction of dosage in
order to prevent the occurrence of acute adrenal insufficiency.

Contraindications:

Dosage and Administration:

Except when used for short-term or emergency therapy as in
acute sensitivity reactions, Solu-Medrol is contraindicated in
patients with arrested tuberculosis, herpes simplex keratitis,
acute psychoses, Cushing’s syndrome, peptic ulcer, vaccina and
varicella.

In treating severe shock there is a tendency in current medical
practice to use massive (pharmacological) doses of corticoste
roids. The following are Solu-Medrol doses suggested by various
authors:
Author

Dose

Repeat

Precautions:

Oaks
Weil
Melby
Cavanagh
Dietzman

100 mg
200 mg
250 mg
15 mg/kg
30 mg /kg

Every 2-6 hours
100 mg every 4-6 hours
Every 4-6 hours
Every 24 hours
In 4 hours if needed

Existence o f diabetes, osteoporosis, chronic psychoses, active
tuberculosis, renal insufficiency or predisposition to thrombo
phlebitis requires that Solu-Medrol be administered with
extreme caution. In the presence of infection, the causative
organism must be brought under control with appropriate anti
bacterials, or therapy with Solu-Medrol should be discontinued.
While therapy with corticoids does not appear to be contraindi
cated in pregnancy, caution is recommended, particularly during
the first trimester. Also, newborn infants of mothers who
received such therapy during pregnancy should be observed for
signs o f hypoadrenalism and appropriate measures instituted if
such signs are present. Since Medrol, like prednisolone, suppres
ses endogenous adrenocortical activity, it is highly important
that the patient receiving Solu-Medrol be under careful observa
tion, not only during the course of treatment but for some time
after treatment is terminated. Adequate adrenocortical suppor
tive therapy including ACTH, must be employed promptly if the
patient is subjected to any unusual stress such as surgery,
traum a, or severe infection. Patients should be advised to
inform subsequent physicians of the prior use of Solu-Medrol.
There have been a few reports of cardiovascular collapse asso
ciated with the rapid intravenous administration of large doses
o f Solu-Medrol (greater than 0.5 grams) in organ transplant reci
pients. The cause and relation to other medications (i.e.,
diuretics) is not known at this time, but physicians should be
alert to this possibility.
Adverse Reactions:

Adverse reactions are not likely to result from short-term intra
venous administration o f Solu-Medrol, but may be anticipated if
continued therapy with oral or intra-muscular corticosteroid
preparations is to follow. Medrol has less tendency than pred
nisolone to induce retention of sodium and water, and in some
cases has been observed to produce diuresis and an increased
excretion o f sodium. Likewise, therapy with Medrol appears to
produce less nervousness and psychic stimulation than that
produced by prednisolone. While epigastric distress has not been
totally lacking in patients receiving Medrol, the incidence and se
verity o f this side reaction to date suggest that although Medrol
has an enhanced anti-inflammatory potency when compared
with prednisolone on a weight basis, the so-called ulcerogenic
potential o f this corticosteroid is no greater, and may even be
less, than that o f prednisolone.
With the exception of the differences noted in the preceding
paragraph, Medrol is similar to hydrocortisone and prednisolone
in regard to the kinds of adverse reactions and metabolic altera
tions to be anticipated when treatment is intensive or prolonged.
Negative nitrogen balance is usually counteracted by a high
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Therapy is initiated by administering Solu-Medrol intravenously
over a period of at least 10 minutes. In general high dose corti
costeroid therapy should be continued only until the patient’s
condition has stabilized, usually not beyond 48 to 72 hours.
Although adverse effects associated with high dose short term
corticoid therapy are uncommon, peptic ulceration may occur.
In other indications initial dosage will vary from 10 to 500 mg
depending on the clinical problem being treated. The larger
doses may be required for short-term management of severe,
acute conditions. The initial dose usually should be given intra
venously over a period o f at least 10 minutes. Subsequent doses
may be given intravenously or intramuscularly at intervals dic
tated by the patient’s response and clinical condition.
Solu-Medrol may be given by intravenous infusion using as the
infusion solution either 5% dextrose in water, isotonic saline
solution or 5% dextrose in isotonic saline solution. Solu-Medrol
is also compatible with most other commonly used infusion
solutions and plasma or whole blood.
Availability:

Solu-Medrol Mix-O-Vial, 40 mg (1 ml)
Solu-Medrol Mix-O-Vial, 125 mg (2 ml)
Solu-Medrol, 500 mg:
Reconstitute with 7.8 ml Bacteriostatic Water for Injection
U.S.P. (benzyl alcohol as preservative)
Solu-Medrol, 1 gram:
Reconstitute with 15.6 ml Bacteriostatic Water for Injection
U.S.P. (benzyl alcohol as preservative)
Product monograph available on request,
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among 110 patients who underwent elec
tive lymphadenectomy, only 7 had
metastases, suggesting that the primary le
sions were histopathologically favourable.
In any event, seven patients are not
enough to evaluate survival with nodal
metastases. Sim’s protocol excluded 35
patients with truncal lesions, 19 patients
with lesions situated over the lymph-nodebearing area and 14 level II lesions, all of
which might have affected the results. The
authors present arguments against lym
phadenectomy for melanoma, emphasiz
ing comparison to the biologic behaviour
of breast carcinoma, which is irrelevant.
A blanket policy against elective lym
phadenectomy, even in the high-risk
groups, is dangerous. In most institu
tions, patient follow-up is less than ideal.
In an appreciable number of patients
nodal metastases will develop, surgical in
tervention may be delayed, local control
may not be possible and survival may be
jeopardized. M orbidity after lym
phadenectomy is cited as a major deter
rent to prophylactic regional node dissec
tion. Most agree that neck and axillary
dissection have an acceptable morbidity.
Groin dissections, on the other hand, are
associated with greater morbidity, but this
is notably lessened when performed by an
experienced surgeon. Holmes and
associates35 have emphasized certain
technical aspects that, in their experience,
have reduced major morbidity to 12%
and minor complications to 15%. If more
strict criteria can be applied to lesions of
the lower extremities, the number of un
necessary groin dissections could be
reduced.
Two factors are not often taken into
account. One is that the presence of
lymph-node metastases alters the pro
gnosis. Indeed, patients may benefit from
the physician’s knowledge that lymph
nodes are free of melanoma, and those
patients whose nodes contain melanoma
may be included in experimental trials
because, in these cases, there is an urgent
need for a more effective adjuvant treat
ment, as suggested by Holmes and
colleagues35 and Das Gupta.26 The se
cond important consideration is the role
of prophylactic lymphadenectomy in
regional control of disease. The efficacy
of regional lymphadenectomy in prevent
ing local recurrence is acknowledged even
by opponents of immediate node dissec
tion in clinical stage I melanoma.40
There is mounting evidence that immuni
ty plays an important role in the tumourhost relationship. Speculation continues
on whether excision of normal lymph
nodes alters the host immune response or
enhances the growth and metastasis of
melanoma. The answer is far from clear.
I believe that selective elective lym
phadenectomy for clinical stage 1
melanoma has a definite place. The corn-
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bination of Clark’s level of invasion and
Breslow’s thickness of the lesion now has
defined the groups that benefit from
regional lymphadenectomy. They include
lesions of level III, more than 0.76 mm
thick, and all lesions of levels IV and V.
In level II lesions, between 0.76 mm and
1.50 mm thick, and level II lesions, 0.76
mm thick or less, the management of the
lymph-node regions rests on the judge
ment of the surgeon who considers other
histologic parameters and tumour loca
tion. For instance, Day and coworkers44
recently have described the “ BANS”
group of lesions — those located on the
posterior back, arm, neck and scalp.
These melanomas have a poor prog
nosis. Knowledge and application of the
previously enumerated histologic para
meters that are known to affect prog
nosis in melanoma, as well as knowledge
of the patient’s medical and socioeco
nomic conditions, should allow the
surgeon to make sound judgements in
managing the lymph-node regions.
In-continuity or Discontinuous
Dissection?

The central issue of this debate is
whether the excision of a segment of skin
and subcutaneous tissue in continuity
from the primary lesion to the regional
lymph nodes is appreciably better and
outweighs the associated functional and
cosmetic problems. Most authors would
agree that the principle of true en bloc
dissection has sound basis in the manage
ment of any cancer. There is little
disagreement in the literature when the
primary melanoma overlies or is close to
the site of regional lymph nodes. As in
other issues concerning this disease, pro
ponents of the extremes are easily found;
there are those who would perform an en
bloc dissection from the distal part of the
leg to the groin27 as well as those who
would condemn it.45 It rests, however,
with the surgeon, considering the
characteristics of the tumour and draw
ing from experience, to decide whether to
do an en-bloc dissection.
Recommendations

Modern treatment of melanoma should
be based on a clear understanding of the
biology and natural history of this malig
nant tumour. Knowledge of the conflict
ing evidence in controversial issues con
cerning the management of melanoma is
presented. In my opinion, the general
consensus in the surgical literature is to
avoid the extremes and try “ the middle
of the road approach” , which can be
summarized as follows.
• Excisional biopsy is preferable,
where it is anatomically acceptable;
histologic parameters that affect manage
ment and prognosis can then be
determined.

• Wide excision, 3 to 5 cm from the le
sion, including the deep fascia in most le
sions, is recommended.
• En bloc in-continuity dissection is
sound for lesions in close proximity to the
regional lymph nodes.
• Regional lymphadenectomy for
clinical stage I melanoma continues to be
debated. Indications for nodal dissection
now favour a “ selective elective lym
phadenectomy” as a result of identifica
tion of risk factors and the general accep
tance of Clark’s and Breslow’s micro
scopic classifications.
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" TH E TW O -STEP M A N A G E M E N T . .

continued from page 102

fice diagnosis most of the time, would do
better to refer the patient to a surgeon
who has this skill, than to oblige her to
endure the two-step procedure.
As Dr. Bassett so aptly points out, the
management of breast cancer is not an
emergency. There is no need to subject
every patient to a breast biopsy. For those
few women in whom the diagnosis of
cancer is delayed for a few weeks or even
months, there appears to be no significant
lessening of ultimate control. It is the
minimizing of patient anguish that
counts, and benign breast biopsies cause
anguish.
In the few patients in whom the di
agnosis of cancer is not clear with office
methods alone, Drs. Bassett, Mueller and
continued on page 173
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Systemic Thermochemotherapy in a Rat Model
The purpose o f th is stu d y w as to
d eterm ine th e e ffe c ts o f syste m ic
h y p e rth e rm ia , w ith and w ith o u t
A d ria m y c in , on tw o rat tu m o u r models.
Fischer rats w e re im planted
s u b cu ta n e o u sly w ith either a
m eth ylch o la n th re n e -ind u ce d sarcom a or
a tra n s itio n a l cell carcinom a. In th e firs t
e xp e rim e n t, 3 2 rats w ith tu m o u r
volum es o f 1 c m 3 w ere divided in to fo u r
groups o f 8 rats receiving: (a)
A d ria m y c in alone (2 m g/kg
in tra p e rito n e a lly) (group 1), (b) system ic
h yp e rth e rm ia alone (w a te r bath
im m ersion to a recta l tem perature of
4 1 .5 ° C fo r 3 0 m inutes) (group 2), (c)
A d ria m ycin and syste m ic hypertherm ia
(group 3) or (d) im m ersion in w a te r bath
a t 3 7 ° C fo r 3 0 m in ute s (control group)
(group 4). Serial tu m o u r volum e and
anim al su rvival w e re m onitored. No
d iffe re n ce s w ere seen am ong the groups
in e ith e r tu m o u r system .
In a second exp e rim e n t, an identical
p ro to c o l w a s used e xce p t th a t each
anim al received its respective trea tm e nt
th re e tim es, a t w e e k ly intervals. In the
rats im p la nte d w ith m ethylcholanthreneinduced sarcom a, tu m o u r volum e
w as lo w e r in g ro u p 3 than in
c o n tro l g ro u p 4 , beginning at day
2 3 (3 7 .5 ± 8 .2 c m 3 vs. 5 2 .3 ± 9 .6
c m 3 [p < 0 .0 5 ]). S yste m ic h yp e r
therm ia or A d ria m y c in alone did not
a lte r tu m o u r g ro w th in relation to the
co n tro l group. In th e tran sitio n a l cell
carcinom a sys te m , tu m o u r volum e was
decreased in b o th groups 1 and 3 at day
3 5 (group 1 = 3 2 ± 5 .4 cm 3, group 3 =
2 8 .1 ± 12 c m 3 vs. group 4 = 4 8 .8 ±
9 c m 3 [p < 0 .0 5 fo r each]).
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A d ria m ycin w ith syste m ic hypertherm ia
w a s no m ore e ffe c tiv e than A d ria m ycin
alone. T u m o u r g ro w th w a s sim ilar in
g ro u p s 2 and 4. These data d e m onstrate
th a t m u ltip le tre a tm e n ts w ith A d ria m ycin
and s y s te m ic h yp e rth e rm ia were
e ffe c tiv e in decreasing th e rate o f
tu m o u r g ro w th in rat tu m o u r m odels,
w hereas a single exposure had no e ffe c t.

Le b u t de c e tte etude e ta it de d e term in e r
les e ffe ts de I'h yp e rth e rm ie system ique,
avec ou sans A d ria m ycine . dans deux
m odeles tu m o ra u x du rat. Des rats
Fischer o n t recu par im p la nta tio n souscutanee un sarcom e provoque par
le m e th ylch o la n th re n e ou un cancer a
cellules de tra n sitio n . Dans la prem iere
experience, 3 2 rats aya n t un volum e
tu m o ra l de 1 cm 3 o n t ete separes en
q uatre groupes. Chacun a recu, s o it a)
I'A d ria m y c in e seule (2 m g/kg par voie
in tra p e rito ne a le ) (groupe 1), b) I'hyp e rth e rm ie syste m iq u e seule (par
im m e rsio n dans un bain-m arie de fa co n a
o b te n ir une te m p e ra tu re rectale de
4 1 .5 ° C pen da n t 3 0 m inutes) (groupe 2),
c) I'A d ria m y c in e e t I'hyp e rth erm ie
syste m iq u e (groupe 3) ou d) une im m e r
sion dans un bain-m arie m aintenu a
3 7 ° C pe n da n t 3 0 m in ute s (groupe tem oin) (groupe 4 ). Le vo lu m e tum oral et
la survie des anim aux o n t ete enregistres
de m aniere repetee. A ve c I'un ou I'au tre
des systd m e s tu m o ra u x, aucune
d iffe re n ce n 'a ete observee entre les
groupes.
Dans une seconde experience, un
iprotocole id e n tiq ue a ete utilise, sa u f que
chaque anim al a recu son traite m e n t
tro is fo is , a in tervalles d 'u n e semaine.
Chez les rats p o rte u rs d 'u n sarcome
p ro vo q u 6 par le m eth ylch o la n th re n e , le
vo lu m e tu m o ra l e ta it plus faible dans le
groupe 3 que dans le groupe t£m oin 4
& p a rtir du jo u r 2 3 (3 7 .5 ± 8 .2 c m 3
c o n tre 5 2 .3 ± 9 .6 cm 3 [p < 0 .0 5 ]).
L 'h y p e rth e rm ie syste m iq u e ou
I'A d ria m y c in e utilise s separem ent n 'o n t
pas m o d ifie la croissance tum orale par
ra p p o rt au groupe tem oin. Dans le
syste m e a cellules concereuses de

tra n s itio n , le vo lu m e tu m o ra l e ta it plu s
fa ib le dans les groupes 1 e t 3 a c o m p te r
du jo u r 3 5 (groupe 1 = 3 2 ± 5 .4 c m 3,
g ro u p e 3 = 2 8 .1 ± 1 2 c m 3 c o n tre
g ro u p e 4 = 4 8 .8 ± 9 c m 3 [p < 0 .0 5
dans chaque cas]). L 'A d ria m y c in e e t
I'h y p e rth e rm ie syste m iq u e
n 'e ta ie n t pas plus e ffica ce s que
I'A d ria m y c in e seule. Les croissan ce s
tu m o ra le s des gro u p e s 2 e t 4 e ta ie n t
sim ilaires. Ces re su lta ts d e m o n tre n t que
des tra ite m e n ts repetes a I’ A d ria m y c in e
e t a I'h y p e rth e rm ie syste m iq u e o n t re d u it
e ffic a c e m e n t la croissance tu m o ra le dans
des m odeles tu m o ra u x chez le rat, a lors
q u 'u n seul tra ite m e n t n 'a eu aucun e ffe t.

Hyperthermia, that is elevation of tissue
temperature above the normal o f 37°C,
has been shown to have a detrimental ef
fect on experimental and human
neoplasm s.1 Observation o f cancer
remissions in patients with severe
erysipelas led Coley2 to use induction
of fever by bacterial injections as an
titumour therapy. Since then, many in
vestigators have studied the use of hyper
thermia in cancer treatment.
Storm and colleagues3 studied the
relation between heating and human
tumour cell death and showed that
percentage cell death varies with both ab
solute temperature attained and duration
of heating. At temperatures of more than
39°C, some cellular injury occurs; hyper
thermic sensitivity is greatest in the phase
o f DNA synthesis.4 At higher
temperatures, percentage cell kill in
creases even with a shorter duration of
heating.3
Tumour hyperthermia has been achiev
ed by either local or systemic means.
Locally, tumours can be heated by
ultrasonography, diathermy, microwaves
or radiofrequency devices.3,5,6 Systemic
heating of patients with metastatic disease
was initiated by Warren7 using a waterbath technique. More recently others8
have modified this technique, and Parks
and associates9 have developed the
methodology for extracorporeal blood
heating to induce systemic hyperthermia,
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making the procedure safer, and less
cum bersom e and tim e-consum ing.
Systemic hyperthermia in advanced
human neoplasms has been anecdotally
reported by L ark in ,8 Parks and
colleagues9 and by Bull and associates10
to improve survival, but in the absence
of controlled studies, the evaluation of
these data remains unclear. The current
study was undertaken first in an attempt
to evaluate systemic hyperthermia in a
reproducible rat tumour model and se
cond to determine whether systemic
hyperth erm ia, w ith or w ithout
chemotherapy, would be of value in two
rat tumour systems.
Material and Methods
Male Fischer (F344) rats were obtain
ed from Charles River Laboratories
(Wilmington, Mass.), individually caged
and allowed water and standard Purina
rat chow ad libitum. The animals were
randomized to treatment groups at an ap
proximate mean weight of 150 g.
Tumours of two types were implanted.
The first was a transplantable sarcoma
originally induced by methylcholanthrene
(obtained from Dr. Murray Brennan at
M em orial Sloan-K ettering C ancer
Center). When implanted subcutaneous
ly, this tumour is locally aggressive, but
does not metastasize. The second tumour
was a transitional cell bladder cancer
transplantable in F344 rats (originally ob
tained from Dr. L. Taranger, department
of urology, University of Saskatoon,
Saskatoon, Sask.). The virulence of this
tum our has been increased by back
passage through FI hybrids.11 This
tu m o u r is locally invasive and
metastasizes to the lungs.
To transplant neoplasms to the ex
perim ental animals, donor tum our
bearing rats had their tumour excised
under ether anesthesia. The tumour was
chopped into 1-mm portions. The fur of
recipient rats was shaved in the mid
dorsal region and the skin prepared with
disinfectant. A small transverse incision
was then made and a subcutaneous
pocket created. A single tumour fragment
was placed in the pocket and the skin was
closed with surgical clips. This method
resulted in the reliable development of a
single measurable subcutaneous tumour
nodule in the mid-dorsal region of each
recipient rat.
Systemic hyperthermia was induced by
immersing each rat in a heated water bath
as shown in Fig. 1. A rectal probe was
placed into each animal and core
temperature measured using a telether
mometer system (Bailey Instruments Ltd.,
Saddle Brook, NJ). The temperature of
the water bath was kept at 0.5°C above
the core temperature desired. By trial and
error it was determined that F344 rats
114

would to lerate a m axim al core
temperature of 42°C for 30 to 40 minutes.
The experiments were subsequently con
ducted at a core temperature of 41.5°C
± 0.5°C for 30 minutes. Peak core
temperature was usually achieved after 10
to 13 minutes of immersion. The rats were
anesthetized by intraperitoneal ad
ministration of ketamine hydrochloride
before induction of hyperthermia. This
methodology is identical to that first
described by Bland and colleagues.12
In experiment 1 (Fig. 2), F344 rats were
im planted
with either
m ethylcholanthrene-induced sarcoma or transi
tional cell carcinoma and the tumours
were allowed to grow to a volume of 1
cm3. The animals were than randomized
into four groups of eight rats per group:
group 1 rats received Adriamycin (2
mg/kg body weight) by a single in
traperitoneal injection, group 2 animals
had systemic hyperthermia alone, group
3 rats received Adriamycin and systemic
hyperthermia, and group 4 rats acted as
a control; they received normal saline intraperitoneally and water bath immersion
at 37°C for 30 minutes. Following treat
ment, serial tumour volume, body weight
and survival were monitored.
In experiment 2, an identical protocol
was used except that each animal receiv
ed its respective treatment three times at
weekly intervals (Fig. 3). This was done
in order to determine if multiple
treatments would be more effective than

a single treatment. Again, serial weights,
tum our volume and survival were
monitored.
Statistical Analysis
Tumour volume was calculated by
caliper measurement of tumour diameter
in two dimensions with volume calculated
as 1/6 AB2. This formula results in a
close approximation of volume for a trun
cated spheroidal mass measured in two
dimensions.13 Comparison of tumour
volumes was by Student’s r-test with p <
0.05 being considered significant. Survival
was compared at different times by x 2
analysis.
Results
Experiment 1
There were no significant differences in
tumour volume with either transitional
cell
carcinom a
(Fig.
4)
or
methylcholanthrene-induced sarcoma
(Fig. 5), regardless of which modality or
modalities were used. Likewise, no dif
ferences in survival were seen, regardless
of treatment.
Although no significant differences in
tumour volume were seen in any treat
ment group, there was a trend towards
decreased tumour volume in the rats with
transitional cell carcinoma at day 21
following systemic hyperthermia with
Adriamycin and with systemic hyperther-

FIG. 3—Method used in experiment 2.

FIG. 1—Water-bath method for inducing
systemic hyperthermia.

FIG. 2—Method used in experiment 1.
MCA = methylcholanthrene-induced sar
coma, FbCa = transitional cell bladder car
cinoma, Adr = Adriamycin, S.H. = systemic
hyperthermia.

FIG. 4—Effect of single-treatment hyper
thermia alone and with Adriamycin on growth
of transitional cell carcinoma.
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mia alone (Fig. 5). This raised the ques
tion of whether multiple treatments would
have a greater effect.
Experiment 2
There was a significant decrease in the
growth rate of transitional cell cancer in
the groups treated with Adriamycin alone
and with Adriamycin and systemic hyper
thermia (p < 0.05) (Fig. 6). This was not

reflected in increased survival as no dif
ferences were seen between groups. In the
rats with methylcholanthrene-induced
sarcoma, given multiple treatments, the
rate of tumour growth was significantly
(p < 0.05) slowed at day 23 in the group
receiving systemic hyperthermia and
Adriamycin, but not in any other group
(Fig. 7). Again, survival was not altered.
Discussion
The data from this study indicate that
multiple treatments with systemic hyper
thermia plus Adriamycin have an in
hibitory effect on the growth rate of
methylcholanthrene-induced sarcomas
whereas a single treatment does not. The
lack of effect on survival may relate to
several factors. First, the decrease in
growth rate of methylcholanthreneinduced sarcoma, although significant,
was modest. Second, the treatments were
terminated at day 14, and improvement
in survival could only be anticipated if the
treatments were extended indefinitely. As
the cumulative effect of repeated hyper
thermia on animal survival is unknown,
it would be impossible to extrapolate an
increase in survival from additional
treatments. Bland and associates12 have
likewise shown a decrease in growth rates
of Morris hepatoma in Buffalo rats,
without a change in the rate of survival.
In experiment 2, with transitional cell
carcinoma, the decrease in tumour
growth rate is obviously an Adriamycindependent variable because the decrease
occurred with Adriamycin alone and with
systemic hyperthermia and Adriamycin,

FIG. 5—Effect of single-treatment hyper
thermia alone and with Adriamycin on growth
of methylcholanthrene-induced sarcoma.

but not with hyperthermia alone. This is
somewhat surprising as in the single treat
ment experiment the trend seen was
towards a decrease in tumour growth with
heat alone. Many other investigators have
studied heat sensitivities of various
tumour models and found that different
neoplasms have different thermal
sensitivities.1’1214 Most of these series
studied the effect of a single treatment on
tumour growth or survival, or both. The
experiments reported here, showing a
significant effect with multiple treatments
where a single treatment failed, suggest
that the lack of thermal sensitivities
previously reported for some tumour
models might be altered by multiple
exposures.
Most previous reports of the favour
able effects of hyperthermia alone have
required temperatures greater than
42°C.12’14 Temperatures in this range,
however, may be lethal to the host as well
as the tumour. For this reason, numerous
other anticancer modalities have been us
ed as adjuvants to hyperthermia in an at
tempt to produce cytotoxicity at lower
temperatures. Adriamycin has been
shown to potentiate the effect of hyper
thermia in some animal models15 and
because of this it was chosen for the cur
rent study. The demonstration of decreas
ed tumour growth in methylcholanthreneinduced sarcoma by hyperthermia plus
Adriamycin when neither modality alone
was successful confirms the findings of
potentiation reported by Hahn and
associates.15 Other drugs, including
bleomycin, alkylating agents and the
nitrosoureas,16 have also been shown to
potentiate the effect of hyperthermia in
some animal systems. To determine the
mechanism by which hyperthermia with
or without chemotherapy alters tumour
growth, additional studies will obviously
be necessary.
Conclusions

FIG. 6—Effect of multiple-treatment hyper
thermia alone and with Adriamycin on growth
of transitional cell carcinoma. * = p < 0.05.

FIG. 7—Effect of multiple-treatment hyper
thermia alone and with Adriamycin on growth
of methylcholanthrene-induced sarcoma. * =
p < 0.05.

We have confirmed the work of Bland
and colleagues12 and have demonstrated
that F344 rats can be successfully heated
systemically to 41.5° ± 0.5°C for 30
minutes providing a reproducible,
workable model for the investigation of
systemic hyperthermia in the rat. A single
treatm ent of hypertherm ia plus
Adriamycin does not significantly alter
tumour growth or survival in F344 rats
implanted with transitional cell carcinoma
or methylcholanthrene-induced sarcoma.
Multiple treatm ents did, however,
decrease the growth rate of methyl
cholanthrene-induced sarcoma when
neither modality was effective alone, sug
gesting potentiation of the effect. The
clinical application of hyperthermia to
human cancer treatment will require fur
ther experimentation using model systems
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such as the one described, so that the
mechanism of action and dynamics of cell
killing can be elucidated.
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Preventing Acetylsalicylic Acid Damage to Human
Gastric Mucosa by Use of Prostaglandin E2
To determine the lowest dose of pro
staglandin E2 (PGE2) capable of prevent
ing the acetylsalicylic acid (ASA)-induced
fall in the gastric transmucosal potential
difference, six healthy men (mean age
24 years) were studied on 5 separate
days, in random sequence. In the control
experiment, 100 ml of 140 mM
hydrochloric acid was instilled five times
into the stomach for 1 5 minutes each
time, during which the transmucosal
potential difference was measured con
tinuously. In the test experiments, 20
mM ASA plus PGE2 in doses of 0, 0.1,
0.5 , or 1.0 mg were added to the con
trol solution during the second and third
instillations. The mean control potential
difference ( ± standard error) was - 50
± 2 mV. During the administration of
ASA there was a 25% reduction in the
potential difference; this change was
statistically significant (p < 0.01). With
all three doses of PGE2 the fall in poten
tial difference was prevented.
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The results demonstrate that ASA
damage to human gastric mucosa can be
prevented entirely by concurrent ad
ministration of as little as 100 fig of
PGE2. This supports the view that
mucosal protection is a physiologic func
tion of PGE2.
Afin d'etablir quelle est la dose minimum
de prostaglandine E2 (PGE2) capable de
prevenir la chute de la difference de
potentiel de la muqueuse gastrique provoquee par I'ASA, six hommes sains
(age moyen 24 ans) ont ete etudies lors
de 5 jours separes, selon une sequence
etablie au hasard. Dans I'experience
temoin, 100 ml d'acide chlorhydrique
140 mM furent instilles cinq fois dans
I'estomac pour des periodes de 15 minu
tes chacune. Chaque fois la difference
de potentiel de la muqueuse fut mesuree
en continue. Dans les essais, 20 mM
d'ASA et de la PGE2 aux doses de 0,
0.1, 0.5 et 1.0 mg furent ajoutees a la
solution temoin durant les seconde et
troisieme instillations. La valeur temoin
moyenne de la difference de potentiel ( ±
erreur type) etait de - 5 0 ± 2 mV. Pen
dant ('administration d'ASA, on constatait une reduction de 25% de la diffe
rence de potentiel; ce changement etait
statistiquement significatif (p < 0.01).
Aux trois doses utilisees, la PGE2 empechait la chute de la difference de
potentiel.
Ces resultats demontrent que les dommages causes par I’ASA a la muqueuse
gastrique humaine peuvent etre prevenus

entierement par I’administration concomitante d'aussi peu que 100 fig de PGE2.
Ceci va a I'appui de I'opinion voulant que
la protection de la muqueuse est une
fonction physiologique de la PGE2.

Prostaglandins are found in high concen
tration in the gastric mucosa of many
species including man. A number of ac
tions of these lipids on gastric mucosa
have been described. They inhibit acid
secretion, stimulate mucus and bicar
bonate secretion, and they possess strik
ing anti-ulcer effects.1 The last property
has been termed “ cytoprotection” .2 The
mechanism of cytoprotection is not yet
understood, nor is it known if the gastric
m ucosal prostaglandins have any
physiologic role.
We have shown in man that very small
oral doses of prostaglandin E2 (PGE2)
can prevent, in a dose-dependent manner,
the increase in fecal blood loss induced
by acetylsalicylic acid (ASA).3 We show
ed earlier4 that a 4-mg dose of PGE2,
associated with side-effects in some sub
jects, prevented the fall in gastric
transmucosal potential difference induc
ed by either ASA or indomethacin. The
purpose of this investigation was to deter
mine the lowest dose of simultaneously
administered PGE2 that would prevent
the fall in potential difference induced by
ASA.
Subjects and Methods
Experiments were performed on six
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healthy men (mean age 24 years). The
study was approved by the local institu
tional review board and was performed
only after we had received informed writ
ten consent from each man.
All men were in excellent health. None
had a history of a bleeding diathesis,
gastrointestinal or liver disease. None was
a regular user of steroids or analgesics or
was an alcoholic. There was no history
of drug sensitivity. All subjects agreed to
avoid alcohol or any analgesic for 1 week
before starting an experiment and for the
duration of the entire study. All subjects
had a complete blood count and
urinalysis and SMA-12 screening on en
try into, and on completion of, the study.
Five experiments were performed — a
control test and four experiments with
ASA and varying doses of PGE2. All
tests were separated by an interval of at
least 1 week and no more than 3 weeks
and were done in each man in random
sequence.
Statistical analysis of the differences
was performed by the two-tailed Stu
dent’s /-test for paired values.
Measurement o f Gastric Transmucosal
Potential Difference
After an overnight fast, a no. 14
French, double-lumen, nasograstric tube

was inserted and positioned so that its tip
lay in the gastric antrum. A polyethylene
tube filled with saturated potassium
chloride in 3% agar was threaded through
one lumen of the nasogastric tube so that
its tip lay close to the tip of the
nasogastric tube and its other end was at
tached to a calomel half-cell filled with
saturated potassium chloride. A similar
but smaller sterile polyethylene tube was
inserted into a peripheral vein and its
other end placed in an identical calomel
half-cell. The two half-cells were attach
ed to an Extech battery-operated pH
meter (model 671; Extech International
Corp., Boston, Mass.), the output of
which was recorded continuously on a
Fisher chart recorder (Fisher Scientific
Co., Pittsburg, Penn.). The gastric con
tents were aspirated and discarded. The
stomach was then rinsed for three con
secutive 5-minute periods with 200 ml of
hydrochloric acid solution (140 mM) dur
ing which time the potential difference
stabilized at about - 50 mV. If the poten
tial difference failed to stabilize within a
narrow range (2 to 3 mV) during this
preliminary wash, the test was aban
doned. This occurred in approximately
5% of all tests; the commonest cause of
failure was a break in the agar gel of the
gastric electrode. A continuous record of
the potential difference was obtained. At

the end of each of five 15-minute periods,
the stomach was completely emptied and
100 ml of fresh isosmotic solution
instilled.
Gastric Insti/lates
During each 15-minute period, 100 ml
of 140 mM hydrochloric acid, made
isosmotic with sodium chloride, was plac
ed in the stomach. This acid-saline solu
tion was the control solution and the
drugs were added to it during the second
and third instillations only. In every in
stance the solution was made isosmotic
with saline. Acetylsalicylic acid was
dissolved to produce a 20 mM solution.
Prostaglandin E2 was added to the instillate in a volume of 1-ml dilute ethanol
containing 0, 0.1, 0.5, or 1.0 mg of pro
staglandin. The PGE2 was prepared in
the standard manner taking care not to
exceed a final ethanol concentration of
5% v/v. All solutions were prepared on
the morning of the test. Solutions were
continuously stirred using a magnetic stir
rer and were kept at a temperature of
37°C until placed in the stomach.
Results

There was no significant change in
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potential difference during the control ex
periment. The mean control potential dif
ference was - 50 ± 2 mV. In response
to 20 mM ASA there was a significant (p
< 0.01) fall in the potential difference,
which persisted after the third period (the
last period ASA was given), but by the
fifth period the potential difference was
no longer significantly different from the
control (Table I). All three doses of
PGE2 prevented the ASA-induced fall in
potential difference. Protection was com
plete even with the lowest dose of PGE2
and thus no dose-response relation was
demonstrable.
The average recovery of gastric instillate was 95%. There were minor dif
ferences in individual subjects and these
probably reflect different rates of gastric
emptying. There was no evidence that any
of-the drugs either inhibited or stimulated
gastric secretion. The amount of mucus
recovered from the stomach appeared in
creased at the highest dose of PGE2.
In none of the six men was any change
detected in any of the hematologic or
biochemical measurements. Side-effects
did not occur at any dose of PGE2 and
no other subjective side-effects were
recorded. Occasionally the gastric aspirate
after administration of ASA alone show
ed the presence of altered blood.
Discussion

The prostaglandins are found in the
gastrointestinal tract and in particularly
high concentration in gastric mucosa.
Many pharmacologic actions of these
substances have been demonstrated but
no physiologic role has been established.
The most striking property of the pro
staglandins is their ability to protect the
gastric mucosa from injury by a wide
variety of exogenous agents. This proper
ty, termed “ cytoprotection” , has been the
subject of a recent review.1 Evidence in
support of this phenomenon is now over
whelming but its mechanism remains
unclear. Several investigators have
postulated that cytoprotection may be the
physiologic role of the gastric mucosal
prostaglandins and that prostaglandins
may be essential for maintaining gastric

mucosal integrity. This view is supported indomethacin.4 In the present study we
by the evidence that some major gastric have shown that this protection by PGE2
damaging agents (e.g., ASA and in- is also effective against ASA-induced fall
domethacin) are also powerful inhibitors in potential difference at much lower
of prostaglandin synthesis.
doses, too small to have any phar
Recent experim ental studies by macologic effect. These studies indicate
Chaudhury and Robert5 have added sup that exogenous prostaglandin ad 
port to the view of cytoprotection as the ministered in amounts that can only be
physiologic role of the gastric mucosal viewed as physiologic exerts a significant
prostaglandins. They demonstrated that protective effect.
the topical administration of a small
The ability of prostaglandins to protect
amount of a substance such as 10% against the ASA-induced fall in potential
ethanol or 5 mM taurocholate can pro difference has been independently con
tect rat gastric mucosa against damage firmed by a group using a synthetic
produced by the subsequent administra analogue o f P G E 2. 10 While the
tion of a necrotizing agent such as ab demonstration of mucosal protection by
solute ethanol, or 80 mM acidified synthetic analogues of prostaglandin en
taurocholate. They postulated that the courages us to explore the therapeutic
“ mild irritants” protect by stimulating potential of exogenous prostaglandins,
the endogenous formation of PGE2 and the evidence that physiologic amounts of
this is supported by their observation that natural PGE2 are equally protective
the protective effect can be blocked by opens up the exciting possibility that we
pretreatment with indomethacin. We may learn how to induce the protection
have shown that canine gastric mucosa of endogenous PGE2 to prevent and
adapts to long-term ASA ad  treat mucosal damage.
ministration6 and, more recently, that
mild restraint for 10 days will protect rat
We acknowledge the secretarial assistance of
gastric mucosa from ethanol injury and Mrs. B.M. Kruska.
that this protection also is abolished by
pretreatment with indomethacin.7
The basis of the treatment investigation
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Experiment

Control
A SA alone
A SA + 0.1
A SA + 0.5
A SA + 1.0
*p < 0.01
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mg PGE?
mg PGE2
mg PGE2
compared

1

100
100
100
100
100
with period 1.

2

3

4

5

102 + 3
82 + 7*
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92 + 7*
98 + 3

103 + 3
75 + 18"
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Randomized Trial of Elective Highly Selective or
Truncal Vagotom y in Chronic Duodenal Ulceration
Between 1973 and 1976, 153 patients
(124 men, 29 women) with un
complicated, chronic, duodenal ulcer
were entered into a prospective ran
domized trial of highly selective
vagotomy (HSV) or truncal vagotomy
and pyloroplasty (TVP ). The study was
conducted in four Manchester hospitals
and the operations were performed by
consultants or chief registrars. The
follow-up was conducted by personal in
terview using a standardized question
naire. The medical gastroenterologist did
not know which type of operation the
patient had had. The patients who had
symptoms were referred back to the
surgeon who performed the operation.
The clinical laboratory and follow-up data
were analysed by computer.
There were no operative deaths. Three
patients died from unrelated causes, 13
were lost to follow-up; 137 (8 9 .5 % )
were followed up for a mean of 4.1
years (range from 2.5 to 5.5 years). A
modified Visick grading was used to
assess the results of surgery. The out
come was good in 8 2 % after TVP and
7 3 % after HSV. This difference and
those in the incidences of early or late
postprandial dumping, bilious vomiting,
weight loss, anemia and heartburn were
not significant.
Diarrhea was more frequent after TVP
(1 3 .4 % ) than after HSV (1 .4 % );
although the difference was significant
(p < 0.025), this complaint did not pre
sent a serious clinical problem. Ulcers
recurred in 15 (2 1 .4 % ) patients follow
ing HSV and in 5 (7 .5 % ) after TVP; this
difference was statistically significant (p
< 0.05).
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Entre 1973 et 1976, 153 patients (124
hommes et 29 femmes) souffrant d'ulcere duodenal chronique sans complica
tion ont participe a une etude prospec
tive randomisee comparant la vagotomie
hyper-selective (VHS) a la vagotomie
tronculaire avec pyloroplastie (VTP).
Cette etude a ete menee dans quatre
hdpitaux de Manchester et les operations
ont ete pratiquees par le consultant ou
par le r6sident-en-chef. Les examens
de rappel ont ete faits lors d'entrevues
personnelles en utilisant un questionnaire
standardise. Le gastro-enterologue n'etait
pas informe du type d'operation subi par
le patient. Les patients qui presentaient
des symptomes etaient adresses au chirurgien ayant pratique I'intervention. Les
examens cliniques et les bilans biologiques de post-cure ont ete analyses par
ordinateur.
On n'a enregistre aucun deces peroperatoire. Trois patients sont morts de
causes non rattachees et 13 ont ete perdus de vue; 137 (8 9 .5 % ) ont fait I'objet
d'une surveillance d'une duree moyenne
de 4.1 ans (ecart de 2.5 ans a 5.5 ans).
Une echelle modifiee de Visick a ete utilisee pour evaluer les r£sultats chirurgicaux. Les resultats de la VTP etaient
bons dans 8 2 % des cas et ceux de VHS
dans 7 3 % . Cette difference ainsi que
cedes pour les vomissements postprandiaux immediats ou tardifs, les
vomissements bilieux, la perte de poids,
I'anemie et les brulures d'estomac
n'etaient pas significatives.
Les diarrhees etaient plus frequentes
apres V TP (1 3 .4 % ) qu'apres VHS
(1 .4 % ); bien que la difference soit signi
ficative (p < 0.025), ce symptome ne
presentait pas un probleme Clinique
grave. II y eut recidive de I'ulcere chez
15 patients (2 1 .4 % ) apres VHS et chez
5 (7 .5 % ) apres VTP ; cette difference est
statistiquement significative (p < 0.05).

In the past 25 years in the United
Kingdom truncal vagotomy and drainage
has been the operation most commonly
performed for chronic duodenal ulcer.1
This procedure is associated with a lower
mortality than partial gastrectomy but a
higher incidence of recurrent ulceration.2

Overall 15% to 25% of patients have sideeffects postoperatively, such as dumping,
diarrhea, vomiting and heartburn in vary
ing degree. Highly selective vagotomy
(HSV) without drainage, introduced by
Johnston and Wilkinson3 and Amdrup
and Jensen,4 involves a specific dissec
tion of the nerves to the fundus and body
of the stomach aimed at producing less
disturbance o f overall vagal supply to the
gut. Reports are available from uncon
trolled series of patients undergoing HSV
for duodenal ulcer5'9 and from a few
controlled prospective clinical trials com
paring HSV with selective gastric
vagotomy and drainage,10 with truncal
vagotomy and antrectomy" and with
truncal vagotomy and pyloroplasty
(TVP).12 High rates of recurrent ulcera
tion after HSV have been reported.13’14
Interim results, after a mean 2.6-year
follow-up, in the present study14 of HSV
versus TVP showed little difference bet
ween the groups. This paper records the
results after a mean follow-up of 4.1
years.
Patients and Methods

Design o f Trial
The protocol of this clinical trial has
already been published.15 Two district
general and two teaching hospitals took
part in the trial; all the operations were
performed by consultants or senior
registrars each of whom already had
clinical experience with both operations.
Men and women scheduled to undergo
elective surgery for radiologically and endoscopically proved uncomplicated
duodenal ulcer were entered into the trial
between June 1, 1973 and June 30, 1976.
Preoperative clinical, radiologic and en
doscopic data, operative and postopera
tive data were recorded on standard pro
formas and were later analysed by com
puter. During the trial, 364 patients with
duodenal ulcer were seen, but to study un
complicated elective cases, 211 (58%)
were excluded for the following reasons;
emergency operations were performed for
perforation or bleeding, pyloric stenosis
was present, there was a concurrent
gastric ulcer, the patient had other
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gastrointestinal disease such as hiatus her
nia or gallstones, or the operation was
technically not feasible (e.g., because of
gross edema of the pylorus or because the
nerves of Latarjet were not clearly visi
ble due to obesity).
Patients were randomized into either
HSV or TVP groups by drawing a trial
card from a box kept in the operating
room. Highly selective vagotomy was per
formed using a standard technique,3
although often anterior and posterior
branches of the nerves of Latarjet were
divided using an anterior approach along
the lesser curvature. Truncal vagotomy
was combined with a standard 6- to 8-cm
Heineke-Mikulicz pyloroplasty. All pa
tients were interviewed 1 month after
operation by the surgeon concerned, and
then at 3, 6 and 12 months postoperatively, and thereafter at 6-month intervals by
a member of the team who did not know
which procedure had been used. Details
of specific symptoms such as pain, diar
rhea and dumping recorded preoperatively were noted again at follow-up. An
overall assessment of the clinical result
was made independently by one of us
(P.C.G.) using the following modified
Visick classification: grade I — patients
with no residual gastrointestinal symp
toms; grade II — patients with some mild
symptoms who were satisfied with the
result of surgery; grade III — those with
more severe symptoms causing some
disability but who were still better than
they were preoperatively and grade IV —
those with recurrent ulceration or disabili
ty as bad as or worse than before the
operation for any reason. All those with
suspected recurrent ulcers had endoscopic
confirmation and were placed in Visick
grade IV.

analyses were made using the x2 test with
Yates’ correction.
Results

There were no operative deaths and no
statistically significant differences in mor
bidity between the groups. Three patients
died of unrelated causes and 13 were lost
to follow-up. One patient died following
operation for recurrent ulceration after
HSV.
There have been 15 (21.4%) proven
recurrent ulcers following HSV and 5
(7.6%) after TVP. Men accounted for 18
recurrences, women for 2. The rate of
recurrent ulceration in both groups in
creased with time after operation, and the
difference between recurrence rates
became statistically significant (p < 0.05).
There was no significant difference in the
number of recurrences after operations
performed by surgeons in training than
those performed by consultants. On
average, the time between operation and
the diagnosis of recurrent ulcer was 35
months for HSV and 36 months for TVP
(range from 12 to 59 months).
The results for the two operations were
similar on Visick grading. Fifty-five pa
tients (82%) had a good result after TVP
compared with 51 (73%) following HSV;
there were 12 patients (18%) with poor
results after TVP and 19 (27%) after
HSV.
Diarrhea, dumping and vomiting were
all more common after TVP (Table I),
but the difference was significant only for
diarrhea (p < 0.025). After TVP, nine
patients (13%) complained of diarrhea
compared with only one (1.4%) after
HSV.

Outcome in Patients with
Recurrent Ulceration
Twenty patients had recurrent ulcera
tion; 13 underwent further elective
surgery and 7 were managed conservative
ly with cimetidine and antacids (Table
IV). Eight patients had a good result
following further surgery but one, in the
HSV group, died following vagotomy and
antrectomy due to anastomotic leakage
and intra-abdominal sepsis. One patient
was lost to follow-up. The condition of
four patients of the seven given cimetidine
was clinically unsatisfactory and they may
require operation in the future. These

Table 1-Symptoms after Vagotomy.
Mean Follow-up 4.1 yr

Patients
Entered into the trial were 153 patients
(124 men and 29 women). Seventy-seven
had HSV and 76 had TVP. The TVP
group consisted of 61 men and 15 women
with a mean age of 41 years. The HSV
group consisted of 63 men and 14 women
with a mean age of 40 years. In only 3
of 150 variables recorded at the
preoperative assessment and analysed by
computer were significant differences
noted between the groups and this is no
more than would be expected by chance.

Symptom

Truncal vagotomy
and pyloroplasty,
no. (%) (n = 67)

Highly selective
vagotomy, no. (%)
(n = 70)

9 1131
81121
11 1101
91131

1 11.41*
5 17.11
16 I23I
7 1101

Diarrhea
Dumping
Heartburn
Vomiting
*p < 0.025.

Table ll-P a tte m of Postoperative Diarrhea
Postoperative period, mo

Follow-up
One hundred and thirty-seven patients
were followed up for between 30 and 66
months (mean 4.1 years). O f these, 70 pa
tients (91%) who had HSV and 67 pa
tients (88%) who underwent TVP were
assessed clinically. One patient in the TVP
group and two in the HSV group died.
Eight in the TVP and five in the HSV
group were lost to follow-up. Statistical
120

It is interesting that both the incidence
and severity o f diarrhea decreased
through the follow-up period (Table II).
Diarrhea was deemed severe if it in
terfered with the patient’s life-style or
necessitated repeated medication. In the
early postoperative period (within 6
months) there was more mild diarrhea
after TVP and five patients had severe
symptoms compared with two after HSV.
However, in the long-term follow-up only
one patient in the TVP group complain
ed of diarrhea severe enough to warrant
grade III classification.
Dumping symptoms were generally
mild and although severe dumping occur
red in one patient following TVP (Visick
grade III) further surgery was not re
quired. Sixteen patients (23%) experienc
ed heartburn after HSV and 11 (16%)
following TVP and this was the cause of
an unsatisfactory result in 3 patients after
HSV and 1 after TVP. The reasons for
unsatisfactory clinical grading are shown
in Table III.

0-6
Procedure

Truncal vagotomy
and pyloroplasty
Highly selective
vagotomy

(L30

30-66
Severe

Mild

Severe*

Mild

Severe

Mild

16t

5

8

2

8t

1

4t

2

5

1

It

0

‘ Interfering with life-style or necessitating repeated medication,
tp < 0.025.
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assessments were made at 6 months to 3
years after treatment.
Discussion

The aim of this trial was to compare
the two operations in uncomplicated
duodenal ulceration. Consequently, 211
patients (58%) of 364 who underwent
surgery for duodenal ulcer and its com
plications during the 3-year trial were ex
cluded. Nevertheless, two well-defined
groups were obtained. Direct comparison
of the results in this study with those ob
tained from non-randomized, retrospec
tive reviews is difficult, especially when
complicated duodenal ulcers or emergen
cy operations were included.
We have now achieved a careful, per
sonal follow-up of a large percentage
(90%) of patients. The trial included
women as well as men; although women
may have a lower risk of recurrent
ulcer,15 they may have a worse
postoperative functional result than
men.2
There was no death in either group at
the initial operation, and there was very
little difference between the two with
regard to wound and chest infections and
length of hospital stay.14
Probably the most important criterion
in the assessment of duodenal ulcer
surgery is the incidence of recurrent ulcer.
Ulcers recurred in 15 patients (21%) after
HSV and in 5 after TVP; this difference
is significant (p < 0.05). Our results for
TVP are comparable to those of several
other workers,11-12 but the incidence of
recurrent ulcer after HSV is much higher
than in most reported series6'9'12 with the
exception of that of Madsen and

Kronborg.16 Since our earlier report in
197914 there has been an increase in
recurrent ulceration in both groups. The
mean time from operation to the
diagnosis of recurrent ulcer was 3 years
(range from 12 to 59 months) in each
group and there must be little doubt that
this represents a real increase in incidence
rather than a delay in diagnosis. Recur
rence was not related to duration of
symptoms before operation in either
group, in contrast to the findings of
Madsen and Kroriborg16 that prolonged
symptoms before HSV were associated
with increased risk of recurrence.
Results of surgery sometimes improve
as more experience of a particular pro
cedure is gained. The surgical teams in
volved in this trial all had gained some
preliminary experience of HSV before
beginning prospective studies and were
already experienced in performing trun
cal vagotomy. Studies of HSV in hands
as experienced with the procedure as most
general surgeons now are with truncal
vagotomy may yield different results.
However, even among those whose ex
perience is greatest with HSV the reported
incidence of recurrent ulcer is
increasing.17
There was little difference between the
two operations with regard to overall
functional results: 82% good results after
TVP and 73% following HSV. If we
assume a good clinical result after revisional surgery for recurrent ulcer in each
group there are still no significant advan
tages for either operation: 90% good
results after TVP and 94% after HSV.
Not unexpectedly, diarrhea, dumping
and vomiting occurred more frequently
after TVP but the difference between the

Table Ill-Reasons for Visick III and IV
Gradings Postoperatively

Reason
Recurrent ulcer
Dumping
Diarrhea
Heartburn
Dyspepsia (normal
findings at endoscopy)
M ultiple sym ptom s
___

Truncal vagotomy
and pyloroplasty
(n = 12)

Highly selective
vagotomy
(n = 19)

5
1
1
1

15
0
0
3

2
2

1
0

Table IV-Recurrent Ulcer (n = 20)
Treatment
Surgery
Partial gastrectom y
Truncal vagotom y and
pyloroplasty
Vagotom y and antrectom y
Cimetidine

Truncal vagotomy
and pyloroplasty

Highly selective
vagotomy

1

5

0
1
3

2
4
4

two operations was significant only for
diarrhea. The incidence of mild and
severe types of diarrhea has diminished
since the early postoperative period and
there was only one patient after HSV and
nine after TVP who continued to ex
perience such symptoms. One patient
after TVP was classified as unsatisfactory
(grade III) because of diarrhea alone.
Prolonged follow-up has shown that
postvagotomy diarrhea in this series did
not present a severe clinical problem.
While eight patients (12%) experienced
dumping after TVP and five (7%) follow
ing HSV, these symptoms were generally
mild in both groups. Nevertheless, it
represents an increase in incidence since
the last follow-up at 2 years, when seven
patients had dumping after TVP and
three after HSV. One patient only had
symptoms severe enough to warrant a
Visick III grading and this was after TVP.
Complaints of bilious vomiting occur
red in nine patients (13%) after TVP and
in seven (10%) after HSV. Vomiting in
association with other troublesome symp
toms was not uncommon. Alone it was
never responsible for an unsatisfactory
result. No significant difference between
the two operations with regard to in
cidence or severity of vomiting could be
demonstrated between the groups.
Heartburn in 16 out of 70 patients
(23%) was found more frequently after
HSV and this high incidence is similar to
the findings of an earlier consecutive
series of HSV from another centre.18
Three patients after HSV and one follow
ing TVP had heartburn severe enough to
justify unsatisfactory Visick classifica
tion, although no patient has required
surgery for this problem.
Good overall clinical results in Visick
grades I and II of 73% of those treated,
and almost total avoidance of diarrhea
after HSV are enough to warrant recom
mending it as a primary procedure for
chronic duodenal ulcer. However, in our
view the crux of the matter lies in the out
come of the 21% with recurrent ulcera
tion. Although on a large scale we do not
yet know the results of operative treat
ment for recurrent ulcers following HSV,
there is good evidence that both the mor
tality and morbidity of surgery for pep
tic ulcer recurrence are higher than for the
primary procedures.19 Similar conclu
sions may be valid for operations for
recurrent ulcer after HSV; in our small
series one patient died following attemp
ted remedial surgery, but sufficient data
are not yet available to evaluate the risks
fully.
From our results we can conclude that
at this stage in the study (mean 4.1-year
follow-up) HSV probably carries a higher
risk of recurrent ulcer than TVP. It does
not appear to be offset by any improve
ment in overall functional results despite
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a significant reduction
postoperatively.
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Primary Perineal Wound Closure
following Excision of the Rectum
Management of the perineal wound
following rectal excision was assessed in
57 patients at the Toronto General
Hospital; 40 had ulcerative colitis. 4 had
Crohn's disease, 10 had carcinoma of
the rectum, 2 had carcinoma of the anus
and 1 had anal incontinence.
The preferred technique was careful
anatomical dissection with meticulous
hemostasis, and primary skin closure
with a laterally placed closed Hemovac
suction system. Alternatively, wounds
were packed and allowed to heal
secondarily.
Overall, the perineal wound healed
primarily in 41 patients (72% ). Primary
closure was possible in 50 patients
(88% ); in 41 (82%) the wound healed
without complication but in 9 (18%) the
wound had to be opened because of
hematoma and abscess (8 patients) or
bleeding (1 patient). In 41 (91% ) of the
4 4 patients with inflammatory bowel

From the division o f general surgery,
Toronto General Hospital, Toronto, Ont.
Presented in part at the 4th annual meeting
o f the Canadian Association o f General
Surgeons, Toronto, Ont., Sept. 18, 1981
Accepted f o r publication N ov. 1, 1982
Reprint requests to: Dr. Z. Cohen, Eaton
Building 9-211, Toronto General Hospital,
101 College St., Toronto, Ont. M SG 1L7

122

disease the perineal wound was closed
primarily; 34 wounds (83% ) healed
without complication.
In seven patients the perineal wound
was packed at surgery because of
bleeding (four), fecal spillage (two) or
sepsis (one). Healing time averaged 6
months.
These results indicate that primary
closure is the optimal management of
perineal wounds. Primary healing is
achieved in a high proportion of patients
and postoperative morbidity is decreas
ed. Results are excellent in patients with
inflammatory bowel disease as well as in
those with carcinoma.
Le traitement de la plaie perineale apres
excision du rectum a ete evaluee chez
57 patients du Toronto General Hospital;
40 souffraient de colite ulc6reuse, 4 de
maladie de Crohn, 10 d'un cancer du
rectum, 2 d'un cancer de I'anus et 1
d'incontinence anale.
La technique preferee consistait a faire
une dissection anatomique soigneuse
avec hemostase meticuleuse, et une fermeture primaire de la peau avec un
systfeme d'aspiration Hemovac ferme,
place latiralement. Sinon, la plaie etait
remplie et laissee a cicatriser par
seconde intention.
Dans I'ensemble. la plaie perineale a
cicatrise par premiere intention chez 41
patients (72% ). La fermeture primaire a

ete possible chez 50 patients (88%);
chez 41 (82% ), la plaie a cicatrise sans
complication alors que chez 9 (18%) elle
dut etre rouverte a cause d'un hematome et d'un abces (8 patients), ou d'un
saignement (1 patient). Chez 41 (91%)
des 44 patients souffrant d'affections
inflammatoires intestinales, la plaie peri
neale a cicatrise par premiere intention;
34 plaies (83% ) ont gueri sans
complication.
Chez sept patients, la plaie perineale a
ete remplie au moment de la chirurgie a
cause d'une hemorragie (quatre), d'un
epanchement de matieres fecales (deux)
ou d'une sepsie (un). Le temps de cica
trisation a ete de 6 mois en moyenne.
Ces resultats indiquent que la ferme
ture primaire est le meilleur traitement
des plaies perineales. La cicatrisation par
premiere intention est possible chez une
forte proportion de malades et la morbi
dity postoperatoire est reduite. Les resul
tats sont excellents chez les patients
souffrant d'affections inflammatoires
intestinales aussi bien que chez ceux qui
sont atteints de cancer.

Until recently, management o f the
perineal wound follow ing excision o f the
rectum had changed little since Miles’
original description in 1908.* The wound
was left open and packed or partially clos
ed. Although this method gave satisfac-
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tory results, it led to persistently drain
ing perineal sinuses, discomfort for the
patient and prolonged hospitalization in
many cases.2
During the past 15 years, primary
closure of the perineal wound with clos
ed pelvic drainage has been shown to be
effective.2'5 When successful, primary
perineal wound closure improves healing
time and patient comfort, and decreases
hospital stay. The majority of the ex
cellent results reported using primary
perineal wound closure have been achiev
ed following rectal excision for car
cinoma. Healing of the perineal wound
is more troublesome following rectal ex
cision for inflammatory bowel disease.
The wound may remain open for longer
than 6 months after surgery for ulcerative
or granulomatous colitis.6-7 In these pa
tients there are unique problems that lead
to a high incidence of persistent perineal
sinuses.
Since 1977, primary wound closure
following rectal excision has been the
method of choice at the Toronto General
Hospital. This paper is a retrospective
review of patients managed in this way.
We compare the results achieved with
primary perineal wound closure follow
ing rectal excision for carcinoma and for
inflammatory bowel disease.
Patients and Methods

Between July 1, 1977 and Dec. 31,
1981, 57 patients were operated upon at
the Toronto General Hospital by three
staff surgeons or by residents under their
guidance. There were 36 men and 21
women, whose ages ranged from 19 to 88
years (mean 41 years).
Indications for surgery are given in
Table I. Proctocolectomy was perform
ed in 32 patients. Twenty-five patients
had abdominoperineal excision of the rec
tum. This group included 13 patients with
inflammatory bowel disease who had
previously had a subtotal colectomy. A
continent reservoir ileostomy was also
established in 25 of the 57 patients.
All patients underwent mechanical
bowel preparation preoperatively. An
tibiotics were routinely given intravenous
ly before and after operation.

Technique o f Rectal Excision

perineal wound primarily in this group
were excessive bleeding in four patients,
fecal spillage in two and local sepsis in one
patient. There were no operative deaths
in the series. Uncomplicated healing of
the perineal wound occurred in 41 of 50
patients (82%) who had their perineal
wound closed primarily. Of the nine pa
tients who had wound complications, one
had excessive bleeding that necessitated
reopening and exploring the wound and
open packing 24 hours after the original
surgery and the other eight had local sep
sis that required opening the perineal
wound, irrigating and packing it.
Forty-four patients were operated upon
for inflammatory bowel disease. In 41
(93%) (39 with chronic ulcerative colitis
and 2 with Crohn’s disease) the perineal
wound was closed primarily. Healing was
uncomplicated in 34 of these 41 patients
(83%). Similar results were achieved in
the 12 patients who had an ab
dominoperineal excision of the rectum for
either rectal cancer (10) or anal cancer (2).
Nine of these 12 patients (75%) had the
perineal wound closed primarily and in
7 of the 9 (78%) healing was
uncomplicated.

All operations were performed as a
two-team synchronous excision of the rec
tum. Careful anatomical dissection, par
ticularly anterior to the rectum, is man
datory. When the surgery was performed
for inflammatory bowel disease, the
levator ani muscles were divided close to
the rectum. An intersphincteric dissection
was not perform ed. Meticulous
hemostasis was achieved and the pelvic
wound irrigated with distilled water. The
levator ani muscles were not approx
imated. The peritoneum of the pelvic
floor was closed in all cases.
Management o f the
Perineal Wound
In 50 patients (group 1) the skin of the
perineal wound was closed completely
with nonabsorbable sutures. Laterally
placed W-inch Hemovac suction drains
were led into the presacral space before
skin closure. These drains were connected
to a wall suction system until the ab
dominal portion of the operation was
complete. They were then connected to
the Hemovac closed suction system and
left in place for 3 to 6 days until drainage
was minimal.
The perineal wound in seven patients
(group 2) was left open and packed.

Healing Time o f Perineal Wound
The mean time to complete healing of
the perineal wound in the 50 patients
whose wounds were closed primarily
(group 1) was 48 days (Table III). In 41
of these 50 patients the wound healed
without complication and all wounds
were considered healed within 10 days.
Nine patients had their perineal wound
closed primarily but subsequently had
their wound opened. The mean healing
time in this subgroup was 225 days.
The mean wound-healing time for the
seven patients who had the wound pack
ed open at surgery (group 2) was 195
days. The difference in healing time be
tween groups 1 and 2 was statistically

Statistical Analysis
Differences were analysed by Student’s
/-test.
Results

Perineal Wound Healing
Of the 57 patients, 50 (88%) had
primary wound closure (Table II). In only
7 patients (12%) was the wound packed
open. The reasons for not closing the

Disease
C an cer Ire c ta l 10, a n a l 21

Table 11-Results of Primary Wound Closure
Wound closed
Wound healed
primarily, % (no.)
primarily, % (no.)
7 5 19/121

78 (7/91

93 141/441

83 134/411
8 2 141/501

8 8 (50/571

Table l-lndications for Operation
in 57 Patients

In fla m m a to ry b o w e l dise ase
U lce ra tiv e co litis
C ro hn's disease
C arcinom a o f re c tu m
S q u a m o u s cell c a rc in o m a o f anus
In co n tin e n ce

No. of
patients
40
4
10
2
1

58 (7/12)

In fla m m a to ry b o w e l disease
(c h ro n ic u lc e ra tiv e c o litis
40, C ro h n 's d ise a se 41
A ll cases

Indication

Overall % (no.)
healed primarily

Method
P rim a ry c lo s u re (g ro u p 11
U n c o m p lic a te d he a lin g
C o m p lica te d h e a lin g
P acked op en (g ro u p 21

Table Ill-Healing Time of Perineal Wounds
No. of patients
50
41
9
7
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75 (34/44I
7 2 141/571

Mean healing time, d
48
<10
225
195
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significant (p < 0.03) even when the nine
group 1 patients whose perineal wounds
were opened postoperatively are includ
ed. On the other hand, there was no
statistically significant difference in heal
ing time between those wounds packed
open at surgery and those initially closed
but subsequently opened.
Discussion

Our own results, as well as those of
others,2' 10 suggest that after excision of
the rectum the perineal wound can be
closed primarily in most cases. In our
series, 88% of the wounds were closed
and of these, 82% healed primarily. Clos
ing the wound primarily offers many ad
vantages. It obviates the pain and discom
fort of removing packing. It makes pro
longed irrigation and dressing changes un
necessary. It also decreases the incidence
of chronic draining sinuses11 and,
therefore, repeated operative procedures.
Should the primarily closed wound
become infected and require drainage,
there do not seem to be any added risks.
The healing time in this group of patients
was similar to that in patients whose
wounds were packed open at surgery.
To achieve a high degree of success
following primary perineal wound
closure, several surgical principles must
be adhered to. Miles first recognized the
large dead space in the pelvis created
following rectal excision and the poten
tial for hematoma formation. So to avoid
hematomas and subsequent infection,
hemostasis must be exact and measures
to lessen the size of the pelvic cavity must
be taken. Excessive bleeding is minimiz
ed when there is a meticulous anatomical
dissection and careful ligation or
cauterization of vessels. In following this
principle, correct tissue planes are more
easily identified and hemorrhage is lessen
ed. Although a wide dissection is
necessary in carcinoma, one should
dissect close to the rectum in inflam
matory bowel disease in order to lessen
the size of the dead space. Suction drains
should be positioned in such a way as to
lie at the level of the closed pelvic
peritoneum and exit dependently along
the curve of the sacrum The suction
drains should be attached to wall suction
as soon as the perineal wound and pelvic
floor are closed to diminish hematoma
formation and clogging of the drains dur
ing completion of the abdominal portion
of the procedure.
Controversy surrounds the type of
closure
used
for
the
pelvic
peritoneum.2,9'10 Theoretically, if the
pelvic peritoneum is left open, the small
bowel will fill and obliterate the pelvic
dead space, thus minimizing the ac
cumulation of blood and decreasing
pelvic sepsis. However, in a randomized
124

study Irvin and Goligher2 found no dif
ference in wound sepsis whether the
peritoneum was left open or closed
(45.8% vs. 42.9% ). Alpsan and
colleagues10 found a 44% incidence of
wound sepsis if the peritoneum was
closed compared with 22% when it was
left open. In our series, the pelvic
peritoneum was closed in all cases.
Because of the high rate of perineal
wound healing in our series, we believe
that closure of the pelvic peritoneum pro
bably is not a major factor contributing
to pelvic sepsis after rectal excision.
In our experience fecal spillage when
the rectum is inadvertently entered dur
ing dissection should not necessarily
preclude primary perineal wound closure.
In six of our patients the rectum was
entered. The wound was left open in two
but was closed in four, who underwent
meticulous bowel preparation and had
minimal contamination. All four had
wound healing without a pelvic abscess.
However, in the presence of gross fecal
contamination, we would not recommend
primary perineal wound closure. Irvin
and Goligher in their series2 reported
that 32 of 64 wounds healed when there
was no contamination, while all 9 that
were contaminated became infected. In
the series of Broader and associates,5 on
ly 5 of 15 contaminated wounds healed.
Our overall results compare favourably
with those reported in the literature.211
All our patients operated upon were in
cluded in the series. There was no selec
tion. Primary perineal wound healing oc
curred in 72%. Managing the perineal
wound in inflammatory bowel disease
presents special difficulties. Persistently
draining perineal sinuses are a particular
problem. Jalan and associates6 reported
that in 106 patients operated upon for
ulcerative colitis, in whom the wound was
packed open, only 10% of wounds were
healed at 2 months, and 37% were still
unhealed at 1 year. This is similar to the
experience of Watts and colleagues7 in
which a persistently draining perineal
sinus developed in 25% of patients. It ap
pears that primary closure of the perineal
wound may lessen the chance of a persis
tent perineal sinus.11 In our series, 83%
of patients with inflammatory bowel
disease who had the perineal wound
treated by primary closure had a com
pletely healed wound within 10 days and
the wound remained healed. Warshaw
and associates3 also found that 82% of
wounds in their 17 patients with inflam
matory bowel disease healed without
complication. Broader’s group5 reported
a 67% perineal wound healing rate in pa
tients with cancer compared with 31% in
Crohn’s disease and 67% in ulcerative
colitis. Irvin and Goligher2 found no dif
ference in healing, but overall the results
were poorer — 45%, 45% and 36%

respectively for cancer, ulcerative colitis
and Crohn’s disease. Since we reported
on only two patients with Crohn’s disease
who had their perineal wounds closed
primarily, it is difficult to make com
parisons with patients who had ulcerative
colitis. However, it appears from the
reports of others that a poorer result is
to be expected in patients with Crohn’s
disease.
While primary suture of the perineal
wound is the optimal method of manage
ment, we recognize that in certain in
stances this may be unsafe. Uncontrolled
bleeding is a definite contraindication to
primary closure. Local sepsis, rectal per
foration and fecal spillage are relative
contraindications also.
Summary and Conclusions

If principles of anatomical dissection,
meticulous hemostasis and adequate
drainage are followed, primary closure
and healing of perineal wounds is prefer
red and can be achieved in most patients.
In a series of 57 patients, the perineal
wound was closed primarily in 88% and
in 82% of these patients the wound heal
ed without complication. The morbidity
was less in these patients and the healing
time was shorter. Excellent results were
achieved in patients operated upon for
ulcerative colitis as well as in those with
cancer.
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Finally, effective
anti-herpes therapy for:
□ Sufferers o f initial
herpes genitalis
□ Immunocompromised
patients with
nonlife-threatening
cutaneous herpes
simplex infections
in a number of double-blind, placebocontrolled studies,' ZO VIRAX has demonstrated
an unprecedented efficacy, selectivity and safety
profile. Z O V IR A X provided normal patients with
initial herpes genitalis and immunocompromised
patients with herpes genitalis or herpes labialis
with prompt, effective relief from the common
symptoms of herpes infections.

ZOVIRAX-treated patients heal faster

.
r

►

ZO VIRAX speeds the healing of herpes
lesions, especially if therapy is started at the
earliest possible moment. In normal women with
initial herpes genitalis treated 6x per day, 86% of
ZO VIRAX patients were healed by day 12 (only
25% of placebo patients were healed within this
timeframe). And in the immunocompromised
group, ZOVIRAX-treated patients were 100%
healed by day 23, whereas only 75% of the
placebo group had similar clinical results.

ZOVIRAX-treated patients become
pain-free faster
ZO V IR A X can significantly reduce the pain
caused by the blister-like sores associated with
herpes infections. (For example, in clinical
studies involving male patients with initial herpes
genitalis, 88 % of ZOVIRAX-treated patients, as
compared to 4 5 % for the placebo group, were
pain-free by day 7.)
Similarly, impressive results were reported
with immunocompromised patients— 100% of
ZOVIRAX-treated patients were pain-free by day
23, whereas only 70% of the placebo group were
pain-free within the same period.

ZOVIRAX-treated patients become
virus-free faster
ZO V IR A X helps stop viral shedding (the
active, infectious state of the virus) by effectively
blocking the replication mechanism of the virus.
This is a particularly important point since
blocking viral replication is the first step in the
healing process.

ZOVIRAX-treated patients experience
few compromising side effects
In extensive controlled clinical studies,
ZO VIRAX therapy proved highly efficacious
without causing any significant side effects. More
placebo patients experienced transient adverse
reactions of mild pain, including burning or
stinging, than ZO V IR A X patients (31.1 % for
placebo; 28.3% for ZO VIRAX).

t

WELLCOME MEDICAL DIVISION
BURROUGHS WELLCOME INC.
KIRKLAND. QUE.

ZOVIRAX is highly effective.. .because
it’s highly selective

The way ZOVIRAX works is the reason it
works so well.
ZOVIRAX is highly active in infected cells
and virtually inactive in healthy cells. In fact,
this unique selectivity of ZOVIRAX is most
dramatically evidenced by in vitro data which
show ZOVIRAX to be 3,000 times more active in
the herpes-infected cell than in the normal cell.
Once it is preferentially taken up and
selectively converted to its active form by the
infected cell, ZOVIRAX interferes with the
reproductive process of the virus, effectively
stopping replication and ending the contagion
period so that the process of healing can begin.
Reference:

1. D ata on file. BURROUGHS WELLCOME INC
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ACYCLOVIR OINTMENT 5%

ANTIVIRAL AGENT
ACTIO NS: ZOVIRAX (acyclovir), an acyclic nucleoside analog, is a substrate specific
for herpesvirus-specified thym idine kinase. It in hibits replication of these viruses.
Normal cellular thym idine kinase does not effectively utilize acyclovir as a substrate.
Herpesvirus-specified thym idine kinase transforms acyclovir to its monophosphate
which is then transformed by cellular enzymes to acyclovir diphosphate and acyclovir
triphosphate. Acyclovir triphosphate is both an inhibitor of, and a substrate for,
herpesvirus-specified DNA polymerase. Although the cellular «-DNA polymerase in
infected cells may also be inhibited by acyclovir triphosphate, this occurs only at
concentrations of acyclovir triphosphate which are higher than those which inhibit
the herpesvirus-specified DNA polymerase. Acyclovir is preferentially taken up and
selectively converted to its active form by herpesvirus-infected cells. Thus, acyclovir
has a very much lower toxic potential for normal uninfected cells because: 1) less is
taken up; 2) less is converted to the active form; 3) cellular «-DNA polymerase has a
lower a ffin ity for the active form of the drug.
INDICATIONS AND CLINICAL U SE: ZOVIRAX Ointment 5% is indicated for the
management of in itia l episodes o f genital herpes simplex infections. It is also indicated
in the management of nonlife-threatening cutaneous herpes simplex virus infections in
immunocompromised patients. The prophylactic use of this preparation has not been
established.
In genital herpes, appropriate examinations should be performed to rule out other
sexually transmitted diseases.
These indications are based on the results o f a number of double-blind, placebocontrolled studies which examined changes in virus excretion, healing of lesions and
relief o f pain. Because o f the wide biological variations inherent in herpes simplex
infections, the following summary is presented merely to illustrate the spectrum of
responses observed to date. As in the treatment o f any infectious disease, the best
response may be expected when therapy is begun at the earliest possible moment.
In immunocompromised patients, 93% were virus negative after 5 days o f topical
ZOVIRAX therapy, whereas only 35% o f placebo recipients were virus negative at the

same time. In patients with herpes labialis, there was a significantly greater decrease in
the amount of virus excreted after one day o f therapy in those receiving ZOVIRAX within
8 hours of the onset of cold sores when compared to identically treated placebo
recipients.
Because complete re-epithelialization o f herpes-disrupted integument necessitates
recruitment of several complex repair mechanisms, the physician should be aware that
the disappearance of visible lesions is somewhat variable and w ill occur later than the
cessation o f virus shedding. All immunocompromised patients who received topical
ZOVIRAX had healed their lesions 23 days after the initiation o f a 10-day course of
therapy; 75% o f placebo patients had healed lesions at that point. Some placebo
patients continued to have visible lesions for more than 30 days.
Pain associated with herpes infections is highly variable in frequency and intensity.
One hundred percent of the ZOVIRAX-treated immunocompromised patients were painfree by day 23 versus 70% o f placebo-treated patients.
Whereas cutaneous lesions associated with herpes simplex infections are often
pathognomonic, Tzanck smears prepared from lesion exudate or scrapings may assist in
the diagnosis. ' Positive cultures for herpes simplex virus offer the only absolute means
for confirmation of the diagnosis. 1
CONTRAINDICATIONS: ZOVIRAX Ointment 5% is contraindicated for patients who
develop hypersensitivity or chemical intolerance to any of the components of the
form ulation, such as polyethylene glycol.
WARNINGS: ZOVIRAX Ointment 5% is intended for topical use only and should not
be used in the eye or on mucous membranes.
PRECAUTIONS: The recommended dosage, frequency of application and duration of
treatm ent of ZOVIRAX Ointment 5% should not be exceeded (see DOSAGE AND
ADMINISTRATION).
It is not known whether acyclovir is excreted in human m ilk. Because many drugs
are excreted in human milk, caution should be exercised when ZOVIRAX is
administered to a nursing mother.
All animal studies carried out to date on reproduction and teratology have been
negative. However, since animal reproduction studies are not always predictive of
human response, ZOVIRAX Ointment 5% should be used during pregnancy only if the
physician feels the benefit w ill outweigh the possible harm to the fetus.
Safety of use of ZOVIRAX Ointment 5% in children has not been established.
There exist no data, at this time, which demonstrate that the use of ZOVIRAX
Ointment 5% will prevent transmission of infection to other persons.
Since most cutaneous herpes simplex virus infections result from reactivation of
latent virus, it is unlikely that ZOVIRAX Ointment 5% w ill prevent recurrence of
infections when applied in the absence of signs and symptoms. ZOVIRAX Ointment
5% should not be applied in an attem pt to prevent recurrences; application should
commence only at the earliest prodromal sign of disease onset.
Although clinically significant viral resistance associated with the use of ZOVIRAX
Ointment 5% has not been observed, this possibility exists.
ADVERSE REACTIONS: Because ulcerated genital lesions are characteristically
tender and sensitive to any contact or manipulation, patients may experience
discomfort upon application of ointment. In the controlled clinical trials, m ild pain
(including transient burning and stinging) was reported by 103 (28.3% ) of 364
patients treated with ZOVIRAX Ointment 5% and by 115 (31.1%) of 370 patients
treated with placebo; treatment was discontinued in 2 of these patients. Other local
reactions among acyclovir-treated patients included pruritus in 15(4.1% ), rash in 1
(0.3 % ) and vulvitis in 1 (0.3% ). Among the placebo-treated patients, pruritus was
reported by 17 (4.6% ) and rash by 1 (0.3% ).
In all studies, there was no significant difference between the drug and placebo
group in the rate or type of reported adverse reactions.
SYMPTOMS AND TREATMENT OF OVERDOSAGE: Overdosage by topical application
of ZOVIRAX Ointment 5% is unlikely because of lim ited transcutaneous absorption.
DOSAGE AND ADMINISTRATION: Apply ZOVIRAX Ointment 5% liberally to the
affected area 4 to 6 times daily for up to 10 days. A sufficien t quantity of ointment
should be applied to adequately cover all lesions. A finger cot or rubber glove should
be used while applying ZOVIRAX in order to prevent: (1) autoinoculation of other
body sites or (2) transmission of infection to other persons. Therapy should be
initiated as early as possible following onset of signs and symptoms.
AVAILABILITY: ZOVIRAX Ointment 5% is available in tubes of 15 g. Each gram
contains 50 mg acyclovir in a polyethylene glycol base. ZOVIRAX Ointment 5% is for
topical administration.
Product Monograph available on request.
REFERENCE: 1. Naib ZM, NahmiasAJ. Josey WE: Relation of cytohistopathology of
genital herpesvirus infection to cervical anaplasia. Cancer Res 33:1452 -63 , 1973.
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Effective Liver Blood Flow: Determination
by Galactose Clearance
Effective liver blood flow is the portion
of total flow that perfuses functional
sinusoids and is available for metabolic
exchange. Clearance of galactose from
blood at concentrations below 10 mg/dl
(0.555 mmol/l) measures this index and
is calculated during continuous infusion
of 5% D-galactose at a rate of 50
mg/min. The low galactose concentra
tions are measured accurately by a new
fluorometric assay, which gives a preci
sion ± 0 .2 mg/dl (0.011 mmol/l). In
healthy people, plasma galactose
clearance was 1366 ± 1 7 2 ml/min, and
hepatic extraction was 95% . Clearance
in cirrhotics depends on the stage of
their disease: in a stable group of pa
tients with advanced cirrhosis, clearance
was 835 ± 87 ml/min with hepatic ex
traction ranging from 60% to 95 % . The
day-to-day coefficient of variation was
4.5% . Direct comparison with flowprobe liver blood flow measured in 11
normal dogs showed that galactose
clearance was not significantly different.
These findings support the hypothesis
that galactose clearance correlates with
effective liver blood flow.
Le debit sanguin hepatique utile est la
partie du debit total qui perfuse les capillaires sinusoides fonctionnels et qui participe aux echanges metaboliques. La clairance du galactose a des concentrations
inferieures a 10 mg/dl (0.555 mmol/l)
permet de mesurer cet index. Elle est
calculee durant une perfusion continue
de D-galactose a 5% , a la vitesse de 50
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mg/min. Les faibles concentrations de
galactose sont mesurees avec exactitude
grace a une nouvelle methode de dosage
fiuorimetrique qui donne une precision de
± 0 .2 mg/dl (0.011 mmol/l). Chez des
sujets sains, la clairance du galactose
plasmatique etait de 1366 ± 1 7 2
ml/min, et I'extraction hepatique de
95% . Chez I'individu cirrhotique. la clai
rance depend du stade devolution de la
maladie: chez un groupe de patients sta
bles souffrant de cirrhose avancee, la
clairance etait de 835 ± 87 ml/min avec
une extraction hepatique variant entre
60% et 95% . Le coefficient de variation
quotidien etait de 4.5% . La comparaison
directe avec le debit sanguin hepatique
mesure par catheterisme chez 11 chiens
normaux, a montre que la clairance de
galactose n'gtait pas significativement
differente. Ces resultats corroborent
I'hypothese voulant que la clairance du
galactose soit en rapport avec le debit
sanguin hepatique utile.

Homer Smith and associates,1 in their
classic work on renal clearance in 1938,
defined effective renal blood flow as the
blood flow to active excretory tissue. Ef
fective flow can only be measured by a
clearance technique, and they showed that
the best substance (a) had to be that with
the highest possible clearance, (b) must
be used at sufficiently low blood concen
trations to be below the maximal removal
capacity of its pathway and (c) must not
be interfered with by other solutes. Of the
many substances tested, Hippuran was
found most suitable and has been widely
used to measure effective renal blood
flow.
Can the same principles be applied to
measure effective liver blood flow? There
are obvious differences between the liver
and kidney, such as the dual blood inflow
to the liver and the inability to collect test
substances cleared by the liver. However,
by the application of basic phar
macokinetics, blood clearance- can be
calculated for substances highly extracted
by the liver. Clearances will approximate
effective liver blood flow if two condi
tions are fulfilled. First, the test substance
must be totally cleared at each pass

through functioning liver tissue, and se
cond, it must be removed by the liver
alone. Effective liver blood flow is that
portion of total flow which is available
for metabolic exchange.
Galactose was chosen as a potential test
substance fulfilling these criteria because
previous work has shown that there is a
high clearance of the substance from the
liver, particularly at low blood con
centrations.2,3 This ability of the liver
to clear galactose from blood stems from
several facts: (a) galactose is actively
transported into the hepatocyte, (b) it has
its own metabolic pathway, converting it
to glucose, (c) it is water soluble and (d)
it has no protein-binding ability.
Clearance of galactose from blood can be
studied as both zero-order and first-order
kinetic phases. At blood concentrations
above 40 mg/dl (2.22 mmol/l) the
metabolic pathway is saturated and the
liver removes a maximum amount of
galactose, depending on the functional
hepatocyte mass. This observation has
been substantiated and used by many as
a true test of liver function.4,5 In con
trast, galactose clearance from blood at
concentrations below 40 mg/dl (2.22
mmol/l) shows an exponential decline,
the pathway is no longer sathrated and
the liver blood flow is rate-limiting in
clearance.
This paper reviews the development of
a method for measuring galactose
clearance at blood concentrations below
10 ml/dl (0.555 mmol/l). We present data
in support of our hypothesis that this
method fulfils the criteria of a test
substance suitable to measure effective
liver blood flow. The several stages of
development will be reviewed in turn,
with emphasis on methodology and
clinical relevance. The stages are: (a) a
new biochemical method with the re
quisite sensitivity for measuring galactose
clearance at blood concentrations below
10 mg/dl (0.555 mmol/l), (b) study of the
clearance kinetics of galactose in this con
centration range to determine if galactose
approaches the ideal test substance for
measuring effective liver blood flow and
(c) validation of galactose clearance
against flow-probe measurements in nor-
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mal dogs, conditions under which effec
tive flow should approximate anatomic
flow.
Assay of Low Galactose
Concentrations in Blood
The biochemical requirement to enable
calculation of clearance to within ±5%
was the ability to assay galactose in the
blood concentration range 0 to 10 mg/dl
(0 to 0.555 mmol/1) with an accuracy of
+ 0.2 m g/dl (0.011 mmol/1). This pro
jected requirement was calculated from
the pathophysiologic limitations of liver
blood flow. The details of the new
method have been published elsewhere,6
but we shall emphasize some salient
features.
Work on galactosemia showed the
feasibility of measuring relatively high
galactose concentrations in a drop (25 ^1)
of blood. The converse, however, prov
ed more difficult; at low galactose con
centrations, interfering compounds in
blood came into play. The main interfer
ing substances, uric acid and glutathione,
are coprecipitated with protein by
zinc/alkali in the initial assay step. The
clear filtrate so formed is then assayed for
galactose by a continuous flow method.
The primary reaction is the oxidation of
galactose by galactose oxidase, with
subsequent detection of hydrogen perox
ide by peroxidase and a fluorometric
substrate. Pretreatment of samples for
removal of interfering substances, use of
fluorometry and of p-hydroxphenylacetic
acid as the fluorometric substrate and op
timizing the concentration of galactose
oxidase were the main developmental im
provements in this assay. Its precision, in
20 samples assayed in duplicate at 1 ,4 ,
7 and 10 mg/dl (0.056, 0.222, 0.389 and
0.555 mmol/1), four times on each of 5
days, is shown in Table I. This represents
an accuracy of ± 0.2 mg/dl (0.011
mmol/1), which is in the necessary range
for the proposed clearance studies.
At these low concentrations certain
technical pitfalls can reduce this accuracy
and need to be avoided:
• Sample collection (3 ml) should be
into fluoride (Vacutainer tube M3273 PS;
Becton Dickinson Co., Rutherford, NJ)
and samples should be placed on ice.
Galactose is metabolized by erythrocytes
at an hourly rate of 1.4 mg/dl (0.078
mmol/1) at 37°C;7 this loss will substan
tially alter sample concentrations but is
abolished by using fluoride collection. In
terms of total blood clearance this
erythrocyte metabolism contributes only
2.3%.
• For sample storage, plasma must be
separated within 1 hour of collection and
stored at -2 0 ° C .
• Whole blood galactose concentra
tions can also be assayed. Pretreatment
of samples by zinc/alkali hemolyses the
erythrocytes and precipitates all interfer
130

ing compounds, rendering a clear filtrate
for analysis. For those samples stored as
plasma for subsequent analysis, the con
version of plasma to whole blood concen
tration was calculated by concomitant
assay in 10 samples, the conversion fac
tor being
j _ (0.5 x hematocrit)
100

• To ensure stability of galactose,
whole blood assay should be done on
fresh samples. The zinc/alkali filtrate
should be assayed within 3 hours. In
plasma stored at -2 0 °C no galactose is
lost at 2 months.
• Galactose oxidase of first-class purity
is required for the low galactose concen
trations under study. We have found
Worthington Chemical Co. (Freehold,
NJ) to be the most reliable supplier; five
other sources have been checked and the
only other supplier with sufficiently pure
enzyme was P .L . Biochemicals
(Milwaukee, Wise.). The fluorometric
substance p-hydroxphenylacetic acid is
less stable than the other reagents; stock
solution should not be carried for more
than 3 weeks.
In summary this new assay has the re
quisite sensitivity for calculating galactose
clearance in the 0 to 10 mg/dl (0 to 0.555
mmol/1) blood concentration range, but

attention to detail is required to maintain
this accuracy.
Clearance Kinetics of Galactose
at Concentrations below 10 mg/dl
(0.555 mmol/1)
This series quantitates the distribution
and elimination kinetics of galactose dur
ing continuous intravenous infusion of 20
to 100 mg/min of galactose. Continuous
infusion to steady state proved to be the
best method for clearance data analysis
in this concentration range. All the
clearance values in this series are plasma
values. The details are published
elsewhere.7
Distribution and Elimination
Fig. 1 illustrates the kinetics o f distribu
tion and elimination in a healthy cirrhotic
subject infused with 5% D-galactose at
50 m g /m in for 140 minutes and
monitored for 60 minutes thereafter.

In a series of five healthy subjects and
five cirrhotic patients thus studied, the
data were analysed by a curve-fitting pro
gram with the following results.
• The infusion and postinfusion
curves, computer-fitted to multicompartmental models, best fitted a single com
partment model.
• All subjects achieved 95% of steady
state by 60 to 80 minutes.

Table I-G alactose Assay. Precision and Reproducibility
Studies at Four Concentrations Measured Four Times in
Each Run on 5 Days
Expected concentrations, mg/dl
Precision/reproducibility
Overall mean (+ SEMI
Standard deviation
Sample to sam ple
W ithin run
Day to day

1

4

7

10

0.971+0.0661

3.97 (±0.060)

7.07 (±0.090)

9.85 1+0.0511

0.074
0.083
0.166

0.151
0.151
0.198

0.087
0.154
0.243

0.130
0.207
0.217

FIG. 1—Plasma galactose concentration versus time curve during infusion of 50 mg/min
of galactose for 140 minutes and for 60 minutes postinfusion, in healthy patient and cirrhotic
patient. Triangles (cirrhotic patient) and crosses (healthy patient) indicate measured values. Solid
line (cirrhotic) and broken line (healthy) indicate predicted values.
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• Clearance can be calculated from
either of the following equations: (a)
clearancess = infusion rate/(Css - C0)
or (b) clearanceAUC = total dose infused/AUC0.„, where Css = estimated
plasma steady state concentration, CQ =
plasma concentration at time zero (range
0.1 to 1.9 mg/dl [0.006 to 0.105 mmol/1])
and AUC0_„ = area under plasma con
centration versus time curve from zero
time to infinity.
The mean ( ± SD) clearances^ for the
healthy subjects (1366 ± 172 ml/min)
and cirrhotics (835 ± 87 ml/min) were
not significantly different from the mean
clearancesA(JC (1396 ± 481 and 824 ±
140 ml/min respectively).
In all further studies clearance was
calculated from equation a. Estimated
plasma steady state concentration was at
tained more rapidly by a priming bolus
injection of 500 mg galactose at zero time
and was defined from five blood samples
drawn from 60 to 100 minutes.
Galactose Infusion at Two Rates
In five normal subjects, infused at rates
of 50 and 100 mg/min, and nine cir
rhotics, infused at 25 and 50 mg/min, we
tested the hypothesis that clearance is a
first-order kinetic reaction and is indepen
dent of hepatic extraction. For this to be
true, doubling the infusion rate should
double Css - C0, or clearance should be
unchanged. The ideal was approached in
all subjects: the ratio of clearance2 to
clearance! was 0.919 ± 0.088; this
equates to a mean 8.1% reduction in
clearance at twice the infusion rate.
Several f ctors, such as change in
baseline, extrahepatic removal and
decreased hepatic extraction, may con
tribute to this.7
Hepatic Extraction
Extraction across functioning liver

tissue needs to be calculated to validate
the fact that clearance measures effective
flow; this extraction cannot be measured.
But how much total hepatic extraction is
achieved at these low galactose
concentrations?
In two healthy subjects hepatic extrac
tions were 93% and 95%. In nine patients
with cirrhosis extraction ranged from
60% to 95% (mean 79%). These data are
important in showing that galactose is
highly extracted, even by the cirrhotic
liver, and support the concept that from
60% to 95% of flow in the cirrhotics was
effective flow.
Day-to-Day Reproducibility
For any test to be of value in follow
ing the progression of disease or the
follow-up of patients, it must be
reproducible. Assessment of this variable
in 11 subjects, studied twice within 1 week
under identical conditions, showed that
the coefficient of variation was 4.5%.
Extrahepatic Clearance
The ideal test substance for measuring
effective liver blood flow must be cleared
by the liver alone. We have already shown
that 2.3% of galactose clearance at these
blood concentrations can, at least in
theory, be metabolized by erythrocytes.
Renal galactose clearance, calculated in
six subjects with a timed urine collection
during galactose infusion at plasma
steady state, amounted to 2% of total
clearance. Galactose is a ubiquitous com
pound; cell-wall synthesis requires galac
tose and the body continually turns over
a small background pool. It is possible
there are other extraheptic clearance
routes; however, the available data sug
gest that by far the greatest clearance is
by the liver.
Conclusions
These kinetic studies on the clearance
of galactose at concentrations of 0 to 10
mg/dl (0 to 0.555 mmol/1) show that it
approaches the ideal test substance for
measuring effective liver blood flow: (a)
it is kinetically simple to analyse at steady
state during continuous infusion, (b) it is
avidly removed by the liver, with minimal
extrahepatic clearance and (c) there is in
direct evidence supporting virtually com
plete extraction by functional liver tissue
on each pass.

400 r

Galactose Clearance and Flow-Probe
Measurement of Liver Blood Flow
in Healthy Dogs

150

Flow probe

Galactose clearance

FIG. 2—Galactose clearance and flow-probe
measurement of liver blood flow in 11 healthy
dogs. Analysis of variance shows no significant
difference between these two methods.

One of the steps in validating any new
method must be direct comparison with
the accepted standard. There is no ac
cepted standard for measuring effective
liver blood flow, but assuming that effec

tive flow will approximate total flow in
the normal liver, we made this com
parison in normal dogs using in
traoperative flow-probe measurement for
anatomic flow.
Eleven conditioned dogs, with a mean
(± SD) weight of 10.2 ± 0.79 kg were
studied by the two methods concurrent
ly. Galactose clearance was measured
during continuous infusion of 10 mg/min
of 5% galactose. Plasma steady state was
defined over 50 minutes when the dog was
hemodynamically stable. This was cor
rected to blood Css as previously defin
ed and clearance calculated from equa
tion a. Flow-probe measurement of
anatomic liver blood flow was made by
surgical dissection and isolation of the
hepatic artery and portal vein. Flow pro
bes were placed around each vessel and,
with the dog stabilized, two recordings
were made during definition of the galac
tose steady state. Two measurements were
compared by analysis of variance (Fig. 2).
The mean galactose clearance intraoperatively (279 ± 64 ml/min) was not
significantly different from the mean
flow-probe measurement (304 ± 44
ml/min). The coefficient of variation be
tween the two methods was 12.5%.8
The flow-probe method is the most ac
curate one available for measuring liver
blood flow, but is is not clinically ap
plicable. These data support the
hypothesis that galactose clearance
measures effective liver blood flow,
which, in this particular model, approx
imates anatomic flow.
Comment

Normal liver function depends on
hepatocellular integrity and adequate liver
perfusion. Quantitative measurement of
both these indices gives a better profile
of how the liver is responding to a disease
process than do standard liver function
tests, such as measurement of serum
bilirubin, glutamic oxaloacetic trans
aminase and albumin levels and the pro
thrombin time. Galactose clearance, as
presented in this paper, quantitates the
flow component of function.
The removal of substances from blood
by hepatic clearance is influenced by three
factors: the intrinsic elimination capaci
ty (hepatocyte function), hepatic extrac
tion and liver blood flow. Galactose
clearance, in the blood concentration
range 0 to 10 mg/dl (0 to 0.555 mmol/1),
measures clearance at infusion rates one
fifth to one tenth of intrinsic elimination
capacity, is virtually independent of
hepatic extraction and is thus a flowdependent clearance.
The liver has a myriad of metabolic
pathways; to develop a full functional
profile, other pathways that determine
hepatocellular integrity as well as liver
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perfusion must be studied in a similar understanding and quantitation of disease
manner. Hepatocyte function can be states will be achieved.
assessed quantitatively by measuring the
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Predicting Outcome
after Endorectal Ileoanal Anastomosis
The aim of this study was to determine
whether anorectal manometry could
predict clinical outcome after closure of
a diverting ileostomy made at the time of
colectomy, mucosal proctectomy and en
dorectal ileoanal anastomosis for chronic
ulcerative colitis. Tw enty-tw o patients
were studied, 6 with ileoanal
anastomosis and 16 with ileal pouchanal anastomosis. Resting anal sphincter
pressures and pressure-volume curves
(compliance) of the neorectum were
assessed before the diverting ileostomy
was closed and results were correlated
with frequency and leakage of stools 1
month after closure. Before stomal
closure, the mean ( ± standard error of
the mean) resting sphincteric pressure
was 44 ± 5 cm H 20 , while neorectal
compliance was 2.3 ± 0.3 ml/cm H20.
One month later daily stool frequency
was 12 ± 1, while severe leakage oc
curred in four patients during the day
and in eight at night. The greater the
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sphincteric pressure and the compliance,
the fewer were the number of stools per
day (p < 0 .0 1 ). When pressure and
compliance were considered together as
an index of anorectal function, the cor
relation of stool frequency and leakage
was even stronger (p < 0.001). The
authors conclude that anorectal
manometry can predict early clinical out
come after ileoanal anastomosis.
Le but de cette etude etait de determiner
si la manometrie ano-rectale pouvait predire les resultats cliniques apres fermeture d'une iteostomie de derivation pratiquee au moment d'une colectomie,
d'une protectomie de la muqueuse et
d'une anastomose ileo-anale endorectale
pour colite ulcereuse chronique. Vingtdeux patients ont ete etudies, 6 porteurs
d'une anastomose ildo-anale et 16 d'une
anastomose entre le diverticule ileal et
I'anus. Les pressions du sphinctere anal
au repos et les courbes de pressionsvolumes (compliance) du neorectum ont
et§ mesurees avant la fermeture de
I'ileostomie de derivation et les resultats
ont ete relies a la frequence et a la fuite
des selles 1 mois apres la fermeture.
Avant fermeture de I'abouchement, la
pression sphincterienne moyenne au
repos ( ± I'erreur type) etait de 44 ± 5
cm H20, alors que la compliance neorectale etait de 2.3 ± 0.3 ml/cm H20 . Un
mois plus tard, la frequence quotidienne
des selles etait de 12 ± 1, alors qu'une
fuite importante est survenue chez quatre patients durant le jour et chez huit
patients durant la nuit. Plus grandes
etaient la pression sphincterienne et la

compliance, moins nombreuses etaient
les selles quotidiennes (p < 0.01).
Quand la pression et la compliance ont
ete pris ensemble comme indice de la
fonction ano-rectale, une correlation
encore plus forte avec la frequence des
selles et les fuites a ete observee (p <
0.001). Les auteurs concluent que la
manometrie ano-rectale peut predire le
resultat clinique immediat apres anasto
mose ileo-anale.

Colectomy, mucosal proctectomy and en
dorectal ileoanal anastomosis is an attrac
tive alternative to proctocolectomy and
conventional or continent ileostomy for
patients with ulcerative colitis or familial
polyposis.1-4 The operation avoids a per
manent stoma and preserves the transanal
flow of feces. Most patients do well after
closure of the temporary, diverting il
eostomy, done at the initial operation to
facilitate healing o f the ileoanal
anastomosis; some, however, experience
severe diarrhea and leakage of stools,
especially during the first few months
after operation. A means of iden
tifying those patients likely to have a poor
clinical result could alter the manage
ment. We wondered if manometrie
measurements of anal sphincteric pressure
and neorectal compliance before closure
of the ileostomy could predict the clinical
outcome after closure.
Patients and Methods
Twenty-two patients, 11 women and 11
men whose mean age (± standard error)
was 31 ± 2 years (range from 16 to 48
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years), constituted the study population.
In six, the distal cut end of the ileum had
been sutured directly to the dentate line
after the colectomy and mucosal proctec
tomy, while in the other 16 patients a “ Jshaped” pouch,2 constructed from the
distal 25 to 30 cm of ileum, had been so
sutured. All patients had a temporary,
diverting ileostomy.

the mean maximal resting anal sphincter ficient. Resting pressure and neorectal
pressure was calculated.
compliance were also considered together,
Compliance o f neorectum.—To meas by computing a single variable, log (R x
ure compliance of the distal bowel, a soft, Co). Logarithmic transformation was
latex balloon (10 x 5 cm) attached to a used to reduce the influence of the large
polyethylene tube (outer diameter 0.3 cm, values generated by the product R x Co.
inner diameter 0.25 cm) was filled with One-way analysis of variance was used to
water and inserted transanally into the compare the index, log (R x Co), among
distal bowel 10 cm above the anasto three groups of subjects defined by severi
mosis. With the balloon in position, the ty of leakage. Two-group comparisons
tube was attached to a Statham pressure were based on the independent sample tAnorectal Manometry
transducer, which was, in turn, connected test.
Anal sphincter pressure.— Resting in to the Brush chart recorder. The balloon
traluminal pressure at the anal sphincter was inflated serially with 10-ml incre
was measured using a polyglass probe ments of water at 4-minute intervals. Results
(diameter 1.2 cm) through which four Measurements were terminated when 200
channels were perfused with water at 0.1 ml had been instilled or when the patient Anorectal Manometry
ml/min by means of a low compliance, complained of persistent discomfort. The
Resting sphincter pressure.—The mean
pneumohydraulic system. Pressures ap balloon was withdrawn, and its response
plied to the lateral openings of the chan to similar distension was measured in a maximal intraluminal pressure ( ± SEM)
nels, which ended 90° apart and 1 cm water bath at 37°C. The in-vitro calibra in the distal 2 cm of the anal canal at rest
from the tip of the probe, were transmit tion curve was subtracted from that ob was 44 ± 5 cm H20 (range from 10 to
ted to water-filled strain gauges (Statham tained from the distal bowel to determine 99 cm H20). Resting pressure among pa
PDS; Statham Instruments, Oxnard, the in-vivo response. A pressure-volume tients with direct ileoanal anastomosis
Calif.) and recorded on a Brush 260 chart curve was plotted and the compliance of (40 ± 10 cm H20 ) did not differ from
recorder (Gould Instrument, Cleveland, the distal bowel calculated as the that in patients with ileal pouch-anal
anastomosis (45 ± 6 cm H20 , p >
Ohio). Manometric measurements were reciprocal of the slope of the curve.
Index o f anorectal function.—The pro 0.05). Women had a lower resting
performed as previously described.4 The
duct of anal sphincter resting pressure (R) pressure (34 ± 5 cm H20 ) than men (55
results were expressed in cm H20 .
± 7 cm H20 , p = 0.02).
Because of individual variation in the and neorectal compliance (Co) was also
Compliance o f neorectum.—The
length of the sphincteric segment and calculated as an index of anorectal func
overall neorectal compliance was 2.3 ±
scarring of the anastomosis in some pa tion (log [R x Co]).
Clinical correlation.—Clinical outcome 0.3 ml/cm H20 (range from 0.6 to 4.8
tients, a mean of eight pressure
measurements was obtained in the distal after endorectal ileoanal anastomosis was ml/cm H20). The 16 patients with an il
2 cm of the anal canal in each subject and assessed 1 month after closure of the eal pouch anastomosis had a larger com
diverting loop ileostomy from informa pliance (2.7 ± 0.3 ml/cm H20 ) than the
30
tion obtained by letter or telephone, or 6 with direct ileoanal anastomosis (1.3 ±
both. Patients were asked to report the 0.4 ml/cm H20 , p = 0.03).
j=
25
number of bowel movements every 24
'T
(NJ
hours and to quantify leakage of stool Clinical Results
$ 20
during day and night (0 = none, 1 =
o
minimal, 2 = severe). Leakage that was
3
15
One month after re-establishment of in
if)
easy to manage and that did not cause testinal continuity, the patients had
o
10
discomfort to the patient was classified
12 ± 1 stools/d (range from 4 to 25) with
o
as minimal.
9 ± 1 bowel movements (range from 3
Z
5
to 16) during the day and 3 ± 1 (range
Statistical Analysis
0
from 0 to 10) at night. Severe leakage of
0
20
40
60
80
100
stools occurred more often at night, in
Resting pressure, cm H^O
The association between resting
eight patients, than during the day, in
pressure, compliance and stool frequen four patients.
FIG. 1—Scattergram of stool frequency
cy was assessed using the correlation coefversus resting anal sphincteric pressure after
ileoanal anastomosis, r = 0.5, p < 0.01.
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FIG. 2—Scattergram of stool frequency ver
sus neorectal compliance after ileoanal
anastomosis, r = 0.6, p < 0.003.

FIG. 3—Scattergram of stool frequency ver
sus log (R x Co) after ilioanal anastomosis,
r = 0.8, p < 0.001. R = resting anal sphinc
ter pressure, Co = neorectal compliance.

Anal sphincter resting pressure and
neorectal compliance correlated inverse
ly with stool frequency (p < 0.01); that
is, the greater the resting pressure and the
the neorectal compliance, the fewer the
number of stools per 24 hours (Figs. 1 and
2). Moreover, when resting pressure and
neorectal compliance were considered
together as an index, an even better cor
relation was found (Fig. 3). The greater
the index, the fewer were the number of
stools per 24 hours (p < 0.001).The cor
relation was stronger for patients with
straight ileoanal anastomosis (r = 0.9)
than for patients with ileal pouch-anal
anastomosis (r = 0.7). Among 12 patients
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with an index (log [R x Co]) of 2 or less,
the number of stools per 24 hours was 15
± 2. In contrast, the remaining 10 pa
tients with an index greater than 2 had on
ly 8 ± 1 stools/d. The index in 11 patients
who never leaked stools during the day
was greater (2.1 ± 0.07) than the index
in 4 patients who leaked frequently (1.2
± 0.05, Fig. 4). Similarly, the index in
five patients who never leaked at night
(2.2 ± 0.1) was greater than that of eight
patients who had severe nocturnal leakage
(1.7 ± 0.2). Using analysis of variance,
we noted significant differences for log
(R x Co) between groups defined by
severity of leakage (none, minimal,
severe) during the day (p = 0.004) but not
at night (p = 0.088).
Discussion

Our results support the hypothesis that
anorectal manometry can predict early
clinical outcome after endorectal ileoanal
anastomosis. Indeed, anal sphincter
resting pressure and neorectal compliance
measured before closure of the diverting
ileostomy correlated significantly with the
frequency of evacuation and leakage of
stools 1 month after closure. Our
measurements identified patients who ex
perienced a poor initial clinical result. The
knowledge could influence the timing of
closure of the temporary ileostomy in the
future. These results are in agreement
with those of Nicholls and colleagues,3
who showed that leakage of mucus occur
red more frequently in patients with a low
anal sphincter resting pressure.
Impairment of the reservoir function of
the distal bowel is a major factor con
tributing to incontinence. Several in
vestigators have observed that a small,
fibrotic rectum that is undistensible is
associated with poor continence.5,6 Pa
tients in whom pelvic sepsis develops after
ileoanal anastomosis may have fibrotic
changes around the neorectum, impaired
compliance and poor continence. Ileorectal anastomosis performed for familial
polyposis in patients with a healthy rec
tum is expected to preserve rectal com
pliance; in fact, excellent continence
results.7 Pemberton and associates8 have
demonstrated in dogs that the terminal il-

eum subjected to chronic intermittent
obstruction can progressively dilate, in
crease its compliance and become an ef
fective storage segment for stool. Patients
in our series with ileal pouch-anal
anastomosis had better compliance than
those with straight ileoanal anastomosis,
and had fewer stools daily.
None the less, other factors are also in
volved in fecal continence. For example,
Schraut and Block9 showed that reduc
ing propulsive peristalsis within an un
distended distal enteric reservoir cut back
the stool frequency. They further stress
ed the necessity for a reservoir that does
maintain some propulsive peristalsis. Pro
pulsive peristalsis obviates incomplete
evacuation, obstipation and the need for
pouch intubation.
Some aspects of our methodology
deserve comment. At the time of our
tests, the anal sphincters and the distal
bowel had been defunctionalized for 2
months. This may explain, at least in part,
the small resting anal sphincter pressure
observed. In a previous study, anal
sphincter pressure after ileonal
anastomosis was similar to that in healthy
volunteers, when the patients were tested
at least 4 months after restoration of in
testinal continuity.4 A fter ileoanal
anastomosis, the anal sphincter may even
compensate by increasing its resting
pressure to combat leakage, at least dur
ing the day.
We acknowledge the statistical help of Alan
R . Zinsmeister, Ph D .
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High Intermuscular Anal Abscess and Fistula:
Analysis of 25 Cases
Although the majority of anal abscesses
and fistulas are of the simple or low
variety (intersphincteric or transsphinc
teric in Parks' classification), some of the
simple, but high intermuscular, type are
not recognized clinically and are not pro
perly treated because they do not pre
sent the usual visible signs.
Characteristically, there is no external
swelling, induration or opening and there
is high extension with a palpable mass or
induration above the levator ani.
Out of 350 patients with anal
abscesses and fistulas treated by the
first author. 25 (7 % ) patients had a high
intermuscular abscess. Of these 25, 14
(5 6 % ) had a history of anal problems.
Eight of these 14 had undergone anorec
tal surgery previously, and in 3 laparo
tomy was added, 2 being left with a
diverting colostomy. On the other hand,
11 (4 4 % ) patients had no previous anal
manifestation and 9 of them presented
with an acute abscess. All patients had a
palpable mass or induration above the
levator ani and in all but one a primary
opening was found on the dentate line.
Fistulotomy was done in 22 of the 25
cases and incision and drainage into the
anorectum in the other 3.

Bien que la majorite des abces et fistules
anaux soient du type simple ou bas
(intersphincterien ou trans-sphincterien
dans la classification de Parks), certains
de type simple mais intermusculaire
haut, ne sont pas reconnus ci I'examen
et ne regoivent pas le traitement qui
s'impose parce qu'ils ne presentent pas
les signes habituels. De facon caracteristique, il n'y a pas d'inflammation
externe, d'induration ou d'orifice, et il
existe une extension haute avec masse
palpable ou induration au-dessus du
muscle releveur de I'anus.
Sur 350 patients porteurs d’abces et
de fistules anaux traites par le premier
auteur, 25 (7 % ) avaient un abces
intermusculaire haut. De ces 25,
14 (5 6 % ) avaient des antecedents de
problemes anaux. Huit des 14 avaient
subi dans le passe une chirurgie anorectale et pour trois s'etait rajoutee une
laparatomie, 2 d'entre eux recevant une
colostomie de derivation. D'autre part.

11 patients (4 4 % ) n'avaient eu au prea
mble aucun symptome anal; 9 d'entreeux presentment un abc&s aigu.
Tous avaient une masse palpable ou une
induration au-dessus du releveur de
I'anus et chez tous sauf un, on trouva un
orifice primaire sur la ligne ano-cutanee.
Une fistulotomie fut pratiquee dans 22
des 25 cas et chez les 3 autres, on
proceda par incision et drainage dans
I'ano-rectum.
Les auteurs concluent que pour poser
rapidement le diagnostic et mettre en
route le traitement approprie, le chirurgien doit etre aux aguets, avoir une
connaissance parfaite de I'anatomie
chirurgicale des abc&s et fistules anaux,
et prendre les mesures suivantes: a)
rechercher un orifice primaire au niveau
de la ligne ano-rectale, b) faire passer
une canule dans cette ouverture jusqu'a
la cavite ou I'induration, et c) diviser le
muscle circulaire et le sphincter interne
jusqu'a ce que la partie superieure de
I'orifice soit atteint.

The authors conclude that for prompt
diagnosis and proper treatment the
surgeon should be highly suspicious of
the condition, have a perfect knowledge
of the surgical anatomy of anal
abscesses and fistulas and follow three
steps: (a) look for a primary opening at
the dentate line, (b) pass a cannula from
this opening into the cavity or induration
and (c) divide the circular muscle and in
ternal sphincter until the upper end of
the tract is reached.
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FIG. I—Parks’ classification of fistula-in-ano. A = intersphincteric fistula (low), B =
intersphincteric fistula (high, intermuscular), C = transsphincteric fistula, D = suprasphincteric (left) and extrasphincteric fistula (right).
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An anatomical classification of fistula-inano was proposed by Parks and col
leagues in 1976,1based on the relation of
the fistulous tract to the different muscles
and muscle planes of the anorectal region
(Figs. 1 to 4).
Although this classification appears
simple and helps us to understand the
pathogenesis of fistula-in-ano, the
surgical treatment of some of these
fistulas is still difficult. The simple or low
intersphincteric fistula is usually easy to
manage but the other types present several
pitfalls either in identification of the tract
or in the extension of the surgical pro
cedure. The suprasphincteric and extrasphincteric types (Fig. ID) cannot be
treated by division of the fistulous tract
because incontinence will follow. In deal
ing with a transsphincteric fistula (Fig.
1C) the surgeon will often hesitate to
divide the tract because he is uncertain
about its height in relation to the puborectalis muscle. Finally, some types of high

FIG. 2—High intermuscular fistula with
high blind tract or abscess.

intersphincteric fistula are not recogniz
ed or treated as such for various reasons.
• They are infrequent; until recently
they were considered to be submucosal.
• They do not present the common
clinical signs of abscess and fistula: a
tender and red swelling or induration, or
an external opening to the perianal area.
• The main finding is a mass or indura
tion in the rectal wall above the anorec
tal ring; this leads the clinician to suspect
an abscess in the supralevator space or a
supra- or extrasphincteric type of fistula.
Bearing these considerations in mind,
we report our experience with 25 cases of
high intermuscular (intersphincteric)
abscess and fistula-in-ano to describe the
various modes of presentation at the time
of diagnosis and to emphasize the impor
tance of precise identification of the con
dition, which will persist or recur when
improperly treated.
Patients

Between Mar. 1, 1969 and Feb. 28,
1982, 350 cases of anal abscess and fistula
were treated by one of us (D.B.). Twentyfive (7.1 %) were classified as having high
intermuscular abscess and fistula because
there was no external or cutaneous open
ing, a mass or induration was palpable
above the anorectal junction, a primary
opening was found at the level of the den
tate line and a fistulous tract extended
from the primary opening to the palpable
mass or induration above the anorectal
junction (Fig. 2). Included are two pa
tients who presented an external opening
in addition to the other characteristics.

Table 1—Clinical Signs in 25 Cases of High
Intermuscular Abscess and Fistula
No. of
Sign
patients (%)
R ectal m a ss o r in d u ra tio n a b o ve
th e a n o re cta l rin g
P rim a ry o p ening a t th e d e n ta te line
S e c o n d a ry o p ening in th e re c tu m

2 5 (1001
2 4 1901
9 1301

N o se c o n d a ry re cta l op ening

FIG. 3 .—High intersphincteric (inter
muscular) fistula. Complete fistula with
secondary rectal opening.

FIG. 4—High intermuscular abscess with
perianal extension.

(abscess c a v ity o r high b lin d tra c t
S e c o n d a ry s k in opening
P erianal e xte n sio n o f th e a b sce ss

10 IB4I
3 (121
3 1121

FIG. 5 — High intersphincteric (inter
muscular) fistula with secondary skin opening.

There were 15 men and 10 women,
ranging in age from 25 to 74 years (mean
38 years). Eleven of the 25 patients were
seen during their first episode, 9 with an
acute abscess.The other 14 had a previous
history of anal problems, only 3 present
ing with an acute condition. Eight pa
tients had undergone anorectal surgery
previously, three of whom had ex
ploratory laparotomy, two being left with
a diverting colostomy. The clinical signs
are summarized in Table I. On rectal ex
amination, we could palpate a mass or in
duration above the levator ani muscle
plane in all patients, and in 24 we found
a primary opening at the dentate line at
the time of operation.
The fistula was located in the posterior
quadrants in 17 cases, the right posterior
in 9, left posterior in 6, both right and left
posterior in 1 and posterior midline in 1.
In the remaining eight patients, the fistula
was located anteriorly. There was a com
plete fistula with a rectal opening (Fig. 3)
in nine patients, an abscess cavity or a
high blind tract (Fig. 2) in nine, perianal
extension of a high abscess (Fig. 4) in five
and a secondary opening at the level of
the skin (Fig. 5) in three. Two of these
three had a low intersphincteric and one
a transsphincteric fistula.

Surgical Treatment and Results

Division of the fistulous tract
(fistulotomy) was accomplished in 22 pa
tients. The proximal part only of the in
ternal sphincter and circular muscle of the
rectum was divided in 14. No fistula
recurred but in one patient a typical anal
fissure developed and was managed by
division of the lower half of the internal
sphincter 6 months later. Six were treated
by division of the whole length of the in
ternal sphincter and of the circular
muscularis of the rectum without recur
rence. Distal internal sphincterotomy only
was done in two patients; one had a recur
rent abscess 10 months later. This abscess
was successfully managed by dividing the
proximal part of the fistulous tract. Final
ly, three patients underwent internal
drainage of an abscess cavity into the rec
tum. In the first patient the primary open
ing was not identified. He had a recur
rent abscess, and proximal fistulotomy
was performed 3 years later. The second
patient presented with an abscess in the
rectovaginal septum. She was known to
have Crohn’s disease of the ileum and
duodenum, although her rectum ap
peared normal. The recurrent abscess that
developed after 6 months was successfully
treated by division of the whole length of
the internal sphincter. A third patient was
also treated by internal drainage only but
the follow-up period is too short to deter
mine the possibility of recurrence.
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Discussion
High intermuscular abscess was first
described by Eisenhammer in 1953.2 For
the first time he stressed the importance
of the internal anal sphincter in the
pathogenesis and treatment of anal
abscesses. He also noted the inter
muscular (i.e., between the circular and
longitudinal muscularis propria of the
rectum or between the internal and exter
nal anal sphincters) nature of these
abscesses that were, until then, considered
to be submucosal. Finally, he establish
ed that this form of abscess could be
cured by division of the internal sphinc
ter and circular muscle of the rectum. In
19543 he insisted that anal abscess and
fistula were different stages of the same
condition and that they could be treated
by the same surgical procedure, even
simultaneously. He called them fistulous
abscesses. Others4’7 later wrote that
primary fistulotomy at the time of divi
sion and drainage of the abscess was both
feasible and even advantageous. In our
experience (unpublished data) we were
able to find a primary opening and carry
out immediate fistulotomy in 75% of all
anal abscesses.
P ark s8 in 1961 showed that anal
glands penetrated through the internal
sphincter into the intersphincteric plane
in 50% of histologic sections of the anal
canal. He postulated the cryptoglandular
origin o f anal abscesses. The classifica
tion o f Parks and associates1 sum
marized all the previous concepts as well
as their own clinical and surgical ex
perience into a single anatomical concept
that has contributed greatly to our
understanding and management of these
fistulas. In spite of this knowledge,
abscesses and fistulas-in-ano sometimes
still present difficulties for the surgeon
confronted with an atypical type such as
the high intermuscular variety. This is il
lustrated by our series in which 32% of
patients had previously undergone anal
surgery and 12% a laparotomy. The dif
ficulty in establishing the exact nature of
the problem is illustrated by the fact that
only 50% of referred cases were thought
to be anal abscess or fistula by the pa
tient’s physician (Table II). It is also inter
esting that out of the 12 referred pa
tients, 3 had a tentative diagnosis of rec
tal tum our and in 2 the diagnosis was
fever o f unknown origin. Three main
reasons explain the misdiagnoses and the
treatment failures:
1. High intermuscular abscess or fis
tula, or both, is relatively uncommon.
The rate varies from 5% to 15% in large
series (Table III1-4-6’7).
2. The common signs of anal abscess
and fistula, a tender, red swelling at the
anal margin and pus coming out of a
perianal skin opening, are absent. These
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signs may exist with a high intermuscular and internal sphincter only. Bleeding is
lesion but they represent extension of the brisk and of arteriolar origin so the use
fistula in the distal portion of the in of an electrosurgical knife and forceps is
tersphincteric plane. Only three of our pa strongly recommended. When there is an
tients had a perianal skin opening and five abscess, evacuation of pus is aided by
had a perianal abscess as external digital exploration of the cavity. For a
manifestations of that perianal extension. chronic fistula, curettage of the granula
Clinical manifestations of a high inter tion tissue is done and healing by second
muscular abscess or fistula, or both, have intention follows. Incision of the whole
been well described by Eisenhammer.9 length of the internal sphincter including
They include a palpable, tender, fluctuant its lower half remains controversial.
swelling located in the rectal wall above Parks and associates1 did not recom
the levator ani muscle plane. When seen mend it unless there was a low in
in the chronic phase the swelling is re tersphincteric extension of the tract, with
placed by an indurated fibrotic area that or without a skin opening. The whole
may partially or almost totally surround length of the sphincter was divided in six
the rectum above the anorectal junction. of our patients because of a distal or
These signs were found in all our patients. perianal extension of the abscess in three
Furthermore, at operation, careful ins and for a low intersphincteric tract in the
pection reveals the primary opening in the other three, two of whom also had a
anal canal at its expected location on the secondary skin opening. Goldberg and
dentate line. Eisenhammer4 even stated colleagues10 recommended that the
that the primary opening is never found whole internal sphincter be divided in
every case of high intermuscular fistula.
anywhere else.
3.
Surgery may be inadequate or insufIncontinence is uncommon because the
ficient, as when the abscess only is drain internal sphincter is the only muscle that
ed or fistulotomy is incomplete. In many is incised and the voluntary muscles of
centres surgical treatm ent of anal continence remain intact.
abscesses is commonly scheduled at the
end of the operating day and left to the Conclusions
most junior of the resident staff with lit
Although rare, the existence of high in
tle or no supervision. Very often some
form of drainage is done in the emergen termuscular anal abscesses and fistulas is
cy d ep artm en t with inadequate well established. Both the abscess and the
anesthesia, a so-called “ office pro fistula represent different stages of the
cedure” . Even under optimal conditions, same condition. Physical signs are always
when a surgeon discovers a mass or a present and should be sought thoroughly.
fibrotic scar that extends above the Diagnosis and treatment of high inter
anorectal junction, he may imagine a muscular abscess and fistula require that
complicated type of fistula that extends the surgeon (a) be highly suspicious of the
above the sphincters and beyond his com possibility of this condition especially in
petence, he may be hesitant, even afraid, a patient with severe anal pain and no
to do more than a simple drainage pro clinical signs, (b) have a perfect working
cedure. Two of our three patients had knowledge of the anatomy of anal abscess
and fistula and (c) look for a primary
recurrence after drainage alone.
opening at the dentate line, gently thread
Proper surgical treatment of high in a probe into that opening in a proximal
termuscular abscess or fistula, or both, direction towards the palpable induration
is simple and is associated with few if any or mass and incise the whole length of the
complications. Division of the tract along tract.
its whole length requires incision of the
To these ends, we recommend that all
mucosa, submucosa, circular muscularis
patients with suspected anal abscess be
Table II—Clinical Diagnosis in Patients
with High Intermuscular Abscess and Fistula
No. of
patients
Diagnosis
Patients initially seen by
the authors In = 131
Anal abscess
Anal fistula
Severe pain (cause unknownl
Referred patients In - 121
Recurrent abscess
Recurrent fistula
Rectal mass (probably tumourl
Fever of unknown origin
Crohn's disease of rectum

9
2
2
3
3
3
2
1

Table III-R a te of High Intermuscular Abscess
and Fistula in Urge Series
Author
Year Total
No.
%
Eisenhammer4 1966
500*
NS
8.0
McElwain and
associates6 1975
1000*
151
15.1
Parks and
associates1 1976
49
400t
12.2
Hanley7
1978
840t
NS
5.0
Present series 1982
350*
25
7.1
NS - not stated.
‘ Abscess only.
tFistula only.
*Abscess and fistula.
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carefully examined under general or
regional anesthesia with the right in
struments available for proper and im
mediate fistulotomy.
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Effect of Repeated Delayed Hypersensitivity
Skin Tests on Skin-Test Responses
To determine whether repeated skin
tests can augment a previously weak
delayed hypersensitivity response or con
vert previously nonreacting tests and
thus yield false-positive data, the authors
carried out retrospective analysis of 426
skin tests on 107 patients who had a
mean of 4.3 weekly tests with five recall
antigens. They also skin tested 10
healthy volunteers weekly for up to 6
weeks. Reactions (induration measured
in millimetres) were recorded and a
regression and correlation analysis was
carried out. Analysis of variance was us
ed to compare reaction means of
volunteers for each recall antigen at each
time interval. All volunteers were reac
tive to two or more antigens.
In the volunteer group there was no
augmentation of initially reactive antigen
responses except for Varidase and only
after 5 weeks. Of 16 initially negative
responses to some antigens in this same
group, only 3 were converted to reac
tions of more than 5 mm, all responses
being to purified protein derivative. No
conversion occurred in the hospitalized
patients. There was no significant cor
relation between repeated skin tests and

From the departments o f surgery and
microbiology, Royal Victoria Hospital and
McGill University, Montreal, PQ
Presented at the 5th annual meeting o f the
Canadian Association o f General Surgeons,
Quebec City, PQ, Sept. 14, 1982
Supported in part by the Medical Research
Council o f Canada grant no. MT-5642
Accepted fo r publication Oct. 5, 1982
Reprint requests to: Dr. N. V. Christou,
Rm. S10.30, Department o f surgery, Royal
Victoria Hospital, 687 Pine Ave. W, Mont
real, PQ H3A 1A1

the delayed hypersensitivity response to
the antigens except for Candida in the
retrospective patient group, up to 160
days from the original skin test. The data
indicate that there is no augmentation of
the delayed hypersensitivity response or
conversion of initial nonreacting skin
tests with any of the antigens tested ex
cept Candida.
Dans le but d'etablir si la repetition des
tests cutanes pouvait augmenter une
reaction d'hypersensibilite retardee
prealablement faible ou transformer un
test negatif, et donner de la sorte des
resultats faussement positifs, les auteurs
ont analyse de maniere retrospective
426 tests cutanes pratiques chez 107
patients qui avaient subi en moyenne 4.3
tests hebdomadaires a I'aide de cinq an
tigenes de rappel. Ils ont aussi fait des
tests cutanes hebdomadaires chez 10
volontaires sains pour des periodes allant
jusqu'a 6 semaines. Les reactions (Tinduration mesuree en millimetres) ont ete
enregistrees et soumises a des analyses
de regression et de correlation. Une
analyse de variance a ete employee pour
comparer les moyennes des reactions
des sujets volontaires a chacun des an
tigenes de rappel, a chaque periode.
Tous les volontaires reagissaient a deux
antigenes ou plus.
Dans le groupe de volontaires, on n'a
assiste a aucune augmentation des
reponses antigeniques initialement
positives, sauf pour Tantigene Varidase
et seulement apres 5 semaines. Dans ce
meme groupe, des 16 reactions initiale
ment negatives a certains antigenes,
seulement 3 se sont transformees en
reactions de plus de 5 mm, toutes a la
tuberculine purifiee. Aucune conversion
n'est survenue chez les patients
hospitalises. II n'y avait aucune correla

tion significative entre la repetition des
tests cutanes et la reaction d'hypersen
sibilite retardee aux antigenes, sauf pour
Candida, jusqu'a 160 jours apres le test
cutane initial, dans le groupe de patients
etudies en retrospective. Ces resultats
indiquent qu'il n'y a pas d'augmentation
de la reaction d'hypersensibilite retardee
ou de transformation des tests cutanes
negatifs a chacun des antigenes, sauf
pour Candida.

Failure of the delayed hypersensitivity
skin-test response to recall antigens, or
anergy, can identify surgical patients who
are at increased risk of death from
sepsis.1,2 The sequential delayed
hypersensitivity skin-test response can be
used to monitor a patient’s course in
hospital,3 provided the skin tests do not
augment a previously weak response, or
cause conversion of previously nonreactive responses. We report here on a
retrospective and a prospective study,
both of which show that there is no
significant augmentation of the delayed
hypersensitivity response or conversion of
initially nonreacting skin tests with five
recall antigens.
Patients and Methods

Both studies were approved by the
ethics committee on human experimenta
tion of the Royal Victoria Hospital in
Montreal. The method of skin testing was
the same for both studies. Injections were
made intradermally in the upper arm.
Five recall antigens were used, 0.1 ml per
injection: Candida, 1:100 dilution (Hollister-Stier Laboratories, Mississauga,
Ont.); undiluted mumps skin-test antigen
(Eli Lilly Co., Indianapolis, Ind.);
purified protein derivative (PPD), 5 TU
(Connaught Laboratories, Willowdale,
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Ont.); Trichophyton and Varidase, 100
units/ml (Hollister-Stier Laboratories).
The resulting induration was recorded in
millimetres at 24 and 48 hours. The mean
of the two greatest diameters was obtain
ed. All readings were carried out by a
nurse experienced in skin testing.
Study 1
A retrospective analysis was made of
107 patients (60 men, 47 women), admit
ted to the surgical wards and the inten
sive care unit of the Royal Victoria
Hospital. A mean of 4.3 weekly tests per
patient were performed, giving a total of
426 sequential tests. The longest follow
up was 22 weeks. The mean age of the pa
tients was 58 ± 8 years. A regression and
correlation analysis was carried out using
the time of skin test as a dependent
variable and the mean diameter of indura
tion as the independent variable.
Study 2
A prospective assessment was made of
six weekly skin tests on 10 healthy male
volunteers ranging in age from 26 to 54

years. The mean weekly induration for
each antigen was evaluated and analysis
of variance was used to assess statistical
significance of differences from the
reading of week 1.
Results

Study 1
The 107 patients included those
responding to two or more antigens (reac
tive), one antigen (relatively anergic) or
none of the antigens (anergic). The only
antigen showing a weakly significant cor
relation between diameter of induration

and time was Candida (R2 = 0.31, p <
0.05) (Figs. 1 to 5). None of the other four
antigens (mumps, PPD, Trichophyton
and Varidase) showed an increase in the
diameter of induration with time. Of all
the reactive patients skin tested at least
four times, none showed subsequent reac
tivity to antigens to which they were in
itially nonreactive.
Study 2
All the volunteers were reactive. Two
reacted to all five antigens, two reacted
to four, five to three and one reacted to

Table 1-M ean Diameter of Induration (± Standard Error) of Skin-Test Antigens
_______________ in 10 Volunteers Tested Weekly for 6 Weeks
Week
Antigen

1

Candida

8.2 + 1.1
10.8 + 0.7
2.7 + 1.8
2.4 + 1.0
18.9 + 2.4

Mumps
Purified protein
derivative
Trichophyton

Varidase

2

3

4

9.7 + 1.0
9.9 + 0.5

8.2 + 0.7
10.4 + 0.5

8.6 + 0.6
10.8 + 1.1

8.7 + 1.0
9.1 + 1.0

10.3 + 1.0
12.1 + 1.0

4.9 + 2.8
3.7 + 1.7
20.8 + 2.3

4.5 + 2.4
5.0 + 1.4
20.0 + 2.1

6.0 + 2.4
5.0 + 1.5
21.0 + 2.3

6.0 -f 2.5
4.4 + 1.4
26.0 + 2.9

6.5 + 2.5
4.0 + 1.4
31.0 + 3.5*

5

6

*p < 0.05 by analysis of variance and r-test distribution.

FIG. 1—Retrospective study. Diameter of induration with time for
Candida (X = 3.1 + 0.6Y, R2 = 0.31, p < 0.05).

FIG. 2—Retrospective study. Diameter of induration with time for
mumps (X = 6.53 + 0.02Y, R2 = 0.06).

FIG. 3—Retrospective study. Diameter of induration with time for
FIG. 4—Retrospective study. Diameter of induration with time for
purified protein derivative (PPD) (X = 0.59 + 0.12Y, R2 = 0.04). Trichophyton (X = 2.8 + 0.01Y, R2 = 0.06).
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two antigens. Conversion to reactivity
was defined as taking place if three con
secutive responses with no induration
were followed by one or more positive
responses with induration greater than 5
mm. Three such conversions took place,
all to PPD. One occurred after 3 weeks,

one after 5 weeks and one at the end of
6 weeks. Of the five antigens, only
Varidase showed a significant (p < 0.05)
increase in the diameter of induration
with time, and only after 6 weeks (Table
I). One volunteer was tested 10 times over
a period of 6 years with the same re

sponses. Application of regression and
correlation analysis to the mean weekly
diameters of induration confirmed that
Varidase was the only antigen to show a
weak positive correlation (X = 30.4 +
2.1Y, R2 = 0.44, p < 0.05) (Figs. 6 to
10) .
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FIG. 5—Retrospective study. Diameter of induration with lime for
Varidase (X = 12.7 + 0.001Y, R2 = 0.03).

FIG. 6—Prospective study. Diameter of induration with time for Can
dida (X = 8.1 + 0.24Y, R2 = 0.14).

F,G J-Prospective study. Diameter of induration with time for
mumps (X = 10.3 + 0.17Y, R2 = 0.11).

FIG. 8-Prospective study. Diameter of induration with time for PPD
(X = 2.4 + 0.75Y, R2 = 0.18).

F*G' ^ Prospective study. Diameter of induration with time for
Trichophyton (X = 3.1 + 0.27Y, R2 = 0.11).

FIG. 10—Prospective study. Diameter of induration with time for
Varidase (X = 30.4 + 2.1Y, R2 = 0.44, p < 0.05).
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Discussion
Sequential, delayed hypersensitivity
skin testing can be used to monitor the
clinical course of a patient after opera
tion. However, if the response is
augmented by sequential testing, an in
crease in the diameter of induration may
not reflect improvement in clinical course.
There are other causes of false results
such as faulty technique in administering
the antigen, careless measurement of the
reaction and misinterpretation of results,
all of which can be corrected with
rigorous control. The possibility of a
booster effect with repeated testing,
analogous to the anamnestic response in
serology, however, cannot be controlled.
Data in this area are available only for
PPD . Tuberculin sensitivity wanes in
some individuals.4 Ferebee and Mount5
presented some evidence of a booster ef-

feet with PPD, using two skin tests ad
ministered 1 year apart. Recently
Keystone and associates,6 using five an
tigens administered twice, 6 weeks apart,
showed some mild booster effect with
Candida and Varidase, in agreement with
our data.
The slight augmentation in the delayed
hypersensitivity response seen in this
study is not significant enough to interfere
with the usefulness of repeated tests to
monitor the patient’s clinical course. The
retrospective study showed that only Can
dida had a weak booster effect, whereas
Varidase was the only antigen showing a
weak booster effect in the prospective
study and then only after the sixth week
ly test. This situation is encountered in
frequently in the usual clinical course of
a patient after operation. Based on the
results of this study, we believe that se
quential delayed hypersensitivity skin

testing can be used to monitor the clinical
course of surgical patients and false
positive reactions due to a booster effect
of repeated testing will be minimal.
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Prostaglandin Cytoprotection and Lysosomal Stability
in Acute Canine Gastric Erosions
Prostaglandin cytoprotection may be
related to lysosomal stability. In six
mongrel dogs, bacterial peritonitis was
created by the intraperitoneal instillation
of Bacteroides fragiiis, Pseudomonas
aeruginosa. Streptococcus faecalis and
Klebsiella pneumoniae in addition to
canine gallbladder bile. In three dogs,
gallbladder bile alone was instilled. Three
of the six dogs with bacterial peritonitis
also received 16,16-dimethyl prostaglan
din E2 (PGE2) (0.2 ftg/kg intramuscularly
q6h) 24 hours before and for 3 days
after the induction of peritonitis. In the
dogs with bacterial peritonitis not receiv
ing PGE2, gastroscopic examination
demonstrated acute fundic erosions.
None of the other dogs developed acute
gastric erosions. In the dogs with
bacterial peritonitis not receiving PGE2,
fundic mucosal biopsy specimens
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demonstrated decreased lysosomal
stability. In the dogs receiving PGE2,
lysosomal stability was similar to that in
the animals with bile peritonitis.
These experiments demonstrate that
PGE2 prevents the development of acute
gastric erosions by stabilizing lysosomal
membranes.
La cytoprotection exercee par les prostaglandines est possiblement reliee a la
stabilite lysosomiale. Chez six chiens
batards, une peritonite bacterienne a ete
provoquee par I'instillation de Bacteroi
des fragilis, de Pseudomonas aeruginosa,
de Streptococcus faecalis et de Klebsiella
pneumoniae ajoutee a de la bile vesiculaire de chien. Chez trois chiens, seule la
bile a ete instillee. Trois des six chiens
atteints de peritonite bacterienne ont
aussi recu de la 16,16-dimethyl prostaglandine E2 (PGE2) (0.2 fig/kg par voie
intramusculaire aux 6 heures) 24 heures
avant et durant 3 jours apres I'induction
de la peritonite. Chez les chiens en peri
tonite bacterienne qui n'avaient pas recu
de PGE2, I'examen gastroscopique a
demontre des erosions fundiques aigues.
Aucun des autres chiens n'a developpe
d'erosions gastriques aigues. Chez les
chiens en peritonite bacterienne qui
n'avaient pas regu de PGE2, la biopsie de
la muqueuse fundique a demontre une
diminution de la stabilite lysosomiale.
Chez les chiens qui avaient regu de la
PGE2, la stabilite lysosomiale etait sem-

blable a celle des animaux qui avaient
une peritonite biliaire.
Ces experiences demontrent que la
PGE2 previent I'apparition des erosions
gastriques aigues en stabilisant les mem
branes lysosomiales.

The development of acute gastric erosions
can be prevented by the administration of
16,16-dimethyl prostaglandin E2 (PGE2).
Its mechanism of action is not acid reduc
tion but a phenomenon known as
cytoprotection, which has been attributed
to the increased secretion of mucus or
bicarbonate, to alterations in mucosal
blood flow and to increased production
of cyclic AMP.
We studied the possible relation of pro
staglandin cytoprotection to alterations in
lysosomal enzyme release and lysosomal
stability.
Material and Methods
Nine, male, mongrel dogs, weighing
between 20 and 25 kg, were deprived of
food for 18 hours. They were then
anesthetized and underwent gastroscopic
examination. Multiple biopsy specimens
of fundic mucosa were obtained. In three
animals bile peritonitis was induced by in
stilling 0.4 ml/kg of canine gallbladder
bile into the peritoneal cavity through a
small infraumbilical incision. In the other
six dogs bacterial peritonitis was induced
by instilling an 18-hour broth culture of
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Bacteroides fra g ilis (0.4 m l/k g ),
Pseudomonas aeruginosa (0.04 ml/kg),
Streptococcus faecalis (0.04 ml/kg) and
Klebsiella pneumoniae (0.04 ml/kg) with
canine gallbladder bile (0.4 ml/kg) into
the peritoneal cavity. Three of the six
dogs also received PGE2 (0.2 jtg/kg in
tramuscularly q 6h ) beginning 24 hours
before the induction of peritonitis and
continuing for 3 days after. Gastroscopy
was repeated 24 and 48 hours after induc
tion of either bile or bacterial peritonitis
and biopsy specimens of fundic mucosa
were obtained. Rectal temperatures were
recorded and blood cultures were obtain
ed at 4, 24, and 48 hours after induction
of bile or bacterial peritonitis. On the
third day, the animals were killed and the
gastric mucosa was examined grossly for
the presence of mucosal erosions.
Fundic mucosal biopsy specimens were
washed in sterile ice-cold sodium chloride
and then hom ogenized in citrate
phosphate buffered bovine serum
albumin and centrifuged at 800 g for 5
minutes. The resulting pellet was discard
ed and the supernatant was centrifuged
at 60 000 g for 60 minutes. The pellet was

then suspended in 1 ml citrate phosphate
bovine serum albumin and freeze-thawing
was applied to the solution 10 times. The
solution was centrifuged at 17 000 g for
20 minutes. The supernatant and pellet
were
each
assayed
fo r
/3-Nacetylhexosaminidase activity.1 Percent
stability was calculated as follows:
% lysosomal _
stability
—

EAP
x too,
EAS + EAP

where EAP is the enzyme activity of the
pellet and EAS is the enzyme activity of
the supernatant.
Statistical analysis of the findings was
by the unpaired f-test.
Results
All six dogs with bacterial peritonitis
had positive blood cultures 4 hours after
instillation of bacteria (Table I). The ad
ministration of PGE2 did not alter the
bacteremic profile. None of the dogs with
bile p eritonitis had bacterem ia.
Gastroscopic and autopsy findings in
dogs with bacterial peritonitis are depicted
in Table II. All three dogs with bacterial

Table 1-Results of Blood Culture in Six Dogs with Bacterial Peritonitis
Time after instillation of
bacteria and prostaglandin
Time after instillation of
E2 (n = 3), h
bacteria (n = 3), h
4
24
48
4
24
48
Bacteria
1
2
1
2
1
1
Bacteroide fragilis
2
1
1
1
1
Pseudomonas aeruginosa
1
Streptococcus faecalis
1
1
1
1
1
Klebsiella pneumoniae

Table ll-Gastroscopic and Autopsy Findings in
Dogs with Bacterial Peritonitis
Gastroscopy
Experimental group

Day 1

Bacteria
Dog 1
2
3
Bacteria plus PGE,
Dog 1
2
3

Day 2

+++

++

++

++

+++

+

Autopsy
Day 3
+
+

+

-

-

-

-

-

- = norm al mucosa, + = m ucosal petechiae, + + = m ultiple non-bleeding erosions, + + + = m ultiple bleeding
erosions.

Table Ill-Lysosomal Stability’ t
Group

1

Bile
Bacteria
Bacteria

38.3 + 9.5
19.2 + 3 .6 *
44.3 + 7.0

+

PGE2

'F ig ure s are mean percentages
standard error o f mean.
(P ercent stability preperitonitis - 42.6 + 6.6.
* p < 0.05, a significant decrease from control group.

Postperitonitis day
2
40.6 + 8.6
26.4 + 10.4
41.6 + 7.4

3
39.8 + 6.4
34.6 + 8.4
43.6 + 4.8

peritonitis not receiving PGE2 had acute
fundic gastric erosions on the first day.
These quickly resolved so that at autop
sy (day 3) only two dogs had minimal
petechiae. Of the other three dogs, receiv
ing PGE2, only one had several petechiae
in the fundus. Bacterial peritonitis
resulted in a significant (p < 0.05)
decrease in gastric mucosal lysosomal
stability on day 1 (Table III). Administra
tion of PGE2 prevented this decrease in
lysosomal stability, but bile did not alter
it.
Discussion
Three experiments demonstrate that in
a canine, septic m odel, b acterial
peritonitis leads to acute erosions in the
fundus of the stomach. Associated with
the appearance of gastric mucosal
damage is the development of lysosomal
instability. The pathophysiology of acute
gastric erosions is unclear. Richardson
and associates,2 Sethbhakdi and asso
ciates3 and Ozdemir and Zimmermann4
have all demonstrated that alterations in
mucosal blood flow and ischemia underlie
the development of acute gastric erosions.
Menguy5 showed that alterations in
mucus secretion lead to gastric mucosal
damage.
The relation between lysosomes and
tissue damage has been extensively in
vestigated. Lysosomal enzymes are acid
hydrolases confined within the lysosome.
Disruption of the lysosomal membrane
with release of the enzymes leads to tissue
damage in the pancreas,6 liver7 and
myocardium.8 Lysosomal enzymes can
also cause acute gastric erosions.9' 11 In
this study we have demonstrated that
sepsis-induced acute gastric erosions are
associated with decreased lysosomal
stability. The mechanism for the sepsisinduced lysosomal instability can be ex
plained by the demonstration that en
dotoxins that cause acute gastric
erosions12 disrupt lysosom al m em 
branes.13
That prostaglandin E2 prevents acute
gastric erosions by mechanisms other than
acid reduction has been rep o rted
previously.1415 Possible mechanisms are
stimulation of active sodium transport,16
increased secretion of bicarbonate17 and
of gastric mucus glycoprotein.18 P ro 
staglandins also stabilize lysosomal
membranes19 by increasing lysosomal
membrane cyclic A M P.20
References
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Because “biphasic infection”
threatens to complicate surgery
of the large bowel...

control sepsis with
an antibiotic to arrest primary
gram-negative aerobic infection
in combination with
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to treat or prevent
secondary abscess formation
Rupture of the large bowel can result in contami
nation of surrounding tissues with gram-negative
pathogens initiating primary aerobic infection. While
the primary infection often responds to a gram-negative
antibiotic, e.g. gentamicin, secondary anaerobic
invaders may persist and produce abscess formation.
This“biphasic infection” process increases morbidity
and delays recovery.
Dalacin C Phosphate IV during and following surgery to
control anaerobes such as Bacteroides fragilis, along with
appropriate antibiotic therapy to control gram-negative
aerobic pathogens, can prevent abscess formation,
reduce morbidity and speed recovery.
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Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also
by causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infec
tions where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species and microaerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci)
when the patient is intolerant of, or the organism resistant to other appropriate antibiotics.
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in
patients previously found to be hypersensitive to this compound, the parent compound, clinda
mycin, or clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydro
chloride) has not been demonstrated, it is recommended that Dalacin C Phosphate not be used in
patients who have demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn
(infants below 30 days of age), or in pregnant women.
Warnings: Some cases of severe and persistent diarrhea have been reported during or after therapy
w ith Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated
w ith blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has
been performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary, con
tinued only with close observation. Significant diarrhea occurring up to several weeks post-therapy
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes
may respond to simple drug discontinuance. Moderate to severe cases, including those showing
ulceration or pseudomembrane formation, should be managed with fluid, electrolyte, and protein
supplementation as indicated. Corticoid retention enemas and systemic corticoids may be of help in
persistent cases. Anticholinergics and antiperistaltic agents may worsen the condition. Other
causes of colitis should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a princi
pal cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco
mycin were administered orally four times a day for 5 -1 0 or more days, there was a rapid observed
disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
It should be noted that serious relapses have occurred up to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Precautions: DalacinC Phosphate (clindamycin phosphate), like any drug, should be prescribed
w ith caution in atopic individuals.
Dalacin C Phosphate must bedilutedforintravenousadministration. (See Dosageand Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms-particularly
yeasts. Should superinfections occur, appropriate measures should be taken as dictated by the clin
ical situation.
As w ith all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy.
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic
liver function tests should be performed during prolonged therapy. Blood counts should also be
monitored during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in
patients with impaired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are
not effective means of removing the compound from the blood. Periodic serum levels should be
determined in patients with severe hepatic and renal insufficiency.
Adverse Reactions: Local.
(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin
phosphate) intramuscularly (with a solution containing 150 m g/m l), six (1.5% ) demonstrated local
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at the
injection site and two developed sterile abscesses.
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous
infusion, 14 (7.3% ) demonstrated local reactions. Eleven patients developed superficial thrombo
phlebitis and one patient developed both superficial and deep thrombophlebitis. The majority of
these cases developed in conjunction with the use of indwelling I.V. catheters and it is difficult to
know how much the drug contributed to the irritation. Two patients developed localized erythema,
swelling and pain at the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as
follows:
Number of Patients
Rash ........................................................................................................................................................... 7
U rticaria....................................................................................................................................................... 1
P ru ritu s .......................................................................................................................................................1
Fever, Leucocytosis...................................................................................................................................1
Nausea, with or without vo m itin g .............................................................................................................1
Diarrhea (See also under “ Warnings” ) ....................................................................................................4
Hypotension................................................................................................................................................1
Hypertension..............................................................................................................................................1
Shortness of B re a th ...................................................................................................................................1
S uperinfection*.........................................................................................................................................4
Cardiac a rre s t**......................................................................................................................................... 1
Bad or bitter taste in m outh........................................................................................................................5
*Superinfection is a complication of antibiotic therapy in general and is not necessarily a true side effect
of clindamycin phosphate.
*Due to underlying myocarditis in this patient.
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Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hema
tology, urinalysis and liver and kidney function tests. Some of these tests were abnormal initially and
returned to normal during therapy with Dalacin C Phosphate, while others were normal initially and
became abnormal during therapy. Overall evaluation of clinical laboratory values in these patients
does not indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or
renal systems. Transient elevations of serum transaminases have occurred in some patients, but
other liver function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to
increase and there have not been clinical signs of drug-induced hepatic toxicity.
Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No specific
antidote is known. Doses as high as 1200 mg every six hours (4800 m g/day) by infusion for five
days have been given without adverse effects.
DOSAGE AND ADMINISTRATION
Adults
Intramuscular Injection: 600 m g/day in 2 equal doses.
Moderately severe infections: 600 to 1200 m g/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 m g/day in 2, 3 or 4 equal doses. Intramuscular injections of more
than 600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to
I.V. administration to a dilution of 300 mg in 50 ml of diluent (6 m g/m l) or more, and infused in not
less than 10 minutes. Administration of more than 1200 mg in a single 1 hour infusion is not recom
mended. Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, each
infused over 20 minutes or longer.
Severe infections: 1800 to 2700 m g/day by continuous drip or in 3 or 4 equal doses, each infused
over 20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by con
tinuous drip or in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and infusion rates:
Dose

Diluent

300 mg
600 mg
900 mg
1200 mg

50 ml
100 ml
150 ml
200 ml

Time
10 min.
20 min.
30 min.
45 min.

Alternatively, drug may be administered in the form of a single rapid infusion of the first <
lowed by continuous I.V. infusion as follows:
To maintain serum
Rapid
Maintenance
clindamycin levels
infusion rate
infusion rate
Above 4 mcg/ml
10 m g/m in. for 30 min.
0.75 mg/min.
Above 5 mcg/ml
15 m g/m in. for 30 min.
1.00 mg/min.
Above 6 mcg/ml
20 m g/m in. for 30 min.
1.25 mg/min.
Children: (Over one month of age)
Intramuscular injection: 10 to 15 m g/kg/day in 2. 3 or 4 equal doses.
Moderately severe infections: 15 to 20 m g/kg /d a y in 3 or 4 equal doses.
Severe infections: 20 to 30 m g/kg /d a y in 3 or 4 equal doses.
Intravenous Administration:
Moderately severe infections: 15 to 25 m g/kg /d a y by continuous drip or in 3 or 4 equal doses, each
infused over 20 minutes or longer. In severe infections, it is recommended that children be given no
less than 300 mg/day regardless of body weight. (Dilute Dalacin C Phosphate Sterile Solution in the
same manner as for adults.)
Dilution and Compatibility:
4 ml (600 mg) Dalacin C Phosphate when diluted with 1000 ml of the following commonly used
infusion solutions was found to be physically compatible and demonstrated no significant change in
pH or antimicrobial potency over a period of 24 hours:
Sodium chloride injection
Dextrose 5% in water
Dextrose 5% in saline
Dextrose 5% in Ringer's Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride
Dextrose 21/2% in Lactated Ringer's Solution (Hartmann's Solution).
Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it
is not recommended that Dalacin C Phosphate be mixed with any infusion solution containing B
vitamins.
Supplied:
Dalacin C Phosphate contains the following per ml of sterile solution:
Clindamycin phosphate equivalent to clindamycin base 150 mg
Benzyl alcohol 5 mg
Disodium edetate 0.5 mg
Water for injection q.s.
When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid to maintain a
pH range of 5.5 to 7.0.
Dalacin C Phosphate is available in 2 ml and 4 ml ampoules.
NOTE: Do not store below 15°C.
Product Monograph available upon request,
PRODUCT OF

826

ce

1377.1c

R E G IS TE R E D T R A D E M A R K : D A L A C IN .

T R A D E M A R K : D A L A C IN C

MEMBen

U p jo h n
ANTIBIOTIC
RESEARCH

THE UPJOHN COMPANY OF CANADA
865 YORK MILLS ROAD/DON MILLS, ONTARIO

P AA B
CCPP

VOLUME 26, NO. 2, MARCH 1983 / THE CANADIAN JOURNAL OF SURGERY

CANADIAN CARDIOVASCULAR SOCIETY
G erard M. G u ir a u d o n , m d , frcs [C], f a c c ;* G eorge J. K l e in , m d , fr c pic j , FACC;t
D ouglas J o n es , ph D;t C ha rles R. Ke r r , m d , FRCP[C]f

Surgical Treatment of
W olff-Parkinson-W hite Syndrome
The Wolff-Parkinson-White syndrome
may be associated with life-threatening
or disabling tachyarrhythmia, owing to
the presence of an atrioventricular ac
cessory pathway (Kent bundle). The first
division of a Kent bundle was reported in
1969, but this surgery is still confined to
a few centres.
Between September 1981 and October
1982, 19 patients (13 men, 6 women)
aged 16 to 46 years (mean 25 years)
with the Wolff-Parkinson-White syn
drome associated with refractory ar
rhythmia underwent surgery. Kent
bundles were localized in the elec
trophysiology laboratory and by in
traoperative cardiac mapping. The 19 pa
tients had a total of 22 distinct Kent
bundles.
The bundles were divided using openheart (13 patients) or closed-heart (6 pa
tients) technique. All Kent bundles were
confirmed as nonfunctioning before
discharge. A delta wave recurred in two
patients. The Kent bundle was not func
tional in one patient. The other is con
trolled by a drug that was previously in
effective. There were no complications
or deaths.
Kent bundles can be divided with
minimal morbidity and a high success
rate (more than 90% ). Surgery is in
dicated in patients with refractory ar
rhythmias or in young patients who
would be required to take medication for
life.
Le syndrome de Wolff-Parkinson-White
peut etre complique de troubles du
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rythme severes. Les arythmies sont dues
a la presence d'une voie auriculoventriculaire accessoire (faisceau de
Kent). La premiere section d'un faisceau
de Kent date de 1969, mais cette chirurgie est confinee a quelques centres.
Entre septembre 1981 et octobre
1982, 19 patients (13 hommes, 6 fem
mes), ages de 16 a 46 ans (moyenne 25
ans), presentant un syndrome de W o lffParkinson-White complique d'arythmies
furent operes. Le siege du faisceau de
Kent a ete determine par les exploita
tions electro-physiologiques preoperatoires et la cartographie per-operatoire —
22 faisceaux de Kent ont ete identifies.
La technique classique a coeur ouvert
(13 patients) ou la plus recente techni
que a coeur ferme (6 patients) ont ete
utilisees. Tous les faisceaux de Kent
etaient fonctionnellement interrompus a
la sortie de I’hopital. La conduction est
reapparue chez deux patients. Un est
"asymptomatique", I'autre est controle
par une drogue prdcedemment inefficace.
II n'y eut ni deces, ni complication.
Le faisceau de Kent peut etre sectionne avec une morbidity minime, et un
taux eleve de succes (plus de 90% ). La
chirurgie est indiquee quand les
arythmies sont resistantes, ou quand un
traitement k vie est envisage chez un
jeune patient.

The Wolff-Parkinson-White syndrome,
characterized by paroxysmal tachycardia
associated with an electrocardiographic
pattern of a short P-R interval and a wide
QRS complex initiated by a slurred
upstroke,1 is due to an accessory
atrioventricular pathway, analogous to
that described by Kent.2 The Kent bun
dle is an atrioventricular tract made of
working myocardium, stretching across
the atrioventricular sulcus and carrying
impulses that bypass the normal atrioven
tricular node-His bundle system. The
Kent bundle is distinct from atrio-Hisian
tracts3 or Mahaim fibres that connect the
atrioventricular node or His bundle
directly to ventricular muscle.4
The arrhythmias encountered in

Wolff-Parkinson-White syndrome in
clude supraventricular re-entrant
tachycardia and atrial flutter or fibrilla
tion. The re-entrant circuit sustaining the
tachycardia includes the atria, the normal
conduction system, the ventricles and the
abnormal atrioventricular accessory
pathway or Kent bundle. During atrial
flutter or fibrillation the ventricular rate
will depend on the functional anterograde
conduction of the Kent bundle. A
pathway capable of sustaining rapid con
duction may drive the ventricles at high
rates which may degenerate into ven
tricular fibrillation. Surgical ablation of
the Kent bundle will cure both ar
rhythmias. The first successful division of
the Kent bundle was performed in 1969
by Sealy and associates.5 Since then, the
surgical technique has improved and ac
cessory pathways in any location can be
removed with excellent results.6-8
Surgery is indicated in patients with
disabling, supraventricular re-entrant
tachycardia that is refractory to drugs or
with life-threatening atrial flutter. The
criteria for “ refractory” vary in each in
stitution and factors such as the age of
the patient, disability resulting from the
arrhythmias and drug compliance must be
weighed against the surgical success rate.
In this report, we describe our experience
with 19 patients operated on between
September 1981 and October 1982 for
surgical correction of the W olffParkinson-White syndrome.
Patients and Methods

Of the 19 patients, 13 were male and
6 were female. They ranged in age from
16 to 46 years (mean 25 years). The age
at onset of the first symptom varied from
4 to 30 years (mean 15 years). All patients
but one had palpitations, four patients
had syncope, six required cardioversion,
four were short of breath during the at
tacks of arrhythmia and two patients had
associated cardiomyopathy.
All patients underwent extensive electrophysiologic studies before operation to
determine the functional properties of the
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normal atrioventricular conduction sys
tem and the accessory Kent bundle(s), to
reproduce the arrhythmias clinically, in
duce “ potential” arrhythmias and deter
mine their mechanisms, and to assess the
role o f the Kent bundle(s). Electrophysiologic testing utilizes endocardial
recording and pacing techniques with
electrode catheters generally inserted into
the right atrium, right ventricle and cor
onary sinus (left atrium). The common
“ p itfa lls ” in perform ing these
preoperative studies are overlooking
multiple Kent bundles and failing to
recognize dysrhythmias not involving the
Kent bundle.
The indications for surgery in our pa
tients are summarized in Table I.
Intraoperative Evaluation
Electrophysiologic testing is necessary
during the operation to verify and refine
the localization of the Kent bundle by car
diac mapping and to verify ablation of the
Kent bundle. Epicardial mapping is more
detailed in the region of the atrioven
tricular groove as this is the area of the
Kent bundle insertion. Ventricular map
ping during sinus rhythm locates the ven
tricular insertion of the Kent bundle, the
site of earliest ventricular electrical activi
ty preceding the onset of QRS on surface
leads. The atrial insertion is located by
retro g ra d e atrial m apping during
supraventricular re-entrant tachycardia.
If this cannot be induced, retrograde
atrial mapping can be carried out during
ventricular pacing but is less accurate
because of retrograde conduction over
both the accessory pathways and the nor
mal atrioventricular conduction system.
Kent bundles bridge the atrioven
tricular anulus anywhere except in the
region of the subaortic curtain,9,10 where
there is no direct continuity between
atrium and ventricle. The atrioventricular
anulus can be conveniently classified in
to four regions: the left and right free
walls and the posterior and anterior sep
tal areas. The surgical technique is
modified, depending on which of these
regions contains the accessory pathway.
Of the 22 Kent bundles present in these
19 patients, 1 bundle was located in the
right free wall, 16 in the left free wall, 3
in the posterior septal area and 2 in the
anterior septal area.

Surgical Technique
Division of the Kent bundle can be car
ried out using either an open-heart or
closed-heart technique. We used the openheart technique in 13 patients and the
closed-heart technique in 6.
Open-Heart Technique
For this technique cardiopulmonary
bypass and cross-clamping of the aorta
associated with cold cardioplegia are
necessary. The area adjacent to the anulus
is approached through the atrial endocar
dium (Fig. 1).
The free-wall Kent bundle.—The ap
proach to this bundle is through a right
or left atriotomy similar to that for mitral
or tricuspid valve surgery. An endocar
dial transmural atrial incision is made at
the atrial insertion of the Kent bundle as
close as possible to the atrioventricular
anulus. There is no reason to leave a cuff
of atrium at that point. The atrioven
tricular pad is approached through that
incision. The ventricular and atrial walls
of the atrioventricular sulcus are dissected
and freed of all attachments. The cor
onary artery and coronary vein or the cor
onary sinus are avoided. The epicardium
is allowed to remain intact. The atrial wall
is then reattached to the atrioventricular
anulus using running sutures.
The posterior septal Kent bundle.—
This bundle is approached through a right
atrial incision. The region is exposed
through an endocardial right atrial inci
sion along the septal leaflet of the
tricuspid valve and the inferior com
missure, extending to the inferior leaflet.
The four walls of the “ pyramidal”
posterior septal region (the posterior
superior process of the left ventricle, right
atrial septal wall, left atrium and right
ventricular wall) are then dissected and
freed from the atrioventricular pad. The
right coronary artery and its branches are
avoided. The coronary sinus is carefully

controlled and freed of all attachments.
The dissection can be extended to left or
right, depending on the point of insertion
of the Kent bundle. The atrioventricular
node and His bundle lie on the central
fibrous body and the membranous sep
tum, which are avoided. Mapping of the
His bundle potential can verify the loca
tion of this structure.
The anterior septal Kent bundle. —This
is exposed through a right atrial incision
anterior to the membranous septum along
the tricuspid anulus, opposite the anterior
commissure and leaflet. The walls of that
region are dissected in the same way as
for the posterior bundle. The right cor
onary artery, which travels through the
area, is avoided.
Closed-Heart Technique
We recently developed a closed-heart
technique to avoid cardiopulmonary
bypass and cross-clamping the aorta.
The atrioventricular pad and its
vascular contents are mobilized from the
atrioventricular sulcus. The atrial side of
the sulcus is freed of all attachments as
is the ventricular side adjacent to the
anulus. The region adjacent to the anulus
is fragile and not dissected. Cryoablation
of this region and the adjacent atrial and
ventricular walls is then carried out
(Fig. 1).11
Results of Operation
All patients tolerated the procedure
well. There were no complications. Twen
ty Kent bundles were divided and 2 were
modified.
There was always a good correlation
between the location of the Kent bundle
by preoperative and intraoperative
testing. Three patients had two Kent
bundles, in one a second left lateral bun
dle was found intraoperatively, adjacent
to the one indicated preoperatively. In
one patient, the Kent bundle insertion was

Table 1 - Indications far Surgery
Indication

No. of
patients

R e f r a c t o r y s u p r a v e n t r ic u la r
r e - e n t r a n t ta c h y c a r d ia

19

A t r ia l f ib r illa tio n

8

D r u g s id e - e f f e c t

1

L a c k o f c o m p lia n c e

1
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FIG. 1—Schematic drawings showing region of atrioventricular junction and surgical ra
tionale for ablation of Kent bundle. (1) Normal anatomy. (2) Endocardial approach to Kentbundle ablation; arrows show planes of dissection. (3) Epicardial approach combines dissec
tion and mobilization of atrioventricular pad and cryoablation of area adjacent to anulus.
A = atrial wall, CA = coronary artery, V = ventricular wall, Va = atrioventricular wall.
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M ah aim I: Kent’s fibers and the A-V paraspecific con
duction through the upper connections o f the bundle of
His-Tawara. Am Heart J 1947; 33: 651-3
SEALY WC, HATTLER BG JR, Bl.UMENSCHEIN SD,
COBB FR: Surgical treatment of W olff-Parkinson-W hite
syndrome. Ann Thorac Surg 1969; 8: 1-11
Sealy WC, Wallace AJ, Ram m ing KP, G allagher
J J, SVENSON RH: An improved operation for the defi
nitive treatm ent o f the W o lff-P ark in so n -W h ite
syndrome. Ann Thorac Surg 1974; 17: 107-13

not a single spot but a wide area, sug
gesting a bundle 2 to 3 cm wide or several
adjacent bundles.
E lectrophysiologic testing postoperatively, using temporary epicardial
pacing wires, demonstrated no evidence
of Kent bundle conduction at the time of
discharge (8 days after operation) in any
patients. Recurrence of the delta wave
was noted in two patients postoperatively after 3 weeks of follow-up. In one, no
tachycardia could be induced and the ac
cessory pathway was considered to be
nonfunctional. In the second, the delta
wave was associated with tachycardia,
which could be completely controlled by
a single drug, previously ineffective. The
remaining 17 patients are well and taking
no medication.

and minimal morbidity. Mortality has
been infrequent in other centres and is
generally due to the severity of associated
organic heart disease.13 The open-heart
technique is now well established and
associated with good results.
The closed-heart technique is promis
ing. It shortens the operative time and
avoids the need for cardiopulmonary
bypass.14 The chance of severing the
Kent bundle seems higher. The technique
we describe is the only one that separates
or ablates the atrial wall of all possible
ventricular attachments. However, this
technique applies essentially to free-wall
Kent bundles, present in 77% of our pa
tients. This percentage is consistent with
the dominance of the free-wall Kent bun
dle reported in other surgical series.8

Discussion

Conclusions

Removal of accessory atrioventricular
(Kent) pathways provides a definitive cure
for most patients with the W olffParkinson-White syndrome. Infrequent
ly, other types of accessory connections
(Mahaim, Brechenmacher) may be in
volved and their close relations to the nor
mal atrioventricular conduction system
endanger this system if ablation is
attempted.
Our results are similar to those of
others.8,12 They show that this operation
can be performed with a high success rate

The low morbidity and high success
rate of curative surgery for W olffParkinson-W hite syndrome should
broaden its indications to patients other
than those with life-threatening or disabl
ing arrhythmias. Surgery is an attractive
alternative for young patients with
tachyarrhythmia facing a lifelong com
mitment to antiarrhythmic drugs.

11. K lein GJ,. Sealy WC, P r itc h ett EL, H arrison L,
H arrison L, H ackel DB, D avis D, Kasell J,
W allace AG, G allagh er JJ: Cryosurgical ablation
of the atrioventricular node-His bundle: long-term follow
up and properties of the junctional pacemaker. Circula
tion 1980; 61: 8-15
12. U th er JB, J ohnson DC, Ba ir d DK, R ic h a r d s DA,
DENNISS AR, Ross D, LECKIE BD: Surgical section of
accessory atrioventricular electrical connections in 108 pa
tients (abstr). Am J Cardiol 1982; 49: 995
13. GUIraudon G, F rank R, F o n ta in e G: Le traitement
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L ’information Cardiologique 1979; no 1: 59-63
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Early Changes in Venous Arterial Autografts:
a Scanning Electron Microscope Study
The use of autogenous vein as an arterial
substitute has been advocatd for many
years. Methods of harvesting generally
cause spasm of the vein and it has been
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shown that preventing the spasm by
applying papaverine improves long
term patency. The present study was
undertaken to see if the reported long
term patency of such grafts was
associated with improved short-term ap
pearance of the venous endothelium as
viewed with the scanning electron
microscope.
Two groups of dogs were studied;
those sacrificed at 3 hours and those at
24 hours after replacing excised
segments of the carotid and femoral
arteries with cephalic veins. One of the
veins was removed in the standard man
ner allowing spasm followed by disten
sion back to its pre-spasm state; in the
other, spasm was prevented by the
topical application of papaverine before
removal.

The study shows that venous en
dothelial integrity is preserved by the use
of papaverine and this improved ap
pearance of the endothelium persists for
the first 24 hours after insertion into an
arterial milieu. But the study also
demonstrated that there was extensive
activity of polymorphonuclear leukocytes
associated with the endothelium in the
early hours after arterialization and that
they appeared to have a deleterious ef
fect on the endothelium.
L'utilisation de veines autologues comme
substituts des arteres est preconisee
depuis plusieurs annees. Les methodes
de prelevement provoquent g^neralement
un spasme de la veine et il a ete
demontr6 que la prevention du spasme
par I'application de papaverine amdliore
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la permeabilite a long terme. La presente
etude a ete entreprise pour voir si la
permeabilite a long terme qui a ete
decrite pour de tels greffons etait reliee a
une amelioration e court terme de I'apparence de I'endotheiium veineux telle
qu'elle apparait au microscope a
balayage eiectronique.
Deux groupes de chiens ont ete 6tudies; ceux-ci etaient sacrifies respectivement 3 et 24 heures apres le remplacement de segments excises d'arteres
carotides et femorales par des veines
cephaliques. Une des veines etait prdlevee de la facon habituelle, permettant le
spasme suivi d'une distension jusqu'a
I'etat pre-spastique. Pour I'autre veine,
on empechait le spasme par ('application
topique de papaverine avant le preievement.
Cette etude demontre que i'integrite de
I'endotheiium veineux est protegee par
I'utilisation de papaverine et que cette
meilleure apparence de I'endotheiium
persiste durant les premieres 24 heures
qui suivent I'insertion en milieu arteriel.
Cette etude demontre egalement qu'il
existait une importante activite des
leucocytes polymorphonucieaires au ni
veau de I'endotheiium dans les premieres
heures qui ont suivi I’arterialisation, et
que ceux-ci semblaient exercer un effet
nocif sur I'endotheiium.

The use of autogenous vein as an arterial
substitute was first suggested in 1906,1
but there is still no universal agreement
as to the best method of harvesting the
vein.2-5 Since intact endothelium pro
duces prostacyclin,6 which inhibits
platelet aggregation and adhesion to the
vessel wall and also exhibits fibrinolytic
activ ity ,7 preservation o f the en
dothelium at the time of vein harvest is
assumed to be of paramount importance.
When the vein is removed, variable
degrees o f spasm occur and it is standard
practice to overcome this with a variety
of distending media and pressures. Spasm
damages endothelium, both in arteries8
and veins,9 and prevention of venous
spasm in harvested saphenous veins has
been shown to be of value in human aor
tocoronary bypass.10
The present study was undertaken to
determine if using papaverine to pre
vent venous spasm results in improved en
dothelial integrity 3 and 24 hours after
arterialization of the vein.

either the femoral or carotid arteries. One
vein was mobilized according to standard
techniques. After removal it was distend
ed with heparinized blood at room
temperature to a pressure not exceeding
50 mm Hg. The graft was then halved and
5-cm segments were anastomosed end to
end with continuous 6-0 Prolene to the

carotid arteries. A segment of the control
vein was fixed before and after distension
by perfusion at a controlled pressure of
50 mm Hg with 4% glutaraldehyde in
sodium cacodylate buffer.
The second cephalic vein was mobiliz
ed differently. Immediately after ex
posure, a hemostat was applied proximal-

FIG. 1—Composite of scanning electron micrographs of control vein 3 hours after arterializa
tion. E = intact endothelium, L = endothelial loss, V = venous valves, F = fibrin (x 4 0 ).

Methods

We used eight, healthy, adult, mongrel
dogs o f both sexes, weighing between 20
and 30 kg. The dogs were given 2 mg/kg
of heparin sodium systemically. Under
general anesthesia, both cephalic veins
were removed and used as venous
autografts to replace excised segments of
150

FIG. 2—Scanning electron micrograph of veins before arterialization. (A) Control vein
after removal, before distension. In centre endothelium is normal but on either side it is wrinkl
ed by contraction ( x 1250). (B) Control vein after distension with blood. Endothelium is in
tact, but nuclei are damaged ( x 640). (C) Same as B. Intercellular junctions are intact, but cells
are bridged by many abnormal strands of cytoplasm and nuclei are almost extruded (x2500).
(D) Normal appearance of papaverine-treated vein (X1250).
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ly and the adventitia of the vein was in
filtrated with 30 to 40 mg of papaverine.
The vein was left for 15 minutes to dis
tend gradually under venous pressure
before being mobilized. Excised segments
of the femoral arteries were replaced by
5-cm segments of this vein preparation.
A preinsertion segment of the preparation
was fixed in distension for later
examination.

Four dogs were killed after 3 hours and
four after 24 hours. After systemic
heparinization the grafts were fixed in situ
by perfusion with 4% glutaraldehyde in
sodium cacodylate buffer at 100 mm Hg
to fix the graft in distension. The artery
proximal and distal to the graft segment
was ligated to prevent leakage of fixative
and to maintain graft distension during
fixation. The vessels were then removed

and stored in the same fixative for 24
hours.
Preparation o f Grafts
fo r Scanning Electron Microscopy
The vein g rafts were opened
longitudinally and pinned out in wash
buffer (0.2M sodium cacodylate, pH 7.3).
A 1.5-cm full-circumference segment was
removed from the centre of the vein graft
and glued onto a glass coverslip with
cyanoacrylic glue. The mounted sample
was post-fixed in 1% osmium tetroxide
for 2 hours, dehydrated through graded
ethanol, critical-point dried from carbon
dioxide in a Bomar SPC-900 Ex critical
point drier (Bomar Co., Tacoma, Wash.),
gold coated in a Polaron E5100 sputter
coater (Polaron Equipment Ltd., W at
ford, Herts., UK) and viewed in a Philips
PSEM 501 electron microscope (Philips
Industries, Einthoven, Netherlands).
Special areas from the samples were
removed, cut into 1-mm cubes and
prepared for transmission electron
microscopy by embedding in Spurs’ resin.
They were then sectioned on an
ultramicrotome and examined in a Philips
TEM 301 microscope.
Estimation o f Endothelial Loss

FIG. 3—Control vein after 3 hours. Areas of endothelial loss expose subendothelium to
which leukocytes and platelets adhere (original magnification x640).

The specimens were viewed at x 40
magnification and photographs were
made o f the entire surface. These
photographs were subsequently mounted
to make a composite of the specimen11
(Fig. 1). Areas of total endothelial loss
and areas covered with fibrin were
estimated by point counting using a sim
ple lattice.12 Venous valves, which were
invariably intact, and the orifices of bran
ches, which were filled with fibrin, were
excluded. Areas that were covered with
leukocytes and were associated - with
variable endothelial loss were simply
ranked on a scale from + to + + + +
(minimal to maximal leukocyte adhesion).

Results
Description o f Electron
Microscopic Changes

FIG. 4—Activity of leukocytes on endothelium. (A) Control vein after 3 hours shows
leukocytes on surface at intercellular junctions (x640). (B) Leukocytes have passed deep to
endothelium raising lumps on surface ( x 1250). (C) Control vein at 24 hours. Large lumps are
raised by leukocytes deep to endothelium which has split (x 1250). (D) Endothelium, in process
of being shed, overlying mass of leukocytes (x 1250).

Before distension, areas of normal en
dothelium in control veins mingled with
areas of wrinkled endothelium caused by
spasm (Fig. 2a). After distension with
blood, the fixed veins showed damaged
endothelial cells that were partly detach
ed from the subendothelial connective
tissue and curled up, often connected by
fine cytoplasmic ridges (Fig. 2, b and c).
Other areas retained an intact endothelial
cell cover. In contrast, the veins
pretreated with papaverine had no areas
of wrinkling and the endothelial cell cover
was intact with no cell damage due to con-
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traction of smooth muscle cells (Fig. 2d).
Three hours after insertion into an
artery, control veins showed extensive
areas of endothelial cell loss, with adhe
sion of platelets and leukocytes to the ex
posed subendothelium (Fig. 3). In areas
o f intact endothelium were many
leukocytes apparently attached to the in
tercellular junctions of the endothelial cell
surface (Fig. 4a). In other areas the
leukocytes appeared as ridges or eleva
tions beneath the endothelial cells (Fig.
4b). By transmission electron microscopy
they were seen between the endothelial
cells and also beneath them. They were
identified as poly m o rp h o n u clear
leukocytes (Fig. 5). Papaverine-treated
veins, 3 hours after insertion into the
artery, showed notably less endothelial
cell denudation or damage. Leukocytes
were associated with the endothelium but
were fewer in number.
Twenty-four hours after insertion, the
control veins showed large numbers of
leukocytes on the surface of the en
dothelium, but there was also con
siderable endothelial cell damage from
leukocytic infiltration beneath the en
dothelium (Fig. 4, c and d). Under lower
magnification, the endothelium appeared
to be intact (Fig. 6), but at higher
magnifications considerable endothelial
loss was apparent (Fig. 7).

shown that venous fibrinolysis after
arterialization depends on the integrity of
the endothelium.7 Also, it has been
shown that exposed subendothelial con
nective tissue is highly attractive to
platelets,13 which not only initiate the
coagulation cascade14 but also release the
proliferating factor of smooth muscle
cells.15 Since the smooth muscle cell is
the predominant cellular component in

intimal hyperplasia that causes graft
stenosis and occlusion, initial prevention
of platelet adhesion has been ad
vocated.16'17
We noted that the leukocyte may
adhere to intact endothelium of arterialized venous grafts, undermine the en
dothelium and apparently destroy it leav
ing exposed ulcers covered with platelets
and leukocytes. This phenomenon was

Statistical Analysis
The percentages of endothelial loss
from control (two carotid arteries) and
papaverine-treated (two femoral arteries)
veins of each dog were averaged. These
results, also expressed as percentages,
were then transformed using an arcsine
transformation to stabilize variance. A
repeated-measures analysis of variance
was performed on the transformed
responses using time (3 and 24 hours) and
treatment (control and papaverine) as fac
tors. The mean endothelial loss at 3 hours
for control veins was 45% compared with
18% for papaverine-treated grafts. At 24
hours these percentages were 20% and
9% respectively. Overall, the control
veins showed a 33% endothelial loss com
pared with 13% for papaverine-treated
grafts (p = 0.044). The effect over time
was not significant. Although we could
not numerically assess this, mean
leukocyte adhesion was + + + for control
veins compared with + for papaverinetreated veins.

FIG. 5—Transmission eleclron micrograph of control vein graft 3 hours after arterializa
tion. Polymorphonuclear leukocyte is on surface of intact endothelium, deep to which is another
polymorphonuclear leukocyte. Cell on left is monocyte (original magnification x 1200).

Discussion
This study shows that avoiding spasm
in vein grafts used for arterial interposi
tion results in improved endothelial in
tegrity before and immediately after
arterialization. This may improve long
term graft patency, because it has been
152

FIG. 6—Control vein 24 hours after arterialization. E = intact endothelium, V = valve,
F = fibrin, O = orifice of branch. Area covered with leukocytes looks intact (original magnifica
tion x40).
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observed by Stewart and associates18 in
veins of dogs subjected to trauma. The
destruction o f endothelial cells in tissue
culture by neutrophils was recently
described by Harlan and colleagues.19
These findings suggest that the
neutrophil, attracted to the endothelium
by a variety o f chemotactic substances,
may exert a damaging effect on intact
vascular endothelium o f grafts.
Previously,20 we found that widely dif
fering methods of graft manipulation —
saline washout, saline distension and
crushing — produced identical patency
rates. This could be explained by the
postoperative activity of leukocytes on
partially damaged endothelium. This
would equalize preoperative differences
in endothelial integrity. In addition to the
polymorphonuclear leukocyte, the occa
sional monocyte was noted in our
specimens. Ziats and Robertson21 show
ed that monocytes may release a growth
factor for vascular smooth muscle that
promotes further growth o f the smooth
muscle stimulated by growth factor
release from platelets. It has been shown
that lidocaine reduces leukocyte
function,22 but to what extent one can
modify leukocyte adhesion to the en
dothelium of arterialized vein grafts is
unknown. We suggest that preventing
such adhesion in venous autografts may
permit even better preservation o f the en
dothelium than using papaverine alone.

Conclusions
The use of topical papaverine to pre
vent spasm o f a vein during its removal
preserves the integrity of the venous en
dothelium. This benefit persists for the

first few hours after arterialization o f the
vein. The polymorphonuclear leukocyte
plays an undetermined role in maintain
ing the integrity o f the venous en
dothelium after the vein is inserted into
an arterial milieu.
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Pseudomembranous colitis is unlikely
to occur, as Flagyl 500 Inj. is highly
effective against C. d ifficile?8 which is
usually associated with this disease5
Clindamycin and cefoxitin, on the
other hand, show little activity against
C. difficile?'8
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ACTIONS
Flagyl (metronidazole) is bactericidal against
anaerobic bacteria, it exerts trichomonacidal activity
and is also active against Glardia lamblla and
Entamoeba histolytica. Its exact mechanism of action
has not been entirely determined as yet. It has been
proposed that an intermediate in the reduction of
metronidazole, produced only in anaerobic bacteria
and protozoa is bound to deoxyribonucleic acid and
proteins, and inhibits subsequent nucleic acid
synthesis.

INDICATIONS AND CLINICAL USES
Bacterial Infection*: The treatment of serious
anaerobic abdominal infections due to susceptible
anaerobic bacteria, such as Bacteroides fragilis (and
other species of Bacteroides), Clostridium,
Fusobacterium, Peptococcus, and Peptostreptococcus
species.
Culture and susceptibility studies should be
performed to determine the causative organisms and
their susceptibility to metronidazole. Based on clinical
judgment and anticipated bacteriological findings,
therapy may be started while awaiting the results of
these tests. In mixed aerobic and anaerobic infections,
consideration should be given to the concomitant
administration o f an antibiotic appropriate for the
treatment of the aerobic component of the infection.
(See Warnings).
Flagyl (metronidazole) has also been used in the
treatment of a small number of cases of brain or lung
infections (some with abscesses) caused by anaerobic
bacteria.

CONTRAINDICATIONS
Flagyl (metronidazole) is contraindicated in
patients with a prior history of hypersensitivity to
metronidazole or other nitroimidazole derivatives.
Flagyl should not be administered to patients with
active neurological disorders or a history of blood
dyscrasia, hypothyroidism and hypoadrenalism.

ADVERSE REACTIONS

WARNINGS
Flagyl (metronidazole) has no direct activity
against aerobic or facultative anaerobic bacteria. In
patients with mixed aerobic/anaerobic infections,
appropriate concomitant antibiotics active against the
aerobic component should be considered.
Known or previously unrecognized moniliasis may
present more prominent symptoms after treatment
with Flagyl.
Studies in rats and mice have provided some
evidence that metronidazole may cause tumors in
these species when administered orally for a long
period at high doses. The relevance of these findings
in humans is not known.
Severe neurological disturbances (i.e. convulsive
seizures and peripheral neuropathy) have been
reported in patients treated with Flaayi (administered
orally or intravenously). These haveheen observed
very infrequently.

PRECAUTIONS
Patients taking Flagyl (metronidazole) should be
warned against consuming alcohol, because of a
possible disulfiram-like reaction. For the same
reason, patients receiving Flagyl should not be
administered disulfiram concomitantly.
Transient eosinophilia and leukopenia have been
observed during treatment with Flagyl. Regular total
and differential leukocyte counts are advised if
administration for more than 10 days or a second
course o f therapy is considered to be necessary.
Metronidazole crosses the placental barrier.
Although Flagyl has been given to pregnant women
without apparent complication, it is advisable that
oral administration be avoided in pregnant patients
and Flagyl be withheld during the first trimester of
pregnancy. In serious anaerobic infections, if the
administration of Flagyl to pregnant patients is
considered to be necessary, its use requires that the
potential benefits be weighed against the possible
risks to the fetus.
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Metronidazole is secreted in breast milk in
concentrations similar to those found in plasma.
Intravenous or oral administration of Flagyl should be
avoided in the nursing mother.
Metronidazole has been reported to potentiate the
anticoagulant effect of warfarin resulting in a
prolongation of prothrombin time. This possible drug
interaction should be considered when Flagyl is
prescribed for patients on this type of anticoagulant
therapy. Clinical experience in cnildren is very limited.
The monitoring of this group of patients is particularly
important. The safety and effectiveness of intravenous
Flagyl in children has not been established.
A rare case of reversible but profound neurological
deterioration haw been reported following a single oral
dose of Flagyl; it is therefore advisable that a patient
taking Flagyl for the first time not be left unattended
for a period of two hours. The appearance of abnormal
neurologic signs demands prompt discontinuation of
Flagyl therapy and, when severe, immediate medical
attention. Gastric lavage may be considered if no
more than two or three hours have elapsed since
administration of the drug.
Treatment with Flagyl should be discontinued if
ataxia or any other symptom of CNS involvement
occurs.
Patients with severe hepatic disease metabolize
metronidazole slowly with resultant accumulation of
metronidazole and its metabolites in the plasma.
Accordingly, for such patients, doses o f Flagyl below
those usually recommended should be administered
and with caution. The determination of serum
glutamic oxaloacetic transaminase (SGOT) by the
Technicon SMA 12/60 system in blood samples from
patients receiving Flagyl may give abnormally low
values. This abnormality is artifactual and caused by
the absorption of metronidazole at the wavelength
where the enzymatic reaction is monitored
spectrophotometrically.
Gastrointestinal: diarrhea, nausea, vomiting,
anorexia, epigastric distress, dyspepsia, constipation.
Month: furred tongue, dry mouth, unpleasant
metallic taste.
Hematopoietic: transient eosinophilia or
leucopenia.
Dermatologic: rash and pruritus.
Cardiovascnlar: palpitation and chest pain.
Central Nervous System: convulsive seizures,
peripheral neuropathy, transient ataxia, dizziness,
drowsiness, confusion, insomnia and headache.
Peripheral neuropathies have been reported in a few
patients on moderately high to high-dose prolonged
oral treatment with metronidazole. It would appear
that the occurence is not directly related to the daily
dosage and that an important predisposing factor is
the continuation of oral and/or I.V. medication for
several weeks or months. Profound neurological
deterioration, within 2 hours after Flagyl
administration has been reported. The occurrence is
not directly related to the dosage level.
Metabolic: An antithyroid effect has been reported
by some investigators but three different clinical
studies failed to confirm this.
Local Reactions: Thrombophlebitis has occurred
with I.V. administration.
Other: Proliferation of Candida albicans in the
vagina, vaginal dryness and burning; dysuria;
occasional flushing and headaches, especially with
concomitant ingestion of alcohol; altered taste of
alcoholic beverages. Darkening of the urine has been
reported. This is probably due to a metabolite of
metronidazole and seems to have no clinical
significance.

SYMPTOMS AND TREATMENT OF
OVERDOSAGE
Symptoms
Massive ingestion may produce vomiting and slight
disorientation.
Treatment
There is no specific antidote. Early gastric lavage
may remove a large amount of the drug; otherwise,
symptomatic treatment.
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DOSAGE AND ADMINISTRATION
TREATMENT OF ANAEROBIC
INFECTIONS
Treatment should be initiated by the I.V. route. Oral
medication may be substituted when it is feasible
and/or practical. Duration of therapy depends upon
clinical and bacteriological assessment. Treatment for
seven days should be satisfactory for most patients.
However in cases where infection sites cannot be
drained or which are liable to endogenous
recontamination by anaerobic pathogens, a longer
treatment may be required.

I. V. ADMINISTRATION:
100 mL (500 mg) by intravenous infusion every 8
hours. The injection should be infused intravenously
at the rate of 5 mL per minute.
Flagyl injection is compatible in a volume ratio of
1:5 with normal saline, dextrose-saline, dextrose 5 per
cent w/v or potassium chloride injections (20 mmof
and 40 mmol). It should not be mixed with sodium
lactate injection 5% w/v, or dextrose injection 10%
w/v.

AVAILABILITY

1
i

Injection 0.5% w/v in Viaflex* plastic bags of
100 mL (500 mg) for intravenous infusion.
FULL PRODUCT MONOGRAPH AVAILABLE ON
REQUEST.
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Cardiac Valve Surgery in Patients w ith
Poor Left Ventricular Function
O f 3 1 6 patients w h o underw ent opera
tion for valvular heart d isea se at the
T oronto W estern Hospital, betw een
Jan u a ry 1 9 7 8 and D ecem ber 1 9 8 1 , 41
(31 men, 1 0 w om en), ranging in age
from 2 4 to 7 4 years, had severely im
paired left ventricular function (ejection
fraction le ss than 4 0 % and left v e n 
tricular end-diastolic pressure m ore than
1 8 m m Hg). All 41 patients were in New
Y o rk Heart A sso c ia tio n (N Y H A ) c la ss III
or IV. Fourteen patients had disease of
the aortic valve, 1 3 of the mitral valve
and 1 4 of both aortic and mitral valves.
T w e n ty -tw o patients also had serious
coronary artery disease.
The valve d ysfu n c tio n w a s corrected
in all patients by replacem ent or repair
and all severe coronary artery ste n o se s
w ere b y p a sse d w ith sap h e n o u s vein
grafts. There were three hospital deaths
and five late d eaths during a m ean
follow -up of 2 6 m o n th s (range from 6 to
4 8 m onths). All patients im proved sy m p 
tom atically by a least one functional
N Y H A class. The actuarial survival in
cluding operative d eaths w a s 7 9 % .
Entre janvier 1 9 7 8 et decem bre 19 81 ,
d es 3 1 6 patients qui ont subi une
operation pour valvulopathie au Toronto
W estern Hospital, 41 (31 hom m es, 10
fem m es) avaient une fonction ventriculaire gauche gravem ent alteree (fraction
d'ejection m oins de 4 0 % et une pression
telediastolique ventriculaire ga u c h e plus
de 18 mm Hg). Les 41 patients faisaient
partie des categories III et IV de la
classification de la N e w Y ork Heart
A sso c ia tio n (N Y H A ). Q uatorze patients
avaient une atteinte d es valvules
sigm oid es de I'orifice aortique, 1 3 de la
valvule mitrale et 1 4 d es valvules mitrale

de sigm o id e s aortiques. Vin gt-deu x
patients avaient a u ssi une maladie
coronarienne grave.
D a n s to u s les cas, le dysfonctionnement valvulaire fut corrige soit p a r
rem placem ent, soit par reparation,
et to u s les re trgcissem en ts coronariens
im portants recurent un pontage par
greffe de veine saphene. O n a
enregistre trois m orts en cou rs
d 'h ospita lisatio n et cinq deces tardifs
durant une periode de surveillance
post-therapeutique m oye nn e de 2 6 m ois
(variant de 6 a 4 8 mois). En ce qui a
trait aux sym p to m e s, to u s les patients se
sont am eliores d 'a u m oin s une classe
fonctionnelle N Y H A . La survie actuarielle.
incluant les deces operatoires, est de
79%.

The prognosis for cardiac disease in pa
tients with inadequate left ventricular
function is poor regardless of the underly
ing cause o f the cardiomyopathy.1•1 The
introduction to clinical practice of aor
tocoronary bypass, intra-aortic balloon
pump assistance, new cardiac valve prostheses and cold cardioplegia has made it
possible to operate on patients with endstage valvular disease with an acceptable
operative mortality and satisfactory
clinical results. This report summarizes a
4-year experience with cardiac valve
surgery in patients with poor left ven
tricular function.

Patients
Between Jan. 1, 1978 and Dec. 31,

1981, 316 patients underwent an elective
cardiac valve operation at the Toronto
Western Hospital. O f these 316 patients,
41 (31 men, 10 women) had severe impair
ment of left ventricular function as defin
ed by an ejection fraction lower than 40%
and left ventricular end-diastolic pressure
higher than 18 mm Hg.
The age o f the 41 patients ranged from
24 to 74 years (mean 60.3 years). All were
operated on for congestive heart failure;
19 also had angina pectoris. Fourteen pa
tients had aortic valve disease, 13 had
mitral valve disease and 14 had both aor
tic and mitral valve disease. The cardiac
rhythm and the New York Heart Associa
tion (NYHA) functional classification o f
these patients are shown in Table I. Three
patients were moribund from hepatorenal
failure secondary to intractable congestive
heart failure. One patient had been on
home peritoneal dialysis for 8 years, and
11 patients were permanently hospitalized
because o f intractable congestive heart
failure.
All patients underwent right and left
heart catheterization and cinecoronary
angiography preoperatively (Table II).

Operative Procedures
All operations (Table III) were per
formed using cardiopulmonary bypass,
hemodilution and systemic hypothermia
(25°C). We avoid ventricular fibrillation
during the operation. The heart is arrested
with cold crystalloid cardioplegic solution
as soon as cardiopulmonary bypass is
established; if the heart fibrillates after

Table 1 - Preoperative C a rd ia c R h y th m and N e w Y o rk
H e a rt A sso c ia tio n ( N Y H A ) Functional C la ssifica tio n
V alvels), no. o f p a tie n ts

From the division o f cardiovascular
surgery, Toronto Western Hospital and
University o f Toronto, Toronto, Ont.
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Canadian Cardiovascular Society, Calgary,
Alta., Oct. 20-22, 1982
Accepted fo r publication Dec. 20, 1982
Reprint requests to: Dr. T.E. David,
Toronto Western Hospital, 399 Bathurst
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Cardiac rhythm
and N Y H A c la ss

Cardiac rhythm
Sinus rhythm
Atrial fibrillation
Pacemaker assisted
NYHA
Class III
Class IV

A ortic
(n =

14)

M itra l
(n =

13)

A o rtic and mitral
(n =

11
1
2

7
6
0

5
8
1

9
5

8
5

6
8
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unclamping the aorta, we immediately
perform cardioversion. The myocardial
septal temperature is recorded throughout
the period of aortic cross-clamping and
is kept around 15°C by topical hypother
mia and intermittent coronary infusion of
cold cardioplegic solution.
All patients had complete correction of
their valvular dysfunction either by
replacement with Carpentier-Edwards
prostheses or repair using CarpentierRhone-Poulence rings in the mitral and
tricuspid position. Since July 1979 we
have preserved the chordae tendinae and
papillary muscles when replacing the
mitral valve in patients with mitral
insufficiency.4 All aortic prostheses were
25 mm or larger and all mitral prostheses
were 31 mm or larger. We had to enlarge
the aortic anulus in four patients. All
serious coronary arterial stenoses were
bypassed with saphenous vein grafts. Six
patients with severe coronary artery
disease and mitral insufficiency had an
intra-aortic balloon pump inserted before
induction of anesthesia. Prophylactic in
sertion of the intra-aortic balloon pump
was not used after 1980.
Results

Hospital Deaths
Three patients died in hospital after
operation. All were NYHA class IV. One
patient died on postoperative day 2 with
low cardiac output. He had undergone
mitral valve replacement and four-vessel
aortocoronary bypass. He had been on
home peritoneal dialysis for 8 years
before operation. Autopsy revealed an
enlarged, diffusely scarred heart with
evidence of sarcoidosis. A second patient
died suddenly on postoperative day 3
after aortic and mitral valve replacement
and triple-vessel aortocoronary bypass.
At autopsy there was evidence of a recent
septal myocardial infarction in an enlarg
ed and diffusely scarred heart. All grafts
were patent and the valves were intact.
The third death occurred in a man who
underwent aortic and mitral valve replace
ment and tricuspid valve repair. He was
moribund before the operation with
hepatorenal failure. He did not improve
following operation and remained in con
gestive heart failure until his death on

postoperative day 28. Autopsy revealed
massive cardiomegaly and a diffusely
scarred myocardium. The prosthetic
valves and tricuspid ring were intact.
Postoperative Course
During the first 12 to 48 hours after

operation, 22 patients required inotropes
or intra-aortic balloon pump assistance,
or both. Two patients required dialysis
postoperatively because of acute renal
failure. Sternal dehiscence occurred in
two patients: in one the wound healed
after reclosure and in the second chronic
osteomyelitis developed and the wound

Table ll-Preoperative Hemodynamic and Angiographic Data
Valvefs) involved
Angiographic findings!
hemodynamic studies
Angiographic findings
Valvular lesion
Aortic insufficiency
Aortic stenosis
Mima^jlyficiency
Mitral insufficiency
and stenosis
Tricuspid insufficiency
Coronary artery disease
Single-vessel
Double-vessel
Triple-vessel
Left ventricular
aneurysm
Ascending aortic aneurysm
Hemodynamic studies*
Cardiac index, l/min • n r2
Ejection fraction, %
Left ventricular enddiastolic pressure,
mm Hg

Aortic

Mitral

Aortic
and mitral

10
4
0

0
0
12

8
6
10

0
0

1
0

4
3

0
2
4

0
4
6

1
1
4

0
2

3
0

0
2

2.03 + 0.19
30 ± 6

1.90 + 0.10
34 + 5

1.81 + 0.20
34 + 6

27.2 + 10.6

24.2 + 5.4

25.2 + 5.9

*Mean + standard deviation.

Table I I I - Operations Performed on 41 Patients with
Poor Left Ventricular Function
Valvefs) involved
Operation and anoxic and
bypass times
Operation
Aortic valve replacement
Mitral valve replacement
Mitral valve repair
Tricuspid valve repair
Replacement of ascending aorta
Resection of ventricular aneurysm
Aortocoronary bypass
Enlargement of aortic anulus
Anoxic time, min*
Cardiopulmonary bypass time, min*
*Mean + SD.

Aortic

Mitral

Aortic
and mitral

14
0
0
0
2
0
6
3
B4.7 + 25.5
81.1 + 32.2

0
12
1
0
0
3
10
0
59.6 + 18.1
89.0 + 13.6

14
11
3
3
2
0
6
1
81.2 + 14.5
105.2 + 31.0

Table IV-Cause of Late Death
Patient
no.
1
2

Age,
yr
61
39

3
4
5

69
63
50

158

Sex
M
M

Valvular
lesion
Aortic + mitral
Aortic + mitral

Coronary artery
disease
No
No

Survival,
mo
3
12

NYHA class,
postoperatively
II
III

M
M
F

Aortic
Mitral
Aortic

No
Yes
No

22
26
35

I
II
I

Cause of death
Gastrointestinal bleeding
Cholecystitis. Congestive
heart failure
Renal tumour
Myocardial infarction
Stroke. Probably embolic
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was still open 2 years after operation. This
patient declined further treatment.
Nineteen patients had a smooth
postoperative course and were discharged
from hospital around the 10th day. The
mean hospital stay after surgery for all
patients was 17.3 days.
On discharge from hospital, all 38 sur
vivors were taking digitalis and diuretics
and anticoagulants orally.
Follow-up
Patients have been followed up for a
mean period of 26 months (range 6 to 48
months). Five patients have died since
they were discharged from hospital (Table
IV). Fig. 1 shows the actuarial survival.
All patients have been assessed by a
cardiologist every 6 months. All survivors
improved symptomatically by at least one
functional NYHA class. Fig. 2 shows the
preoperative and postoperative NYHA
classification of the 33 late survivors; the
functional class postoperatively of those
patients who died late is shown in Table
IV.
All patients are still taking digitalis.
Nineteen are also taking diuretics and 5

FIG. 1—Actuarial survival of 41 patients
with poor left ventricular function.

FIG. 2—Preoperative and postoperative
New York Heart Association functional
classification of 33 late survivors. AVR = aor
tic valve replacement, MVR = mitral valve
replacement or repair.

take diuretics and vasodilators. An
ticoagulant therapy was discontinued in
all patients 4 months after operation.
Discussion
Although this report describes a
heterogeneous group of patients with
valvular disease and poor left ventricular
function, it shows that these patients can
be operated on with an acceptable
operative mortality and gratifying symp
tomatic improvement. An overall reduc
tion in operative mortality for patients
who undergo valve surgery has been
reported with cold cardioplegic myocar
dial protection,5-7 but operative m ortali
ty remains relatively high in patients with
poor left ventricular function.8,9 Three
of our 41 patients died in hospital, an
operative mortality of 7.3%. All three
deaths were cardiac in origin. This
operative mortality appears high when
compared with patients who have better
ventricular function.5,6
The degree of symptomatic improve
ment after valve surgery in patients with
poor ventricular function appears related
to the underlying valvular lesion. Thus,
most of our patients with end-stage aor
tic valve disease became asymptomatic
postoperatively, probably because suc
cessful aortic valve replacement is fre
quently followed by an improvement in
left ventricular function, even if severe
m yocardial dysfunction is present
preoperatively.10,11 Patients with mitral
regurgitation and poor left ventricular
function do not experience the same
lessening of symptoms because left ven
tricular function does not improve follow
ing mitral valve replacement.12,13 More
over, they appear to represent higher
surgical risks. All three patients in this
series who died in hospital had mitral
regurgitation either isolated or combin
ed with aortic valve disease. Our patients
improved after mitral valve surgery but
only two became asymptomatic (Fig. 2).
The lessening of symptoms in these pa
tients is related to relief of stenosis or
regurgitation rather than to improvement
in ventricular function.13,14 Ventricular
function seems to improve after mitral
valve repair415 or mitral valve replace
ment with preservation of chordae tendinae and papillary muscles as long as
myocardial dysfunction is not too far
advanced.4 The improvement in our pa
tients with both mitral and aortic valve
disease was similar to that seen in patients
with mitral valve disease.
We believe that all serious coronary
arterial lesions should be bypassed at the
time of the valvular surgery. This ap
proach seems to decrease operative m or
tality and may enhance long-term
survival.8,9 Twenty-two of our 41 pa
tients had coronary artery disease and all

arterial branches with substantial lesions
were bypassed. In this group there were
two hospital deaths and one late death.
Patients with valvular disease and im
paired left ventricular function have a
lower long-term survival rate after valve
replacement than patients with normal
left ventricular function.6,16,17 The pa
tients in our series were followed up for
a mean of 26 months (range 6 to 48
months). The actuarial survival after 3
years, including operative mortality, was
79%. This result is encouraging.
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Long-Term Follow-up of Patients
with Porcine Cardiac Valve Prostheses

The a u th ors review their fin d in g s from
3 1 6 porcine valve p rosth eses (1 6 3 H an
co c k , 1 5 3 C a rp e n tie r-E d w a rd s) im 
planted in 2 8 7 patients, follow ed up for
5 ye a rs or more. A sin gle valve w a s
rep laced in the aortic position in 110,
the m itral position in 1 3 4 , tricu sp id in 6
and pu lm on ic in 1; m ultiple va lv e s were
replaced in 36 patients. Patients ranged
in a ge from 13 to 8 5 ye ars (mean 5 3 .9
ye ars). F ifty -six p atien ts (1 9 .5 % ) had
u n dergone cardiac surgery p reviously
and 4 0 (1 4 % ) had another card iac pro
cedure perform ed co ncom itan tly (in
clu d in g coronary artery b yp a ss in 2 5 ,
repair of another valve in 6 and im planta
tion of a pacem aker in 5). Early (3 0-d ay)
m ortality w a s 6 .2 % (1 8 patients).
Pa tie n ts were co ntacte d for follow -up
b etw een 6 0 and 8 7 m onths (mean 6 5 .6
m on th s); 14 patients w ere lost to fo llo w 
up. T h e total follow -up w a s 1 2 4 0
p atie n t-years. O verall patient survival, in 
clu d in g operative m ortality, w a s 7 2 .5 %
at 6 ye a rs (79 ± 7 .5 % for aortic valve
rep lacem ent at 6 ye ars, 6 8 ± 7 .7 % for
m itral v a lv e replacem ent at 6 years and
7 5 ± 1 3 % for replacem ent of m ultiple
v a lv e s at 5 years).
S e rio u s late co m p lica tio n s included 12
throm boem bolic eve n ts (aortic valve
replacem ent 2 [1 H a n co ck, 1
C a rp e n tie r-E d w a rd s], m itral valve
replacem ent 9 [6 H a n co ck, 3
C a rp e n tie r-E d w a rd s], m ultiple valve
replacem ent 1 [H an cock]) or 1 per 100
p atie n t-years of follow -up. There were
seve n episodes of in fe ctive endocarditis
(5 H a n c o c k aortic v a lv e s, 2
C a rp e n tie r-E d w a rd s ) and s ix c a s e s of
p aravalvular leak (aortic v a lve rep lace
m ent 3 [2 H a n co ck, 1 C a rp e n tie rE d w a rd s], mitral valve replacem ent 1
[H a n c o ck ], m ultiple valve replacem ent 2
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[1 H an cock, 1 C a rp e n tie r-E d w a rd s]). To
date, there h ave been on ly tw o c a se s of
prosthetic failure, ca lcifica tio n in a H an 
co ck aortic v a lv e and a torn cu sp in a
C a rp e n tie r-E d w a rd s m itral valve. C a u se s
of late death w ere valve-related in 12
c a s e s (throm boem bolism 5, in fective en
docarditis 4 and paravalvular leak 3).
Death w as due to co n g e stiv e failure,
m yocardial infarction or arrhythm ia in 27
and to non card iac c a u se s in the rem ain
ing 16.
Th e long-term clin ica l results using
porcine b iop ro sth esis w ere considered to
be very sa tisfacto ry. R e su lts w ith the
H a n co ck and the C a rp e n tie r-E d w a rd s
prosthesis appear com parable.
Le s auteurs an a lyse n t leurs observations
portant sur 3 1 6 appareils valvu laires par
prothese porcine (1 6 3 p rotheses de
H a n co ck, 1 5 3 de C a rp e n tie r-E d w a rd s)
p o ses chez 2 8 7 patients s u iv is pendant
5 an s ou p lu s. Le s rem placem ents v a lvu 
laires sim ples se repartissent com m e
suit: 110 en position aortique, 1 3 4 en
position m itrale, 6 en position tricuspidienne et 1 en position pulm onaire; 36
patients ont eu des rem placem ents v a l
vulaires m ultiples. L 'a g e d es patients
variait de 13 a 8 5 an s (m oyenne 5 3 .9
ans). Cin q u ante-six patients (1 9 .5 % )
avaient subi prealablem ent une chirurgie
cardiaque et 4 0 (1 4 % ) eurent une autre
intervention cardiaque co ncom itante
(dont 25 p on tage s aorto-coronariens, 6
reparations d 'u n e autre valvu le et 5
im plantations d'un stim ulateur
cardiaque). La m ortalite precoce (a 30
jours) s'etablit a 6 .2 % (1 8 patients).
Le controle des su ite s therapeutiques
fut fait en entrant en co n ta c t a ve c les
patients de 6 0 a 87 m ois (m oyenne 6 5 .6
m ois) aprfes I'operation; 1 4 patients ont
6te perdus de vue. L'e tu d e catam nestique porte sur un total de 1 2 4 0 patientsannees. Pour I'ensem ble d es patients, la
survie, co nsid eran t la m ortalite op£ratoire, etait de 7 2 .5 % it 6 an s (7 9 ±
7 .5 % pour les rem placem ents valvulaires
de I'orifice aortique & 6 a n s, 6 8 ± 7 .7 %
pour les rem placem ents de valvu les
m itrales £ 6 a n s et 7 5 ± 1 3 % pour les
rem placem ents valvu laires m ultiples § 5
ans).

Les co m p lication s tard ives graves
com prennent 12 a ccid e n ts throm boem boliques (2 rem placem ents de valvu les
sigmoYdes de I'orifice aortique [1 Han
co ck , 1 C a rp e n tie r-E d w a rd s], 9
rem placem ents de v a lvu le s m itrales [6
H a n co ck, 3 C a rp e n tie r-E d w a rd s], 1
rem placem ent valvulaire m ultiple [H an
co ck]), soit 1 par 1 0 0 patients-annees;
sept episodes d 'end ocard ite infectieuse,
relies a des v a lv u le s sigm oYdes de
I'orifice aortique de H a n c o ck (2
C a rp e n tie r-E d w a rd s ) et s ix ca s de fuite
paravalvulaire (3 rem placem ents de
valvu le s sigm oYdes de I'orifice aortique [2
H a n co ck, 1 C a rp e n tie r-E d w a rd s], 1
rem placem ent de valvu le m itrale [Han
co ck], 2 rem placem ents valvulaires
m ultiples [1 H a n co ck, 1 C a rp e n tie rEd w ards]). On co m p te a ce jour seulem ent deux e ch e cs de prothese: la
calcificatio n d 'une valvu le sigmoYde de
I'orifice aortique de H a n co ck et la dechirure d'une valve dans une valvule mitrale
de C a rp e n tie r-E d w a rd s. Le s d eces tard ifs etaient relies au x v a lv u le s dans 12
ca s (5 throm boem bolies, 4 endocardites
in fectieu ses et 3 fu ite s para valvulaires).
Le s deces etaient attribuables a une insu ffisa n ce cardiaque, un in farctu s du
m yocarde ou une arhythm ie dans 27
ca s, et a des c a u se s non cardiaques pour
les 16 autres.
Les resultats clin iqu es a long terme de
I'utilisation des b ioprotheses porcines
sont ju g e s tres sa tisfa isa n ts. Le s pro
th eses de H a n co ck et de Carp e n 
tie r-E d w a rd s sem blent donner des resul
tats com parables.

Porcine cardiac valve prostheses were in
troduced to reduce the risk o f throm
boembolism in patients requiring valve
replacement. Tissue prostheses also offer
a reduced risk o f catastrophic prosthetic
failure due to thrombosis, fracture or
other acute mechanical failure. These
benefits are gained at the expense of an
ticipated replacement o f most tissue pros
theses within 10 to 20 years. We review
ed our experience with 316 porcine pros
theses to evaluate the performance and
complications o f prostheses implanted for
5 years or longer.
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Patients
The porcine bioprosthesis was first im
planted at the University of British
Columbia in 1974; since then it has
become the prosthesis used in almost all
patients at this university. Over 1500 have
been implanted to date. This review
reports our experience with the 287 pa
tients, followed up for 5 years or longer,
in whom a porcine bioprosthesis was im
planted. Initially, the Hancock prosthesis
was used (147 patients), but due to supp
ly difficulties in 1976, a complete change
was made to the Carpentier-Edwards
prosthesis (130 patients). In addition, 10
patients who underwent multiple valve
replacement received both a Hancock and
a Carpentier-Edwards prosthesis. Aortic
valve replacement was performed in 110
patients (Hancock in 54, CarpentierEdwards in 56), mitral valve replacement
in 134 (Hancock in 77, CarpentierEdwards in 57), tricuspid valve replace
ment in 6 (Hancock in 2, CarpentierEdwards in 4) and pulmonic valve
replacement in 1 (Hancock). Thirty-six
patients underw ent multiple valve
replacem ents
(H ancock
in
13,
Carpentier-Edwards in 13 and Hancock
plus Carpentier-Edwards in 10).
Patients ranged in age from 13 to 85
years (mean 53.9 years). Mean age was
similar for both types of prosthesis (Han
cock 52.9 years, Carpentier-Edwards 54.6
years). Fifty-six (19.5%) patients had
undergone a cardiac operation previous
ly, including a closed mitral com
missurotomy in 18 patients, open valve
repair in 11 and valve replacement in 22;
other procedures were performed in 40.
Another cardiac procedure was per
formed concomitantly with valve replace
ment in 40 patients (13.9%), including
coronary artery bypass in 25, repair of
another valve in 6, pacemaker implanta
tion in 5 and other procedures in 4 pa
tients. There were 18 early deaths (at
operation or within 30 days of operation)
(6.3%), the rate for aortic valve replace
ment being 1% (1 of 110), for mitral valve
replacement 10% (14 of 134), for
tricuspid valve replacement 17% (1 of 6)

and for multiple valves 6% (2 of 36).
Patients or their family doctor, or
both, were contacted for follow-up by
mail or telephone. Fourteen patients were
lost to follow-up (95.1% complete). The
total follow-up was 1240 patient-years.

Results
Survival
Overall patient survival including
operative mortality (life-table method) at
6 years was 72% (Fig. 1). For aortic valve
replacement it was 79%, for mitral valve
replacement 68% and for multiple valve
replacement 75%. The survival for pa
tients with H ancock and with
Carpentier-Edwards valves differed (Fig.
2), with an overall 5-year survival of 83%
for those with a Carpentier-Edwards
valve and 74% for those with a Hancock
prosthesis. This difference is significant
at p < 0.05, by z-analysis. For those with
a Hancock prosthesis, 5-year survival for
aortic valve replacement was 73 ± 11.7%
and for mitral valve replacement 62 ±
9.8%. For patients with a CarpentierEdwards prosthesis the figures were 84 ±
9.9% and 79 ± 11.2%, respectively.
Causes o f Late Death
Congestive heart failure, myocardial
infarction and sudden death caused 27 of
the 55 late deaths (Table I). Autopsy was
performed on all patients classified as
having sudden death; there was no
evidence of thromboembolism or valve
failure. Valve-related causes (thromboem
bolism, periprosthetic leak and infective
endocarditis) accounted for 12 late
deaths. Cause of late death was unrelated
to the heart or valve prosthesis in 16 cases.
Congestive heart failure appeared to be
a more important cause of late death in
patients with a Hancock than with a
Carpentier-Edwards prosthesis.
Late Complications
There were 27, late, valve-related com
plications (Table II) including 12 throm 
boembolic events (1/100 patient-years of
follow-up), 7 episodes of infective en
docarditis, 6 periprosthetic leaks and 2
cases of prosthetic failure.

Of the 12 thromboembolic events, on
ly 1 occurred in a patient who underwent
aortic valve replacement (0.2% /patientyear), and 10 occurred in patients who
had mitral valve replacement (6 Hancock,
4 Carpentier-Edwards), for an incidence
of 1.8% /patient-year. One event occur
red in a patient with a double valve
replacement. Expressed by the life-table
method, 91% of patients who underwent
mitral valve replacement were free of
thromboembolic events at 5 years, no
matter which prosthesis was used (Han
cock 91 ± 7%, Carpentier-Edwards 91
± 9%). O f the four embolic events
associated with a Carpentier-Edwards
prosthesis, two occurred in patients with
intractable congestive heart failure. There
were 45 patients receiving a Hancock
prosthesis used early in our experience
when no anticoagulants were given,
who had m itral valve replacement.
We subsequently adopted a policy of
long-term anticoagulation for patients
with mitral valve replacement who remain
in atrial fibrillation. All patients with a
replaced mitral valve who suffered an em
bolic event were in atrial fibrillation.
Structural failure of a prosthesis occur
red in two cases. The first was in a
54-year-old woman who underwent
replacement of the aortic and mitral
valves with Carpentier-Edwards prostheses. A cusp of the mitral prosthesis
became torn 54 months after implanta
tion and she underwent elective reopera
tion. The second case was a 35-year-old
man who underwent aortic valve replace
ment with a Hancock prosthesis. Subse
quently, calcification of the prosthesis
produced stenosis, and he required
reoperation at 30 months. A CarpentierEdwards prosthesis was inserted, which
became calcified 24 months later. Mitral
valve disease developed so the patient had
the aortic prosthesis and mitral valve
replaced with mechanical prostheses.

Discussion
Porcine bioprostheses were introduced
to reduce the risk of thromboembolism,
which is a major source of morbidity and
mortality when mechanical prostheses are
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FIG. 1— Patient survival (life-table method ± 2 standard deviations)
according to position of prosthesis. AVR = aortic valve replacement,
MR = multiple valve replacement, MVR = mitral valve replacement.

_L
12

24

36

48

60

72

84

Months

FIG. 2— Patient survival ( ± 2 SD) by type of prosthesis.
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higher mean age of patients in the former
group (55 years) than in the latter (53
years). Further, early in our experience
(with Hancock prostheses), replacement
with porcine prostheses was restricted to
patients with a short life expectancy;
mechanical prostheses were placed in
better-risk patients. Later in our ex
perience, porcine prostheses were used in
almost all patients. Definite resolution of
this difference in survival remains elusive.
The use of porcine prostheses has pro
ved effective in reducing the risk of
thromboembolism. Thromboembolism
occurred very rarely in patients with aor
tic valve replacement, and anticoagulant
therapy can be virtually eliminated in
these patients. For patients with mitral
valve replacement, a risk of embolism re
mains, although it is substantially lower
than that recorded for mechanical
prostheses.L2'5-9 All emboli in patients
who underwent mitral valve replacement
occurred in those in atrial fibrillation, and
the majority were not receiving an
ticoagulants. At present, we recommend
long-term anticoagulant therapy for all
patients with a mitral valve prosthesis
who remain in atrial fibrillation. At pre
sent, 45% of patients who undergo mitral
valve replacement remain on long-term
anticoagulant therapy, due to chronic
atrial fibrillation or the preference of the
attending cardiologist.10
Durability remains an important ques
tion in discussion of tissue valve pros
theses. The report of Lakier and
associates11 in 1980, showing a 15% ac
tuarial rate of prosthetic failure in a group
of 167 patients followed up for 60 to 89
months, was of particular concern. In the
present study, we have 188 patients alive
and followed up for 5 years or longer and

used.1,2 Moreover, the administration of
anticoagulants and their attendant com
plications are avoided in the majority of
patients and there is a reduced risk of
catastrophic failure due to fracture or
thrombosis, which are associated with a
mechanical prosthesis.2-4 With better
control of these complications, tissue prostheses have shown some evidence of im
proving long-term patient survival.5 The
major unanswered questions are those
regarding the durability of porcine prostheses, and the morbidity and mortality
associated with replacement of the
prostheses.
This series presents a number of points
of interest. First, overall patient survival
is satisfactory. The incidence of late death
due to thromboembolism was very low
and there were no deaths due to complica
tions o f anticoagulant therapy or
catastrophic prosthetic failure.
The difference in survival between our
earlier (Hancock) and later (CarpentierEdwards) experience is perplexing. The
difference was mainly due to late deaths
from congestive heart failure in patients
with mitral valve replacement, although
there was also a difference among those
with aortic valve replacement. We found
no evidence that this was due to a dif
ference in function of the prostheses or
to their failure, but autopsies were not
performed in most patients who died of
congestive heart failure. This difference
may be explained by a number of factors,
including the introduction of cold
potassium cardioplegia, a higher propor
tion in the Hancock mitral valve replace
ment group (19.5%) with a class IV New
York Heart Association functional
classification than in the CarpentierEdwards group (14%) and a slightly

Table 1- Cause of Late Death
Cause

Hancock

C o n g e stive he a rt fa ilu re

Type of prosthesis
Carpentier-Edwards

13
4
4

M y o c a rd ia l in fa rctio n
S u d d e n d e a th
T h ro m b o e m b o lis m
P e rip ro s th e tic leak
In fe c tiv e e n d o ca rd itis

2
2
4

C a rcin o m a
O th e r
T o ta l

2

Total
deaths
15

-

4

4

8
4

2
1

3

5
5

1
2
4

5
7
9

39

16

55

Table II—Late Complications

Complication
T h ro m b o e m b o lis m
In fe c tiv e e n d o ca rd itis
P e rip ro s th e tic leak
P ro s th e tic fa ilu re
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Hancock
(n = 147)

Type of prosthesis, no. of patients
(no. of deaths)
Hancock + CarpentierCarpentier- Edwards
Edwards (n = 10)
(n = 130)
4 121
2 111

8 I2I
5 I4I
3 I2I
1

1

2 111
1

Total
no.
12
7
6
2

58 patients followed up for 6 years or
longer, and we have experienced only two
cases of failure of the prosthesis (not in
cluding failure due to infectious endocar
ditis or periprosthetic leak). While con
cern remains as to the late incidence o f
prosthetic failure, the results to date are
satisfactory. Reports of late thrombosis,
particularly of disc valves,2-3 and reports
of mechanical failure of mechanical
prostheses12' 13 remind us that the long
term durability of many mechanical pros
theses also remains uncertain.
The question of which type of pros
thesis, tissue or mechanical, gives better
long-term patient survival and freedom
from morbidity remains unanswered. The
answer depends upon such unknowns as
the mortality and morbidity associated
with replacement of worn prostheses, and
the cumulative mortality and morbidity
of thromboembolism, anticoagulants and
catastrophic prosthetic failure. Our ex
perience with porcine prostheses has been
gratifying. We have experienced a low in
cidence of valve-related complications
and failure of prostheses at implantation
periods of 5 to 7 years.
We thank Joan MacNab, research assistant,
for her aid in the follow-up evaluation.
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Fluorocarbon and Dextran Hemodilution in
Myocardial Ischemia

>

The effect of hemodilution, with a
fluorocarbon erythrocyte substitute and
with dextran, on myocardial ischemia in
duced by occlusion of the left anterior
descending coronary artery was in
vestigated in anesthetized dogs. The
resulting changes were compared to
those in a control group subjected to a
sham-exchange procedure. The
hematocrit was reduced to 23% to 26%
by dilution with fluorocarbon and dex
tran, while it was maintained at 42% to
46% in the control group. At similar
hematocrit levels, during ventilation with
100% oxygen, the fluorocarbon-diluted
blood transported 4 ml/dl more oxygen in
the plasma phase than the dextrandiluted blood. Left ventricular function
was not significantly altered and there
was a marked improvement of blood
flow to the ischemic zone. The mass of
dehydrogenase-stained ischemic myocar
dium (21% of left ventricular mass) was
marginally (p < 0.06) smaller in the
dogs with fluorocarbon-diluted blood
than in the control group (29% of left
ventricular mass). The output of creatine
phosphokinase by the heart was also
reduced (p < 0.05) by hemodilution
with fluorocarbon. These findings sug
gest that hemodilution with an oxygen
transporting blood substitute may have
marginal beneficial effects on the col-
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lateral perfusion of acutely ischemic
myocardium following sudden coronary
artery occlusion.
On a etudie chez le chien anesthesie I'effet de I'hemodilution a I'aide d'un derive
fluorocarbone, substitut d’erythrocyte,
ou de dextran, sur I'ischemie myocardique provoquee par I'occlusion de i'artere
interventriculaire anterieure gauche. Les
changements qui en decoulaient ont ete
compares a ceux d'un groupe temoin
soumis a une hemodilution factice.
L'hematocrite a ete reduit a entre 23%
et 26% par dilution avec le derive
fluorocarbone et avec le dextran, alors
qu'il fut maintenu entre 42% et 46%
chez le groupe temoin. A niveaux
d'hematocrite similaire, durant la ventila
tion avec de I'oxygene a 100% , le sang
dilue avec le derive fluorocarbone
transportait 4 ml/dl plus d'oxygene dans
la phase plasmatique que le sang dilue
avec du dextran. II n'y avait pas d'alteration significative de la fonction ventriculaire gauche et on observait une
amelioration marquee du debit sanguin
dans la zone ischemique. La masse du
myocarde ischemique coloree a la
deshydrogenase (21% de la masse ventriculaire gauche) etait tres legerement (p
< 0.06) plus faible chez les chiens dont
le sang avait ete dilue avec le derive
fluorocarbone que chez les chiens du
groupe temoin (29% de la masse ventriculaire gauche). La liberation de
creatinine phosphokinase par le coeur
etait aussi reduite (p < 0.05) par
I'hemodilution avec un substitut du sang
transporteur d'oxygene peut avoir de
legers effets benefiques sur la perfusion
collateral du myocarde en ischemie
aigue a la suite de I'occlusion soudaine
d'une artere coronaire.
Sudden occlusion o f a major coronary
artery usually leads to infarction in
the ischemic portion o f the myocar
dium, a process that involves complex
and progressive biochemical changes,
resulting in impaired contraction of

the ischemic myocardium.1-3 More
over, remote changes rapidly become
evident in the blood, and its rheo
logic properties are altered.4-6 These
changes may have more important
implications than is generally recog
nized.7 It has been argued that, since
the volume percentage o f erythro
cytes, as expressed by the hematocrit
level, is the principal determinant of
blood viscosity, its reduction by he
modilution may improve the perfu
sion o f marginally ischemic myocar
dium through the available and, pre
sumably, maximally dilated colla
terals.
A number o f experiments have
been reported, using hemodilution
with dextran,8-10 plasma9,11 or crystal
loids.9,12,13 Although the majority of
these studies demonstrated increased
collateral flow, the evidence for im
proved oxygen supply to the ischemic
region is equivocal, since reduction of
the hematocrit level is accompanied by
a proportional decrease in arterial
oxygen content. In two studies14,15
stroma-free hemoglobin solution was
used for hemodilution, following
acute coronary artery occlusion. These
studies reported improved flow to the
ischemic zone, as well as presumptive
evidence of a reduction in the extent
and severity o f hypoxia in the is
chemic zone. Presumably, the ap
parent superiority o f stroma-free he
moglobin over dextran is related to
the ability of the hemoglobin to trans
port appreciable amounts of oxygen
in the plasma phase. Unfortunately,
access to this oxygen may be limited
at normal tissue oxygen tension by the
high affinity o f the stroma-free hemo
globin for oxygen.16 Another potential
erythrocyte substitute, the fluorocar
bon preparation Fluosol-DA, has be
come available. This agent transports
oxygen by virtue of its high solubility;
therefore, the loading and unloading
of oxygen are governed, in a linear
fashion, by the oxygen tension. Two
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reports'7,18 suggest that oxygen supply
to the ischemic myocardium, after
acute coronary artery occlusion in
the dog, is improved after the ad
ministration of a fluorocarbon. The
experiments reported here investigate
possible improvement of the oxygen
supply to the ischemic zone by hemodilution with an oxygen-transporting
fluorocarbon, which is at present the
subject of clinical trials.
Material and Methods
Twenty-three, male, mongrel dogs,
weighing from 14.8 to 24.7 kg, made
up the experimental animals. They
were randomly assigned to three
groups. In eight dogs, group 1, hemodilution was performed with Fluosol-DA 20% (Green Cross Corp.,
Osaka, Japan). In another eight dogs,
group 2, dextran 70 (Abbott Labora
tories, Ltd., Montreal, PQ) was used
for hemodilution; these dogs served
as a control group subjected to he
modilution to a similar hematocrit
but without a significant amount
of oxygen transported in the plasma
phase. The remaining seven dogs,
group 3, had their shed blood reinfused. They served as an additional
time control, subjected to a sham
exchange.
Anesthesia was induced with so
dium pentobarbital (30 mg/kg with
supplemental doses as required). After
endotracheal intubation, catheters
were placed in the femoral arteries
and veins bilaterally. The chest was
opened on both sides in the fifth
intercostal space, with careful hemo
stasis. A short polyethylene catheter
was placed in the left atrium and a
catheter-tip pressure transducer (Mi
cro-Tip PC-350A; Millar Instruments,
Houston, Tex.) was inserted in the
left ventricular cavity through the
apex. A ligature was placed loosely
about a short segment of the left an
terior descending coronary artery,
which was isolated beyond its first
septal branch. On the right, a cath
eter was inserted in the coronary sinus
and fixed so that its tip lay 2 cm
from the valve of the coronary sinus.
This placed the catheter downstream
from all the important tributaries. In
four dogs of group 1, four of group
2 and three of group 3, the vein
draining the ischemic zone was also
catheterized with a fine polyethylene
catheter. Throughout the experiment,
the dogs were ventilated through the
cuffed endotracheal tube with 100%
oxygen, using a Harvard pump with
an expiratory resistance of 4 cm H20.
The rate and volume of ventilation
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were adjusted at the beginning of the
experiment to maintain the arterial
oxygen and carbon dioxide tensions in
the physiologic range. Following the
surgical preparation, a 30-minute pe
riod was allowed for the cardiovas
cular system to stabilize. During a
control preocclusion period, measure
ments were made as follows: An Elec
tronics for Medicine VR-6 Simultrace recorder (Electronics for Med
icine, Inc., White Plains, NY) meas
ured phasic arterial blood pressure
and its derivative (dp/dt), left ventri
cular end-diastolic pressure and lead
II of the electrocardiogram. Cardiac
output was determined by dye-dilu
tion, using indocyanine green dye and
a Waters densitometer (D-400) cuvette
(XC302) system (Waters Instruments
Co., Rochester, Minn.). Calibrations
were performed with the dog’s own
blood, with and without Fluosol-DA
or dextran, as appropriate. Blood sam
ples were drawn anaerobically from
the arterial and coronary sinus cath
eters for estimation of the oxygen ten
sion (Po2), carbon dioxide tension
(Pco2) and pH, which were measured
on an Instrumentation Laboratory
11.113 blood gas analyser (Instrumen
tation Laboratory, Inc., Lexington,
Mass.) at 37°C. The measured values
were corrected using standard nomo
grams.19 Oxygen content was deter
mined using a LEX 0 2-CON TL
oxygen analyser (Lexington Instru
ments. Waltham, Mass.). Arterial
blood samples were used to determine
hemoglobin concentration in whole
blood (by the cyanmethemoglobin
method) and the hematocrit level was
measured in triplicate in capillary
tubes, using a Damon/IEC micro
hematocrit centrifuge (Damon Equip
ment Co., Needham Heights, Mass.).
Oxygen capacity was measured in
whole blood and in the separated
plasma phase. Separate arterial and
coronary sinus blood samples were
drawn into chilled plastic syringes for
the subsequent measurement of crea
tine phosphokinase activity.20
Myocardial ischemia was induced
by tightening the ligature about the
left anterior descending coronary ar
tery. During the next hour the con
trol measurements were repeated. A
rapid exchange transfusion was per
formed; blood (30 to 35 ml/kg) was
removed from the femoral artery and
an equal volume of the experimental
solution in groups 1 and 2 and of
their own blood in group 3 dogs was
rcinfused into the femoral vein. Dur
ing the subsequent 3 hours, measure
ments were repeated at intervals in
all three groups, which were treated

in an identical manner. In addition,
myocardial blood flow and its dis
tribution were estimated from the
trapping of radionuclide-labelled mi
crospheres (15 ± 3 fim) obtained
from the 3M Co. (St. Paul, Minn.).
These were prepared and injected into
the left atrium according to standard
procedures.21 Microspheres labelled
with ytterbium-169 were injected in
the preocclusion period, those labelled
with chromium-51 were injected 1
hour after occlusion and those la
belled with strontium-85 were in
jected 1 hour after the exchange
transfusion. At the end of the ex
periment, the heart was removed and
the atria and right ventricular free
wall were separated from the left
ventricle. The latter was sliced, per
pendicular to its long axis, into 8-mm
slices; the ischemic zone was ident
ified in these slices by staining with
nitroblue tetrazolium,22 at room tem
perature, for 20 minutes. The is
chemic zone thus identified was sep
arated from the apparently normal
zone and the tissue in both zones was
weighed separately for each slice.
Subsequently, these samples were di
gested in 4N potassium hydroxide for
48 hours. Radioactivity in the di
gested samples was determined in a
Packard two-channel gamma spectro
meter (model 3002; Packard Instru
ment Co., Inc., Downers Grove, 111.),
using three passes, at settings pre
viously established to minimize spec
tral overlap. Calculations of relative
and absolute blood flows were made,
using arterial reference samples drawn
during and after the injection of the
microspheres,23 by a Wang 600 cal
culator (Wang Laboratories, Inc.,
Tewkesbury, Mass.), using a pro
gram developed for this purpose.
To quantify the viscosity-modifying
effect of hemodilution, the viscosity
of whole blood was determined, at
eight different shear rates, in sam
ples of citrated arterial blood drawn
at hourly intervals, using a Brookfield-Wells viscometer (model LVT;
Brookfield Engineering Labs., Stough
ton, Mass.). Statistical analyses were
performed, using paired f-tests, to de
tect the significance of changes with
in groups and unpaired t-tests for
comparisons between groups.
Results
Preocclusion
There were no significant differ
ences between the groups in any of
the variables measured (Tables I and
II, Fig. 1). Because of the extensive
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surgical damage inflicted on the thor
acic muscles by the bilateral thora
cotomy, creatine phosphokinase ac
tivity found in peripheral arterial
blood was excessively high (246 to
389 mU/ml, our normal range is
from 10 to 35 mU/ml), even at this
time. For this reason we elected to
measure creatine phosphokinase dif
ferences across the heart and to cal
culate creatine phosphokinase output,
using the measured total myocardial
blood flow, as a semiquantitative in
dex of ischemic myocardial damage,
resulting in leakage of the enzyme.14
Postocclusion
Occlusion of the left anterior de
scending coronary artery was fol
lowed by abnormal cardiac rhythm in
seven dogs; four of these had ventri
cular fibrillation and in one case,
persistent
dysrhythmia
developed
(runs of ventricular premature beats

and bigemini); these four dogs (1 from
each of groups 1 and 2, 2 from group
3) are excluded from the analysis.
In two cases, short runs of ventricu
lar premature beats subsided spon
taneously within 5 minutes and these
dogs remained in sinus rhythm with
out treatment; they were included in
the analysis. All animals reported in
the study survived in sinus rhythm
until the experiment was terminated
3 hours after the exchange transfu
sion. Qualitatively and quantitatively,
the changes during the 60-minute pe
riod following the occlusion were
similar in all three groups. The ar
terial Po» fell marginally in all groups.
The trends observed in hemodynamic
variables (Figs. 1 and 2) were also
similar: while heart rate remained
stable, mean arterial pressure tended
to rise and cardiac output and stroke
volume decreased. A consistent de
crease in left ventricular dp/ dt was
evident, with a rise in left ventricular

Table 1-Blood Measurements*________________________
Measurement
by group___________ Preocclusion

1h
--------------------- PostBXchanfle- h----------postocclusion_______ 1____________ 2____________ 3

Hemoglobin, mg/dl
14.9 + 1.0
15.3 + 1.2
8.2
Group 1
16.4 + 1.2
8.0
Group 2
16.5 + 1.1
15.9
16.6 + 2.1
16.2 + 1.1
Group 3
Hematocrit, %
47 + 3
23
45 + 3
Group 1
24
49 + 2
48 + 4
Group 2
47
48 + 3
50 ± 3
Group 3
Fluorocrit, %t
0
0
8
Group 1
’ Figures are mean + standard error of the mean.
tFractional volume of packed fluorocarbon after centrifugation.

7.9 + 0.9
8.1 + 1.3
15.7 + 1.6

7.4 + 1.1
8.0 + 1.4
15.2 + 1.4

+ 4
+ 3
+ 2

22 + 2
23 + 3
48 + 1

23 + 2
25 + 2
46 + 3

+ 1

7 + 1

6 + 1

+ 0.8
+ 1.5
+ 1.4

end-diastolic pressure. All three
groups exhibited a fall in coronary
sinus Po>. The differences in creatine
phosphokinase values across the heart
widened significantly and the estim
ated output by the heart increased
five- to eightfold (Table III). Estim
ated blood flow to the normal myo
cardium increased in all three groups,
while it was greatly reduced in the
ischemic zone; this was more pro
nounced in the subendocardial than
in the subepicardial layers (Table IV).
The variables measured in group 3,
except for the 10 minutes imme
diately following the sham-exchange
transfusion, were similar to those ob
served in preliminary experiments in
which these variables were followed
for 4 hours after an acute coronary
artery occlusion.
Effects of Hemodilution
Group 3 served as the baseline for
comparison with groups 1 and 2.
Hemodilution
produced
clear-cut
changes in blood oxygen values
(Tables I and II). The hematocrit
level was reduced to 23% to 26%.
Both hemodiluted groups exhibited a
significant (p < 0.006) rise in arterial
blood Po2 (Table II). In spite of the
similar levels of hematocrit and Po2,
the presence of fluorocarbon in group
1 allowed a significantly (p < 0.02)
higher oxygen content in the plasma
phase of arterial blood than did the
aqueous solution in group 2 (Table

Table 11-Blood Oxygen Measurements*
Measurement by group
Arterial blood Po2, mm Hg
Group 1
Group 2
Group 3
Arterial blood Pco2, mm Hg
Group 1
Group 2
Group 3
Arterial blood 02 content,
ml/dl
Group 1
Group 2
Group 3
Coronary sinus Po2, mmHg
Group 1
Group 2
Group 3
’ Figures are mean + SEM.

Preocclusion

1h
postocclusion

1

Postexchange, h
2

3

429 + 59
417 + 49
467 + 67

380 + 49
359 + 62
374 + 52

546 + 53
552 + 47
379 + 51

559 + 42
572 + 59
382 + 49

562 + 53
569 + 48
373 + 52

36 + 3
39 + 2
37 + 2

36 + 3
38 + 3
36 + 4

38 + 2
39 + 2
37 + 3

36 + 3
40 + 2
36 ± 3

37 + 2
40 + 3
37 + 2

21.0 + 1.0
22.9 + 1.3
22.6 + 1.3

21.5 + 1.2
23.8 + 1.2
23.0 ± 1.6

15.4 + 1.3
11.8 + 1.5
22.3 + 1.4

14.6 + 1.7
11.9 + 1.3
22.0 + 1.3

14.0 + 1.3
11.7 + 1.4
21.4 + 1.2

21 + 2
24 + 2
24 + 3

16 + 1
16 + 2
17 + 1

46 + 9
20 + 4
19 + 2

45 + 10
21 + 3
20 + 3

49 + 9
20 + 2
22 + 2

FIG. 1—Hemodynamic variables be
fore and after occlusion and after ex
change transfusions (mean ± standard
error of mean). LVEDP = left ventri
cular end-diastolic pressure, dp/dt
maximum rate of rise of left ventricular
pressure.
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II). Total oxygen content in whole
blood was nearly 4 ml/dl higher in
group 1 than in group 2, although it
was still lower than in the undiluted
blood of group 3 dogs.
In hemodynamic terms, group 1
was characterized by initially higher
than control levels (p < 0.05) of
cardiac output and dp/dt, which sub
sequently declined, and a modest re

duction of left ventricular end-dia
stolic pressure (Fig. 1). In contrast,
group 2 exhibited less, but well-sus
tained, elevation of dp/dt and of
cardiac output. Both of these ap
peared as improvements when com
pared with the group 3. In both
groups 1 and 2, the increments in
microsphere-estimated blood flow to
the ischemic zone were somewhat

FIG. 2— Blood viscosity at eight different shear rates. Preocclusion and 1-hour
postocclusion values were considered for all groups together since there were no
significant differences between them at these times.

Table Ill-C reatine Phosphokinase (CPK) Values
Measurement by group

Aortocoronary sinus
CPK change, mU/ml
Group 1
Group 2
Group 3
CPK output, mll/g • min'1
Group 1
Group 2
Group 3

Measurement

Blood flow
Ischemic core
Subendocardial
Subepicardial
Normal zone
Subendocardial
Subepicardial
Oxygen delivery
Ischemic core
Normal zone
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Postexchange, h
1
2

Preocclusion

1h
postocclusion

8.7 + 3.6
7.9 + 4.3
8.1 + 3.2

51 + 11
62 + 11
51 + 11

24 + 13
66 + 12
71 + 19

26 + 12
60 + 13
89 + 17

12 + 6
10 + 4
10 + 5

80 + 10
76 + 12
86 + 14

69 + 12
79 + 13
152 + 18

50 + 11
82 + 15
306 + 31

Table IV-Myocardial Blood Bow and Oxygen Delivery,
% of Preocclusion Value
t h postocclusion__________
1 h postexchange
Group 1
Group 2
Group 3
Group 1
Group 2
Group 3

17 + 6
28 + 6

19 + 4
26 + 4

20 + 4
26 + 5

25 + 9
38 + 10

35 + 8
39 + 6

21 + 5
24 + 6

132 + 14
146 + 12

140 + 17
127 + 16

126 + 10
141 + 18

178 + 12
169 + 10

180 + 17
196 + 20

96 + 12
103 + 17

24 + 7
140 + 26

23 + 11
132 + 29

24 + 12
133 + 32

26 + 16
174 + 28

17 + 10
189 + 31

23 + 12
101 + 38

smaller than those to the normal zone
(Table IV). Perfusion of the ischemic
zone, 1 hour after the exchange trans
fusion, was 40% to 60% greater in
groups 1 and 2 than in group 3.
When oxygen delivery was calculated
(Table IV), the postocclusion level of
delivery was maintained in group 1,
after hemodilution, while it was re
duced by approximately 26% in
group 2. In the latter, the Po2 meas
ured in the coronary sinus was mar
ginally (though not significantly) re
duced, while there was a marked and
significant (p < 0.01) rise in the
former. In the small number of ani
mals in which venous blood could
be obtained by draining directly from
the ischemic zone, the Po2 rose by an
average of 9 mm Hg in group 1 and
by 3 mm Hg in group 2. The statistical
significance of this finding is doubtful
because of the small numbers. Never
theless, the marked difference in Po2
does suggest improved oxygen supply
by the fluorocarbon in the ischemic
zone.
Blood viscosity was greatly reduced
by hemodilution at all but the highest
shear rates, at the time when a rise
in blood viscosity took place in the
control group 3 (Fig. 2).
In contrast to groups 2 and 3 in
which the output of creatine phosphokinase rose progressively, group
1 actually showed a reversal of this
phenomenon (Table III). The mass
of apparently ischemic myocardium
(Table V) was less in group 1 than
group 3 (p < 0.06).
Discussion
The rationale for the hypothesis
tested in these experiments rests on
the observations8-13 that collateral flow
is increased when blood viscosity is
reduced by hemodilution, but the in
creased flow is balanced by the re
duced oxygen content of the blood.
The present experiments were pre
dicated on the assumption that by
using an oxygen-transporting fluid to
dilute the cellular elements of the
blood, flow could be increased while
oxygen content would be reduced
less than with conventional colloidal
diluents, such as dextran. We found

Table V -M ass of Nitroblue TetrazoliumStained Ischemic and Normal Zones, % of
__________ Left Ventricular Mass_________
Group
Zone___________
1
2
3

Ischemic zone
Normal zone

21 + 5 23 + 6 29 + 7
78 + 7 77 + 9 72 + 11
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that the degree of hemodilution with gestion is further strengthened by the
fluorocarbon used in this study pro elevation of oxygen tension in the
vided approximately 4 ml/dl more blood draining directly from the is
oxygen in the plasma phase than did chemic zone, in the few experiments
dextran. This appears to be sufficient in which this could be accomplished
to improve the oxygen supply to the without trauma.
To date, only two reports17’18 have
marginally ischemic myocardium.
Whether a significant mass of mar appeared in which the effects of
ginally ischemic myocardium is in fluorocarbon hemodilution on myo
fact saved by this procedure is dif cardial ischemia were evaluated.
ficult to prove because of the dif One17 described the changes follow
ficulty in accurately identifying the ing the administration of Fluosol-DA,
marginal zone supplied by the col hydroxyethyl starch or heparin, 15
laterals,21 the boundary of which is minutes after the occlusion of the
irregular.25,26 In fact, the whole con left anterior descending coronary ar
cept of a salvageable marginal zone tery in dogs. The Fluosol-treated
may be in doubt.27,28 There are, how group exhibited marginally better left
ever, three pieces of circumstantial ventricular function and a narrower
evidence suggesting a beneficial ef difference in the polarographically
fect of fluorocarbon hemodilution. measured Po2 between the normal
First, the microsphere data indicated and ischemic myocardium. These
that blood flow to the ischemic zone findings were interpreted as indica
was significantly (p < 0.05) greater tive of a beneficial effect of Fluosol,
following hemodilution with fluoro although they are consistent with
carbon when compared with the pre other interpretations. Glogar and as
dilution levels in group 1 and group 3. sociates18 compared the estimated in
The distribution of flow within the farct size, after the left anterior de
visually identified ischemic zone is al scending coronary artery had been
most certainly not homogeneous28 and occluded for 6 hours, in dogs breath
the core of this zone does not benefit ing 100% oxygen and treated with a
significantly from a general increase fluorocarbon emulsion and with that
in flow. This suggests that the meas in air-breathing dogs comparably di
ured flow increment may be an un luted with Ringer’s solution, and in
derestimate of the actual flow incre untreated air-breathing dogs with a
ment to the peripheral regions of the normal hematocrit level. The fluoro
ischemic zone. Second, the estimates carbon-treated dogs sustained infarcts
of visibly ischemic myocardium, as that were an average of 30% smaller
identified by nitroblue tetrazolium, than those in the control group. Al
indicated that a smaller percentage though the controls were not ideally
of the left ventricle was ischemic at chosen for this experiment, the re
the conclusion of the experiment in sults can be interpreted as suggesting
group 1 than in group 3. This cannot an improvement in oxygen supply to
the territory of an occluded coronary
be adduced as an actual reduction
of the ischemic zone by the experi artery. The present findings are con
mental intervention, since the ana sonant with those of the two pre
tomy of the coronary vasculature vious studies.
varies from animal to animal and
It has been argued29 that the evo
there may have been an inadvertent lutionary development of the normal
but random bias favouring one group hematocrit was based on optimal oxy
over another. This is, however, un gen-transport capacity and that the
likely since the selection of the ani vulnerability of the subendocardial
mals was randomized. Third, although layers to ischemia during hemodilu
much of the creatine phosphokinase tion30 constituted sufficient grounds
detected in peripheral blood during for conventional hemodilution to be
acute myocardial infarction gets contraindicated in the presence of
there by way of the cardiac lymph, coronary artery disease. There is evi
actual estimates of the direct wash dence that hemodilution is associated
out of this enzyme by the collateral with some increase in all components
blood flow must bear some relation of myocardial work31 and the de
to a mass-intensity-product (a rela creased oxygen content necessitates
tive measure of significantly ischemic greater oxygen extraction.32,33 Yet, in
muscle) of myocardial ischemic dam the normal myocardium, normal oxy
age. Only in this sense can reversal gen supply can be maintained, in
of the trend to increasing output of spite of a reduced hematocrit level,34'36
creatine phosphokinase in group 1 and myocardial oxygen consumption
be interpreted as suggesting ameliora remains relatively constant when the
tion of the extent or severity of myo hematocrit is reduced to 30% 32 or
cardial ischemia, or both. This sug even to 20% .34-36 A conservative and

more readily acceptable interpretation
of the present study, as well as that
of others,14’15’17*18 is that hemodilution
with oxygen-transporting blood sub
stitutes does not significantly ag
gravate the extent and severity of
myocardial ischemia in the canine ex
perimental model. This may be of
more than academic interest, since
clinical testing of fluorocarbon blood
substitute is now under way in the
United States and in Japan, with a
view to future clinical use.
Our study may also reveal bene
ficial effects that may not be gen
erally appreciated. First, there is clin
ical, as well as experimental, evi
dence4"6 that the local process of
acute myocardial ischemia is accom
panied by adverse rheologic effects
on the blood. The importance of this
is appreciated by rheologists7'37 but
less well by clinical and experimental
cardiologists. Hemodilution by any
means that reduces the erythrocyte
and fibrinogen concentration of the
blood may reverse this process. It is
probable that some of the results of
the present experiment may be at
tributable to a similar phenomenon.
Second, it is possible that some of
the local effects of myocardial is
chemia are attributable to failure of
perfusion rather than to inadequate
oxygen supply. Hemodilution, by any
means, will increase perfusion and
this effect may be beneficial in re
ducing local acidosis, which may ag
gravate further the perfusion defect at
the microcirculatory level.38 Third,
hemodilution reduces vascular hin
drance36 as well as viscosity. This may
produce a form of unloading and
thereby reduce ventricular oxygen de
mand, while maintaining aortic blood
pressure and, thus, coronary perfu
sion pressure.
In summary, the evidence emerging
from the present report does not al
low an unequivocal conclusion of
definite benefit of fluorocarbon he
modilution in myocardial ischemia; it
does suggest that in the short term,
hemodilution with a fluorocarbon
blood substitute does not have serious
deleterious effects in the face of a
coronary occlusion. This suggests that
it may be found useful in preopera
tive hemodilution in the presence of
coronary artery disease or acute co
ronary occlusion.
The author is indebted to Mrs. D.
Beresford-Kroeger for her assistance in
the conduct of this study. The staff of
the department of experimental surgery,
particularly Mme. M. Bosc-Davy, rend
ered valuable assistance in the surgical
preparation of the animals.
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ETIOLOGY OF CONSTIPATION
• Lack of exercise — reduced muscle tone
• Drug induced - narcotics, analgesics
• Disrupted bowel habits
• Voluntary avoidance of defecation —
(e.g. rectal surgery)

The laxative most recom m ended by Physicians
• Non-systemic action
• Does not interfere with normal digestive processes
(e.g. the absorption of essential nutrients, vitamins,
or drugs)
*- • Does not encourage a "la z y b o w el" or
# T t lead to laxative dependency — can be
used long term
• Causes no "embarrassing'' urgency
• Provides natural source,
water-absorbing fibre which produces
bulk in the colon and

HELPS NORMALIZE
BOWEL IRREGULARITY.
Available in unflavoured Powder or effervescent, low-calorie
Instant Mix (lemon-lime or orange flavour)

CASE 8

A CASE
FOR METAMUCIL:
"THE POST-SURGICAL
(CONVALESCING) PATIENTrr
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Malignant Transformation in an Anal
Condyloma Acuminatum
A 6 1 -year-old man had malignant trans
formation of an anal condyloma acumina
tum, demonstrated by light and electron
microscopic studies.
Intranuclear virus-like particles were
seen in the benign condylomatous koilocytotic cells but these were absent in
the malignant cells. Multinucleation,
syncytial giant cells and nuclear atypia in
a condyloma acuminatum are considered
features of in-situ carcinomatous
change.
Anal condyloma acuminatum requires
wide excision and thorough examination
of anorectal canal in order to exclude
hidden disease, which will predispose to
recurrence. Homosexuality is considered
a predisposing factor.
The authors stress the importance of
histopathologic examination of all ano
rectal warts to exclude malignant
change.
Un homme de 61 ans a subi une trans
formation maligne d'un condylome acumine anal, demontree par microscopies
optique et eiectronique.
Des particules intranucleaires de type
viral ont ete observees dans les cellules
koilocytosique condylomateuse benignes
mais elles etaient absentes dans les cel
lules malignes. Dans le condylome acumine, la presence de cellules multinuclees, de cellules syncytiales geantes et
d'atypie nucleaire est jugee caracteristique d'une transformation cancereuse in
situ.
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Le condylome acumine anal necessite
une excision large et un examen minutieux du canal ano-rectal de facon a
exclure toute maladie cachee qui pourrait
predisposer a une recidive. L'homosexualite est consideree comme un facteur
predisposant.
Les auteurs soulignent I'importance
d'un examen histopathologique de toutes
les verrues ano-rectales pour eliminer la
possibility d'une transformation maligne.

Condyloma acuminatum is a virally
induced warty lesion that has predi
lection for skin and mucocutaneous
areas of the gastrointestinal, respira
tory and genitourinary tracts. Papovavirus has been identified as the
cause of this lesion.1’2 The carcino
genic potential of the papovavirus
group is well demonstrated by the
malignant transformation of the
Shope papilloma, a benign papovavirus-induced lesion commonly found
in cottontail rabbits.3,4 This malignant
change, though frequent in animals,
is rare in man. However, malignant
transformation of condyloma acu
minatum in man has been reported5'7
and is of increasing importance in the
carcinogenesis of the uterine cer
vix.8-10
Recently, we encountered a case of
anal condyloma acuminatum, which
underwent malignant transformation.
We describe the case and demonstrate
the transition from a condylomatous
lesion through in situ carcinoma to
invasive squamous cell carcinoma.

The patient looked healthy. He had
no jaundice and there were no palpably
enlarged lymph nodes. Blood pressure
was 150/70 mm Hg and the pulse was
75 beats/min and regular. Examination
of respiratory, cardiovascular and nerv
ous systems showed no abnormalities.
There were no palpably enlarged ab
dominal organs and no ascites.
Rectal examination revealed a large
wart-like lesion, measuring 5 x 4 x 1.5
cm, surrounding the anus and extending
to the dentate line. A clinical diagnosis
of condyloma acuminatum with a dif
ferential diagnosis of squamous cell car
cinoma was made.
The VDRL test was nonreactive. Re
sults of other laboratory and radiologic
studies were normal. Following sigmoid
oscopy, the anal lesion was excised and
sent for pathological examination.
The patient refused any further sur
gery. The rectosigmoid was thoroughly
examined and found free of disease. He
was well and was symptom-free 6
months after surgery.

Case Report

A 6 1-year-old man presented with a
progressively enlarging left anal lesion
that caused pain after defecation. The
tumour had been present for 3 months.
He also experienced anal irritation, itch
ing, discomfort and occasional bloody
discharge. In 1950 he had undergone
surgical drainage of bilateral groin ab
scesses. He had had a homosexual rela
tionship but was married with two chil
dren. He smoked two packages of ciga
rettes daily. The anal lesion had not
been treated with podophyllin.

FIG. 1—Section of anal lesion shows
acanthotic squamous epithelium with
perinuclear vacuolization and centrally
located basophilic nuclei (hematoxylin
and eosin, reduced by 52% from X350).
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Gross
The anal lesion consisted of an
irregular tissue fragment measuring
5.5 X 3.5 X 1.5 cm. There were
irregular polypoid projections from
the surface of the tissue. A second
small fragment of anorectal tissue,
measuring 1.6 X 0.6 cm, was also
submitted for examination.
Microscopic
Multiple sections showed stratified
squamous epithelium that was kera
tinized. acanthotic and papillomatous,
with rounding of the rete ridges.
Cytoplasmic vacuoles with centrally
located round basophilic nuclei were
present (Fig. 1). This is consistent

with condyloma acuminatum. In
other areas the nuclei were atypical,
with multinucleation, individual cell
keratinization and increased mitotic
activity (Fig. 2), consistent with ma
lignant transformation. In some areas,
the condylomatous lesion was con
tinuous with frankly invasive, welldifferentiated, keratinizing squamous
cell carcinoma (Fig. 3) and in other
areas, infiltrating, well-differentiated
squamous cell carcinoma was seen
(Fig. 4). There was dense chronic in
flammatory cell infiltrate in the subcpidermal region and around the in
filtrating nests of malignant cells.
Electron microscopy of formalinfixed tissue from the lesion showed
smudged, intranuclear, virus-like par
ticles in the koilocytotic cells, but
not in the tumour cells (Fig. 5).

FIG. 2—Acanthosis, nuclear atypia, multinucleation and
increased mitoses can be seen (hematoxylin and eosin, reduced
by 49% from x !5 0 ).

FIG. 4—Area of lesion showing in
filtrating, well-differentiated, keratinizing
squamous cell carcinoma (hematoxylin
and eosin, reduced by 52% from X250).

Discussion

Malignant transformation in a be
nign condyloma acuminatum is no
longer in doubt. Several such cases
have been documented in the cer
vix"'12 and anorectum.6 In some, how
ever, the malignant changes have
replaced the condylomatous lesion,
making the association difficult to
demonstrate. In our case, the condy
loma acuminatum was well demon
strated and areas of malignant trans
formation were indicated by cellular
atypia and syncytial multinucleation.
Although syncytial multinucleation is
ordinarily a feature of benign viral in
fection, the absence of intranuclear
viral inclusions on light microscopy
(Fig. 2), an enormous increase in the
multinucleation and the presence of

FIG. 3— Condylomatous lesion on left is in continuity with
invasive squamous cell carcinoma on right. Chronic inflam
matory cells are present in upper dermis (hematoxylin and
eosin, reduced by 49% from X200).

FIG. 5—Electron microscopic appearance of koilocytotic cell shows aggregates
of intranuclear virus-like particles (arrows) (uranylacetate stain, reduced by 31%
from X 24 200).
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nuclear atypia and numerous mitoses
will point towards real neoplastic
change. The neoplastic progression in
our case was borne out by the pres
ence of frankly malignant, invasive
squamous cell carcinoma adjacent to
the transformed atypical area.
Electron microscopy did not show
viral particles in the invasive tumour
cells; however, these virus-like par
ticles were demonstrated in the koilocytotic condylomatous cells. The exact
nature of the koilocytotic cells, first
described by Koss and Durfee,13 is
controversial. As demonstrated in our
Fig. 1, these cells show perinuclear
cytoplasmic clearing and often pos
sess wrinkled, hyperchromatic nuclei.
Koss and Durfee13 noted an associa
tion of these cells with in situ and
invasive carcinomas of the cervix.
Ayre12 held the view that the koilo
cytotic cells represented the earliest
manifestation of malignancy in hu
man cells caused by viral infections.
This view, though not conclusive, can
be strengthened by the observation
that koilocytotic atypia of the uterine
cervix found often in young women
is associated with a high proportion
of epithelial dysplasia in those wom
en.14 Whatever these cells may rep

resent, it is generally agreed that the
perinuclear vacuolization seen in
them is a cytopathic effect of human
papovavirus, which is the virus re
sponsible for condylomas. Moreover,
some studies15,16 have demonstrated
virus particles in these koilocytotic
cells. The absence of viral particles
in the tumour cells is not surprising.
In animal experiments on the Shope
papilloma, the viral particles usually
disappeared in the transformed cells.3,4
The viral DNA, once incorporated in
the human cell genome, may be dif
ficult to identify on electron micro
scopy as an independent particle.
Similar findings of the absence of
viral particles in transformed human
malignant cells have been docu
mented in skin17 and cervical5 virally
induced epithelial lesions.
By using anti-papovavirus antibody
and immunoperoxidase techniques, it
might be possible to demonstrate the
presence of viral particles. The short
duration of symptoms caused by the
warty lesion before malignant change
occurs in the susceptible individual is
of interest. In a large series of con
dylomatous lesions of the penis that
underwent malignant change, the

average duration of symptoms was 7.5
months.18 Our patient had his symp
toms for only 3 months. An impor
tant differential diagnosis in these
patients includes giant condylomata
acuminata of Buschke and Loewenstein. However, symptoms were more
prolonged in these lesions.18 They are
also slowly growing malignant lesions
from the onset with no areas of tran
sition from the benign to malignant
form.
Anorectal condylomata acuminata
are more frequent in homosexual
men.19,20 It has also been demon
strated that these homosexuals, in
contrast to heterosexuals, harbour in
fections in the rectal mucosal sinuses
and, unless these are eradicated, re
currence is bound to occur.21
It is pertinent to stress the impor
tance of examining all anal and gen
ital warts histopathologically since
only in very few instances will the
gross appearance strongly suggest car
cinoma. Fulguration of anal warts is
to be discouraged.

'
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“ THE TWO-STEP MANAGEMENT . .
continued from page 111

Wright have not indicated why they can
not patiently and sympathetically explain
what the management possibilities are.
For most of us there is a 2- to 3-week wait
for a hospital bed, so that there is ample
time for the unfortunate woman to seek
further opinions, ask further questions,
negotiate a contract and come to terms
with the decision that must be made, and
under far more comfortable circum
stances than hospital confinement. The
patient will be far better reassured by a
confident one-step approach than by the
uncertainty, indecision and procrastina
tion that is inevitable with two pro
cedures. Our job is to minimize patients’
anxiety even if it requires the use of nonfaddish means.
J .E . D evitt ,

m d , frcs [ c ]

Director,
Continuing Medical Education,
University of Ottawa,
Ottawa Civic Hospital,
Ottawa, Ont.
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Du Pont technology, and Du Pont resources to help u s provide you with better
pharmaceuticals. Currently, 17 products are in various stages of developm ent for the
therapeutic treatment o f cardiovascular diseases, disorders of the central nervous
system , infectious diseases, and m etabolic diseases. In addition, research is under
way on new analgesics and on therapeutic agents for the treatm ent of cancer.
Du Pont, through all its subsidiaries and divisions, has a tradition of expertise in health
sciences including m edical x-ray products, radiopharm aceuticals and clinical
laboratory instrumentation.
In ethical pharm aceuticals,
the list of established
products also is impressive.
They are: SYMMETREL®
(amantadine HC1); NARCAN® (naloxone HC1); NUBAIN® (nalbuphine HC1);
COUMADIN® (crystalline warfarin sodium); PERCODAN® (oxycodone/aspirin);
and PERCOCET® (oxycodone/APAP). In the future, w e’11be com bining Du Pont basic
resources with advanced technology. We’ll be pursuing traditional research, and
exploring new frontiers in brand new laboratory facilities... including an $85 million life
sciences R&D centre and a process development facility for pharmaceutical
chem icals. We’11 be expanding existing markets and building new ones. B ecause
at Du Pont, w e’re gathering all our forces to provide better pharm aceuticals...
for better health care.
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Papillary Cystadenoma of the Epididymis
The case of a 30-year-old man with
papillary cystadenoma of the epididymis
is presented. This extremely rare lesion
is often associated with von HippelLindau disease, although in this case
there were no such signs or symptoms.
The gross and microscopic features of
this lesion and theories of its origin are
reviewed. The constant microscopic
features are: efferent duct ectasia with
papillary formation, a lining of cuboidal
epithelium, often with clear vacuolated
cytoplasm, and a stroma of hyalinized
fibrous tissue infiltrated by inflammatory
cells.
On decrit le cas d'un homme de 30 ans
ayant un cystadenome papillaire de
I'epididyme. Cette lesion extremement
rare est souvent associee a
I'angiomatose de von Hippel-Lindau,
bien que dans ce cas, on n'en ait
observe aucun signe ou symptome.
Les caracteristiques macroscopiques et
microscopiques de cette lesion ainsi que
les theories concernant son origine sont
passees en revue. Au microscope, les

caracteristiques retrouvees de facon
constante sont: une ectasie des canaux
efferents avec formation de papilles, une
membrane d'epithelium cuboidal ayant
souvent un cytoplasme clair et vacuolise,
et un stroma de tissu fibreux hyalinise
infiltre de cellules inflammatoires.

Sherrick,1 in 1956, was the first to
describe papillary cystadenoma of the
epididymis. This is an extremely rare le
sio n , there being only 17 cases
documented by the American Tumour
Registry in Washington, DC.2 Of these,
seven were associated with von HippelLindau disease. An additional example of
this rare lesion is reported below.
Case Report

From the departments o f pathology and
surgery, N orfolk General Hospital, Simcoe,
Ont.

A 30-year-old man in good health was seen
at the Norfolk General Hospital with a history
of right testicular swelling present for 1'h years.
The swelling did not vary in size over this
period. He manifested no signs or symptoms
of von Hippel-Lindau disease nor was there
any family history of this disorder.
A firm mass, 1 cm in diameter, was palpable
at the site of the right epididymis. The testes
themselves were unremarkable. A clinical
diagnosis of spermatic granuloma was made.
The lesion was excised.
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Findings

Reprint requests to: Dr. N.R. Kallie, Direc
tor o f laboratories, Norfolk General
Hospital, 365 West St., Simcoe, Ont.
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The specimen was a firm tumour mass,
0.5 cm in diameter, cystic and golden
yellow on cross-section.

FIG. 1—Cystic tumour with papillary projections (right), epididymis
(left) (hematoxylin and eosin).
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The lesion was found on microscopic
examination to be associated with the
epididymis (Fig. 1). It was multicystic,
each cyst having papillary processes pro
jecting into the lumen. These papillary
processes were lined by cuboidal or col
umnar epithelium with basal nuclei. Cilia
were detected in some areas. In places the
cytoplasm was vacuolated, resulting in a
clear cell morphology (Fig. 2). The divi
sion into cysts was achieved by thick
bands of collagen in which a minimal
amount of chronic inflammation was
present.
Discussion

The origin of this lesion is uncertain.
All cases reported involved the epididymis
or area close to it. Sherrick1 suggested
that the glandular, papillary and cystic
nature of the lesion and the tall colum
nar ciliated cells point to an epithelial
origin. The consensus is that this
epithelium is of efferent ductules of the
epididymis.1-4 These efferent ductules are
mesonephric in origin. It is noteworthy
that other tumours similar to the papillary
cystadenoma of the epididymis, such as
adenocarcinoma of the testes in infants,4
arise from the mesonephric duct system.
The cystadenomas also resemble sper
matoceles with respect to location and lin
ing epithelium.1’3
It has also been postulated that this le
sion may be inflammatory in origin5

FIG. 2—Clear cell component of tumour (right) (hematoxylin and

eosin).
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because of the presence of granulation
tissue, cholesterol crystals, giant cells and
calcification in the wall of the cyst.
The association between papillary
cystadenoma of the epididymis and von
Hippel-Lindau disease is well known.2 3
This disease consists of cerebellar
hemangioblastoma with angiomas and
cysts of liver, pancreas and kidneys and
tumours of epididymis and kidneys.2,3
Papillary cystadenomas occur mainly
in young adults.2,3,6 The American
Tumour Registry gives an age range of
from 16 to 68 years, most patients being
in the second and third decades of life.
The clinical presentation is that of a
nodule that has been present for many
years.2 Bilateral lesions have been
seen.2,5
The tumour is not greater than 5 cm in
diameter and is usually brown.2 The cut
surface is cystic3,6 with m ultiple
yellowish areas3,6 that represent the ac

cumulation of lipid. The fluid in the cysts
is clear, watery or blood-stained. The le
sions are usually well circumscribed.
The microscopic findings are common
to all lesions. There is ectasia of efferent
ducts with papillary formation. The ducts
are lined by cuboidal epithelium often
with clear vacuolated cytoplasm. The cells
are sometimes ciliated. The papillary pro
cesses arise from the walls of the ducts
and fill the cysts. The stroma is compos
ed of dense fibrous tissue that is often
hyalinized. Inflam m atory cells and
lipogranulomatous inflammation are
seen.1,2 The clear cytoplasm is attributed
to glycogen accum ulation in the
epithelium.6
The nuclei usually are uniformly oval,
6 to 10 n in diameter, and are hyperchromatic. Mitoses are rare. No malig
nant counterpart of the lesion has yet
been described.6
These gross and microscopic findings

are typical of those seen in the case
presented.
We thank Miss Cindy Maxwell for typing the
manuscript, Mr. B. Cook for preparing the il
lustrations, Mrs. M. Carpenter for collecting
the references and Dr. S. Moore for valuable
criticism.
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Beneficial Effects of Methylprednisolone on Urinary Excretion
of Lysosomal Enzymes in Acute Renal Ischemia
An experimental model of canine normothermic renal ischemia was used to
determine whether lysosomal urinary en
zyme excretion reflects the extent of
ischemic cellular injury, as assessed by
subsequent renal function (serum
creatinine level) and morphologic
changes. The value of a lysosomal
membrane-stabilizing agent (methylpred
nisolone) in protecting kidneys from
ischemic damage by preventing
lysosomal enzyme release was assessed.
Results showed conclusively that
urinary enzyme activities of /3galactosidase and N-acetyl-(3glucosaminidase are valuable indicators
of renal cellular damage and functional
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outcome after ischemic injury, and that
methylprednisolone at a dose of 30
mg/kg, given intravenously 1 hour before
a 1-hour period of normothermic
ischemia, protects the kidney both
biologically and morphologically, by
reducing the excretion of lysosomal en
zymes after revascularization.
Un modele experimental d'ischemie
renale normothermique chez le chien a
ete utilise pour dgcouvrir si I'excretion
urinaire d'enzymes lysosomiaux traduisait I'etendue des dommages cellulaires
ischemique, tels qu'evalues par les changements subsequents de la fonction
renale (niveau de creatininemie) et de la
morphologie du rein. Un stabilisateur de
membrane lysosomiale (le me
thylprednisolone) a ete employ^ pour
evaluer la protection rgnale obtenue contre les dommages ischemiques par I'empechement de la liberation des enzymes
lysosomiaux.
Les resultats montrent de facon concluante que I'activite enzymatique uri
naire de la jS-galactosidase et de la Nacetyl-fj-glucosaminidase est un indi
ca te s important des lesions cellulaires
r£nales et de I'atteinte fonctionnelle consecutives a des dommages ischemi

ques; ils montrent aussi que la methyl
prednisolone, administree par voie
intraveineuse 6 la dose de 30 mg/kg, 1
heure avant une periode d'ischemie
normothermique de 1 heure, protege le
rein, biologiquement aussi bien que
morphologiquement, en reduisant I'excre
tion des enzymes lysosomiaux apres
revascularisation.

Release of lysosomal enzymes during
ischemic injury to the kidney has been
d em o n strated .1' 10 E xperim ental and
clinical studies have shown that this en
zymatic activity can be measured in tissue
homogenate,1 in the perfusate2,3 or in the
urine4' 10 of preserved,1'3 diseased,4,6,7
damaged8 or rejected5,6,9,10 kidneys.
Moreover, the use of protective agents,
such as glucocorticosteroids, has proven
helpful in preventing cellular injury caus
ed by potent acid hydrolases, presumably
by stabilizing the lysosomal membrane
and thereby reducing subsequent en
zymatic release.1'3,9,11' 14 However, this
protection has not been confirmed after
normothermic ischemia.11
The present study was undertaken to
measure lysosomal enzyme activity in the
urine after experimentally induced nor
mothermic renal ischemia, to assess the
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relation, if any, between urinary enzyme
excretion and the degree of renal cellular
damage or functional viability after
ischemic injury. Furthermore, the aim
was to evaluate whether the stabilizing ef
fect o f methylprednisolone on the
lysosom al m em brane15 would be
reflected by reduced enzyme excretion
and, subsequently, improved recovery of
renal function.
Methods
Eleven, male, adult, mongrel dogs
whose weights ranged from 15 to 20 kg
were anesthetized with intravenously ad
ministered sodium thiopental 1 mg/kg,
succinylcholine 20 mg and atropine 0.4
mg. Ventilation was mechanically assisted
after endotracheal intubation and
anesthesia maintained with halothane.
After right nephrectomy and left ureteral
catheterization through a cystostomy with
a small infant feeding tube, vascular oc
clusion of the left renal artery and vein
at their origin was maintained for 1 hour.
To avoid any injury from handling, the
kidney was not totally freed from its other
attachments. All procedures were per
formed under normothermia. During 4
hours after revascularization, hourly col
lections of urine were made to measure
the activities of two lysosomal enzymes,
/3-galactosidase and N-acetyl-f3-glucosaminidase. During the experiment all
animals were perfused with 5% dex
trose and 0.45% saline at an hourly rate
of 5 m l/kg. No other drug was given.
Ischemic renal injury was further
evaluated in the postoperative period by
measuring serum creatinine levels daily.
An autopsy with morphologic examina
tion of the kidney was performed after
the death or sacrifice of the animals.
Two groups of dogs were studied. In
the treated group of six dogs, methylpred
nisolone sodium succinate, 30 mg/kg,
dissolved in sterile water (62.5 mg of
methylprednisolone per millilitre of
diluent) (Solu-Medrol; Upjohn Company
of Canada, Don Mills, Ont.) was injected
intravenously 1 hour before vascular oc
clusion. In the untreated control group of
five dogs, an equal volume of diluent
(0.9% benzyl alchol in sterile water) was
given intravenously.
Measurements of the two lysosomal en
zymes were made on urine samples
refrigerated at 4°C until testing within 24
hours of collection. Previously described
flu o ro m e tric
m ethods
with
4-methylumbelliferyl substrates were us
ed to determine the activity of both
enzymes.9 Activity was calculated in
milliunits (mU) per decilitre (dl) of urine,
1 mU referring to the amount of enzyme
that hydrolyses 1 nanomole per minute of
substrate under the conditions of the
assay. As previously reported9 and in
176

agreement with others,4,6'8’10 the most
reliable method, in any study of urinary
enzyme excretion, is to express these as
units per milligram of creatinine (specific
activities). Results of enzyme activities
were finally calculated as percentages of
their initial urinary values obtained before
vascular occlusion and methylpred
nisolone administration.
Results o f serum creatinine and
lysosomal enzyme measurements were
statistically analysed by a simultaneous
analysis of variance.
Results
All dogs in the untreated group died of
renal failure, the mean value of serum
creatinine reaching 5.6 mg/dl on day 2
after operation (Fig. 1). At that time, the
mean serum creatinine value in the treated
group was significantly (p < 0.01) reduc

ed to 2.4 mg/dl (Table I). Indeed four out
of six dogs of this group survived with
normal renal function postoperatively
(Fig. 1), but the serum creatinine in the
other two increased to levels similar to the
untreated group (p = NS) (Table I). In
successfully treated dogs, the reduction in
serum creatinine values postoperatively
was highly significant (p < 0.001) when
compared with animals, whether treated
or not, who subsequently had renal
failure (Table I).
In the untreated group, enzymatic /?g alactosidase
and
N-acetyl-/3glucosaminidase activities increased pro
gressively in the urine, reaching respec
tively 1080% and 1215% of their initial
values, 240 minutes after revasculariza
tion. In four of the six treated dogs,
urinary enzyme activities were only slight
ly elevated (about 400%) after 60 minutes
of revascularization, returning to near-

Fig. la

FIG. 1—Mean values (± standard deviation) of (a) urinary 0-galactosidase lysosomal en
zymatic activity and (b) urinary N-acetyl-/3-glucosaminidase activity (in % of initial concentra
tion) during first 4 hours after release of normothermic 1-hour renal vascular occlusion and
mean levels ( ± SD) of serum creatinine (mg/dl) in early postoperative days. Control group on
Jeft is compared to methylprednisolone, successfully (circles) ana unsuccessfully (triangles) treated
on right. Numbers of dogs with hourly urine output sufficient to allow enzyme measurements
are indicated in brackets.
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Table I-Serum Creatinine and Lysosomal Enzyme Activity after Renal Ischemia

Group
U n t re a t e d

No. of
dogs
5

Serum
creatinine on
postop day 2,
mgjdl

%
o-galactosidase
activity*

r— 5 .6 + 0 .7 -1

r 1 0 8 0 + 3 9 8 -1

+
p <
T re a t e d
W it h re n a l fa ilu re

6
2

l

p <
W it h o u t re n a l fa ilu re

4

4
p -

0.01

t
2 .4 + 1.5
4 .3 + 0 . 8 J

p - NS

NS

+
5 5 8 + 689
'- 1 5 4 0 + 6 J

0.001

P <
0.01
1 .5 ± 0.3

2 1 7 + 125

'm ll/m g urinary creatinine 240 min after revascularization.

normal values after 240 minutes (Fig. 1).
However, two dogs of this group had
even higher urinary enzyme levels (Fig. 1)
than the untreated group (p = NS) (Table
I) and also died of renal failure. Although
there was no statistical difference in the
enzyme excretion between untreated and
treated animals (Table I), successfully
treated dogs showed significantly lower
enzyme excretion than those who had
renal failure (p < 0.01 for 0galactosidase, [Table I] and p < 0.05 for
N-acetyl-/3-glucosaminidase).
Histologic examination of the kidneys
at autopsy further confirmed the
beneficial effects of glucocorticosteroids,
as predicted by the urinary lysosomal en
zyme excretion. In the untreated group,
the lesions usually seen were those of
severe, advanced, acute, tubular necrosis
with extensive destruction of renal prox
imal tubular cells (Fig. 2). In contrast, the
kidneys of dogs from the successfully
treated group had virtually normal renal
tubules, without significant changes of
acute tubular necrosis (Fig. 3). In both
dogs that did not respond to steroids,
morphologic signs of acute tubular
necrosis were either focal and associated
with calcification or less pronounced than
in the control group, and were
characterized by hydropic degeneration of
the tubular epithelial cells without com
plete necrosis.
D iscussion

FIG. 2—Untreated canine kidney. Debris of necrotic proximal epithelial cells fills tubular
lumen and there are pycnotic nuclei in residual cells (hematoxylin-phloxine-saffron stain, reduced
by 40% from x 400).

FIG. 3—Kidney treated with methylprednisolone shows well-preserved tubular epithelial
cells (hematoxylin-phloxine-saffron stain, reduced by 40% from X400).

The protective effect of methylpred
nisolone against normothermic ischemia
on the kidney has been well
demonstrated.11,14 There is, however,
some controversy with respect to the most
appropriate pharmacologic dose and time
interval needed for optimal protection
before a 2-hour period of ischemia.11,14
Nevertheless, most authors agree, from
experimental models of ischemic renal in
jury, that 30 mg/kg of methylpred
nisolone is effective.2,3,14,16 The same
studies also suggest giving methylpred
nisolone 2 hours before the onset of
ischemia resulting from a normothermic
2-hour period of vascular occlusion14 or
from normothermic and hypothermic
renal storage.2,3 Shortening the pre
treatment interval and increasing the dose
have, however, been effective.11 We
found that 30 mg/kg of methylpred
nisolone administered 1 hour before a
1-hour period of vascular occlusion
resulted in the most appropriate ex
perimental model. Longer periods of
ischemia (up to 2 hours) could not
be used since they did not allow samples
o f urine to be collected after
revascularization. Attempts to modify
either the dose of methylprednisolone or
the schedule of its administration were
ineffective.
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Although the beneficial effect of
methylprednisolone after normothermic
renal ischemia is generally attributed to
a stabilizing effect of lysosomal mem
brane as shown by improved renal
function,11'14 the exact relation between
the amount of urinary lysosomal enzyme
excreted and the degree of renal cellular
dam age has not been clearly
demonstrated. Diminished release of acid
hydrolases either in the tissue
homogenate1 or in the perfusate2 3 with
subsequent reduced tissue damage in ex
perimental models of preserved kidney,
however, suggested that methylpred
nisolone stabilized the lysosomal mem
brane. Similarly, our studies on hepatic
ischemia showed a clear relation between
liver viability and lysosomal enzyme
release, either in the perfusate during
preservation or in the serum after
transplantation of those preserved
livers.1719 Furthermore, morphologic
evidence of the integrity of the renal cell
after pharmacologic protection with
methylprednisolone is not available.
The present study illustrates conclusive
ly that ischemic injury to the kidney,
resulting from normothermic vascular oc
clusion for 1 hour, induces extracellular
release o f lysosomal enzymes (/3g alactosidase
and
N-acetyl-/3glucosaminidase) that can be measured by
their urinary excretion (Fig. 1). These
urinary enzyme activities reflect the
degree of renal cellular damage, as seen
m orphologically (Figs. 2 and 3).
Moreover, they are of definite predictive
value for renal viability, since they cor
relate well with subsequent renal function
(Fig. 1). Finally, methylprednisolone
given intravenously in a dose of 30 mg/kg
1 hour before a 1-hour period of nor
mothermic ischemia appears to be
valuable in protecting the kidney from
ischemic injury, since the mean serum
creatinine level was significantly (p <
0.01) reduced in treated dogs (Table I).
Moreover, four of six animals treated in
this fashion recovered completely from
their ischemic injury (Fig.l). The
significantly reduced enzyme excretion,
observed in the successfully treated group
of dogs (Table I), does support the
hypothesis that methylprednisolone has
a stabilizing effect on lysosomal mem
brane. In our experimental model the
drug is, however, not uniformly effective
in protecting the kidneys from ischemic
damage. The reason for this is not clear,
but it could be attributed to the failure
o f m ethylprednisolone to prevent
lysosomal enzyme release, since in the two
unsuccessful cases, impaired post
operative renal function was preced
ed by high urinary enzyme excretion.
However, the renal lesions seen in these
dogs are only focal or moderate, when
compared with those of the control

group, suggesting a partial responsiveness
to glucocorticosteroids, whatever the pro
tective mechanism may be.
Since other drugs, such as
furosemide,13 allopurinol11'16'20'21 and
aprotinin22 may also be of value in pro
tecting organs from ischemic damage, it
would be worthwhile to use them in
association with methylprednisolone.
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Complications of Anticoagulant Therapy in Patients
with Known Central Nervous System Lesions
Spontaneous intracranial hemorrhage in
patients receiving anticoagulant therapy
is not uncommon. Sometimes this
hemorrhage may be the initial presenta
tion of an occult lesion of the central
nervous system, such as a tumour,
vascular malformation or infarction. Five
such cases, one case of hematomyelia
and one case of spinal subdural
hematoma have been reported in
association with proven lesions of the
central nervous system in patients on an
ticoagulant therapy. One other patient is
reported who had malignant melanoma
with an asymptomatic brain metastasis.
Anticoagulant therapy for deep vein
thrombosis resulted in a spontaneous in
tracranial hemorrhage.
Patients who have potential central
nervous system disease on the basis of
previous clinical neurologic events and
those known to harbour a malignant
tumour should undergo enhanced com
puterized axial tomography before long
term anticoagulant therapy is begun. Pa
tients with confirmed lesions of the cen
tral nervous system are at risk of suffer
ing hemorrhagic complications and
should be monitored very closely during
anticoagulation. The indications for con
tinuing long-term anticoagulation in these
patients should be reviewed frequently.
Les hemorragies intracraniennes spontanees ne sont pas rares chez les patients
qui recoivent des anticoagulants. Parfois,
cette hemorragie peut etre la manifesta
tion initiale d'une lesion occulte du
systeme nerveux central telle qu'une
tumeur, une malformation vasculaire ou
un infarctus. Cinq cas de ce genre, un
cas d'hematomyelie et un cas d'hematome spinal sous-dural ont ete decrits en
association avec des lesions demontrees
du systeme nerveux central chez des
patients sous anticoagulotherapie. On

signale un autre cas chez un patient qui
avait un melanome malin avec presence
asymptomatique d'une metastase cdrebrale. Le traitement par anticoagulant
d'une thrombose veineuse profonde a
entrame une hemorragie intracranienne
spontanee.
Les patients qui, par suite d'un acci
dent neurologique prealable, sont susceptibles de souffrir d'une maladie du
systeme nerveux central devraient subir
un examen pousse par tomographie
transverse axiale avec ordinateur avant
d'entreprendre chez eux un traitement
anticoagulant au long cours. Les patients
qui ont des lesions confirmees du
systeme nerveux central sont exposes a
subir des complications hemorragiques et
devraient faire I'objet d'une surveillance
constante durant une anticoagulothera
pie. Les indications justifiant le maintien
d'un traitement anticoagulant a long
terme chez ces patients devraient etre
frequemment remises en cause.

Anticoagulant therapy is used in a
wide spectrum of diseases. There is
a constant risk of hemorrhage. Intra
cranial hemorrhage may reflect not
only excessive anticoagulation, but
may be the first sign of occult lesions
of the central nervous system such
as tumours, vascular malformations or
infarctions. Seldom is the underlying
disease defined in such cases. Only
seven documented cases exist in the
English literature of hemorrhagic
complications of the central nervous
system in patients who had confirmed
lesions of that system and who were
receiving anticoagulant therapy. We
report a further case and discuss the
implications of this hazardous situ
ation.
Case Report

renal function, the chest film, and scans
of liver, spleen, bone and brain were
all negative for metastases. The patient
was randomized into the no-treatment
arm of an immunotherapeutic trial and
was followed at regular intervals.2 She
was readmitted to hospital 8 months
later with enlarged contralateral inguinal
nodes and multiple subcutaneous nodules
involving the left eyelid, the left pinna
and the right side of the neck. Diagnostic
studies for staging included a chest film
and ultrasonography of the retroperitoneum, neither of which demonstrated
metastases. Enhanced computerized axial
tomography of the brain revealed a small
parasagittal lesion in the left parietal lobe
without edema or mass effect (Fig. 1).
Because the cerebral lesion was asymp
tomatic, we elected to ignore it. The pa
tient underwent a radical groin dissec
tion with concurrent excision of a sub
cutaneous nodule from the right side
of the neck, which proved to be a meta
static malignant melanoma.
Five days later, deep vein thrombosis
of the right leg developed; it was con
firmed by venography. The patient was
immediately given heparin intravenously.
After a 3-day transition period, the hepa
rin was discontinued and she was main
tained on oral warfarin sodium only.
Measurements were made daily of the
prothrombin and partial thromboplastin

A 69-year-old woman, previously in
good health, was admitted to hospital
with a pigmented ulcerative lesion of the
left groin. A level IV malignant mela
noma was removed by radical groin dis
FIG. 1—Enhanced computerized axial
section.1 One of the six inguinal nodes tomogram
showing solitary left para
on the left side contained micrometa- sagittal, frontoparietal metastatic mela
stases. The results of studies of liver and noma.
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times. The prothrombin time ranged
from II to 36 seconds (normal, 10 to
13 seconds) and the partial thromboplas
tin time ranged from 53 to 92 seconds
(normal, 25 to 40 seconds).
Eleven days after anticoagulant ther
apy was started, a right hemiparesis with
an associated verbal aphasia and a right
homonymous hemianopsia developed.
The computerized axial tomogram now
revealed a left parietal intracerebral hem
orrhage extending to the thalamus (Fig.
2). The prothrombin and partial throm
boplastin times were 31 seconds and 61
seconds, respectively. This anticoagulant
effect was rapidly reversed with six
ampules of human Factor IX complex
(approximately 3000 units). Because of
her clinical deterioration, the clot was
surgically evacuated by craniotomy. Firm
brown tissue found within the hematoma
was diagnosed on pathologic examina
tion as metastatic malignant melanoma.
Following the craniotomy, the pa
tient’s dysphasia and hemiparesis quickly
resolved. Anticoagulant therapy was not
resumed. Her malignant melanoma con
tinued to progress with new metastases
in soft tissues and both cerebral hemis
pheres. She died 3 months postoperatively. Permission for autopsy was re
fused.

Discussion
The rate of hemorrhagic complica
tions during anticoagulant therapy has
been reported to range from 5% to
42% in the published series reviewed
by Peyman.3 Coon and Willis4 re
ported hemorrhagic complications in
6.8% of 3862 courses of anticoagu
lant therapy. Forfar5 found an in
cidence of 8.2% among 501 patients,
or 4.3% per treatment-year during
1199 patient-years of treatment. He
morrhagic complications of antico
agulant therapy may involve any part
of the body, especially the gastroin
testinal and genitourinary systems and
the retroperitoneal space. Whisnant*
noted spontaneous intracranial hem
orrhage in 7% of his patients being
given anticoagulant therapy on a
long-term basis for transient ischemic
attacks. Heyman and associates7
noted that 10.4% of deaths due to
intracranial bleeding were attributed
to anticoagulant therapy. Hemorrha
gic complications in the central nerv
ous system are a major cause of
death. Forty-six of the 122 such
deaths reported by Russek and Zohman* and 8 of 23 cases reported by
Duff and Shull9 were due to intra
cranial hemorrhage.
Certain factors predispose to hem
orrhagic complications. Elderly pa
tients and those in heart failure with
hepatic congestion or dysfunction are
more likely to suffer hemorrhagic
complications during anticoagulant
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therapy as are patients taking certain
drugs, such as acetylsalicylic acid and
antibiotics.10 These risk factors may
be minimized by careful monitoring
and regulation of the anticoagulants
given in such patients. While there is
a higher rate of hemorrhage in pa
tients who receive excessive anticoagu
lation, close laboratory monitoring
does not preclude hemorrhage. A vul
nerable period for such complications
has been reported during the transi
tion from intravenously administered
heparin to orally administered anti
coagulants, when suppression of the
clotting mechanisms is increased by
the loading doses of anticoagulants
given orally.4 Ischemic lesions may
predispose to bleeding as a result of
a necrotic, open, vascular bed. Hence,
Heyman and colleagues7 observed
that half of the patients who bled intracranially during anticoagulation
had a history of previous cerebral
ischemic disease. Outside the central
nervous system, a variety of intrinsic
lesions have bled during anticoagulant
therapy.1113 Hemorrhagic complica
tions in patients receiving anticoagu
lants may be the first sign of under
lying intrinsic disease.
When an intracranial hemorrhage
occurs in the central nervous system
following anticoagulation, underlying
disease is seldom found to define the
source of bleeding.14'16 Its cause is
often attributed to a small malforma
tion or infarct that may have been
destroyed by the hemorrhage. There
are only isolated reports of hemor
rhage during anticoagulant therapy in
patients with confirmed intrinsic le
sions of the central nervous system.
Seven cases have been found in the
English literature (Table I). Nourizadeh and Pitts17 reported a patient with
a hemorrhage into a pituitary chro
mophobe adenoma. Abbott and
Stern18 described two cases of profuse
hemorrhage into an edematous brain
around abscesses that were initially
thought to be infarcts. Kawakami and
Mair19 reported a unique patient with
hematomyelia from hemorrhage into
an occult intramedullary ependymoma
of the cervical spinal cord. The pa
tient reported by Apuzzo and asso
ciates20 bled into a pineal cyst, while
those of Everett and associates21 and
Toledo and colleagues22 bled from a
convexity meningioma. Our patient’s
hemorrhage arose from an asympto
matic metastatic malignant melanoma
that had been discovered before anti
coagulant therapy was begun. Thus,
the underlying condition associated
with the hematomas in the seven pre
viously reported cases and our case

included six tumours (one metastatic
malignant melanoma, one chromo
phobe adenoma, two meningiomas,
one spinal cord ependymoma, one
pineal cyst) and two cerebral ab
scesses.
Some tumours and cysts in the
central nervous system are known to
bleed spontaneously, in particular pi
tuitary adenomas, a number of gli
omas and metastatic melanomas.23'25
Presumably the bleeding comes from
necrotic vessels within these lesions.
Anticoagulation increases the risk and
severity of such bleeding. Clinical and
experimental evidence suggests that
recent cerebral infarctions and infarc
tions from septic emboli predispose
to hemorrhage.26 Abbott and Stern’s
two patients were given anticoagulants
for suspected infarction although the
lesion proved to be an abscess in
each case.18 Undoubtedly, excessive
anticoagulation in the presence of le
sions of the central nervous system
is hazardous and must be avoided,
because six of the eight reported pa
tients (including ours) had demon
strated evidence of overanticoagula
tion.
Conclusions

The presence of an occult lesion
of the central nervous system, such
as a tumour, infarct or abscess, pre
sents a definite threat of hemorrhage,
especially if the anticoagulation is
continued for a long time and if con
trol is difficult or erratic. According
ly, patients likely to harbour such
a lesion by virtue of the clinical his
tory of previous neurologic events or
who are known to have malignant tu
mour, should undergo enhanced com
puterized axial tomography before
or shortly after anticoagulation is
started. If an occult lesion is discov-

FIG. 2— Unenhanced
computerized
axial tomogram showing left fronto
parietal, intraparenchymal hematoma.
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ered, the risk of hemorrhagic com
plications is significant. Not only must
extreme caution be exercised in regu
lating the dosage of the anticoagu
lants, but the indication for continu
ing anticoagulation must be con
stantly reviewed. Alternative forms of
therapy to long-term anticoagulation,
such as venous ligation or umbrellas,
should be seriously considered in such
patients.

7.

8.

9.
10.
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Table 1-Summary of Patients with Hemorrhagic Complications during Anticoagulation
_______________ for Confirmed Lesions of Central Nervous System
Patient
Age,
Authors
Sex yr
Nourizadeh and M 45
Pitts, 196517
Abbott and
Stern, 1969'8

Central nervous
system lesion
Pituitary
chromophobe
adenoma
Cerebral
abscess

Indication for
anticoagulation
Myocardial
infarction

M

5

M

58

Cerebral
abscess

Kawakami and
Mair, 197319

M

63

Cervical cord
ependymoma

Apuzzo and
colleagues,
197620
Everett and
colleagues,
198121

M

65

Pineal cyst

Pulmonary
embolism

M

65

Frontoparietal
meningioma

Deep vein
thrombosis

Toledo and
colleagues,
198122

F

59

Spinal
meningioma

Present study

F

69

Cerebral
metastatic
melanoma

Atrial fibril
lation with
cerebral
emboli
Deep vein
thrombosis

Inappropriately
diagnosed as
cerebral
thrombosis
Inappropriately
diagnosed as
cerebral
thrombosis
Pulmonary
embolism

Coagulation
indices
Prothrombin
content,
22%-30%
Clotting time,
32 min

Cerebral
hemorrhage

Craniotomy

Outcome
Died 19 d postop
of perforated
gastric ulcer
Died 5 d postop

Bishydroxycoumarin,
5d

Prothrombin
content, 10%

Cerebral
hemorrhage

Craniotomy

Died 36 h postop

Not specified,
5 mo

Prothrombin
time, 50 s

Hematomyelia

Laminectomy

Bishydroxycoumarin,
6 mo
Heparin, then
warfarin
sodium, 6 d

Prothrombin
time, 50 s
(control 11.5 si
Prothrombin
time, 4 X
control

Pineal
apoplexy

Craniotomy

Died 13 d postop
of recurrent
pulmonary
embolism
Minimal deficit
at 1 yr

Cerebral
hemorrhage

Craniotomy

Warfarin
sodium, 2 yr

Prothrombin
time, 60 s
(control 18 si

Spinal
subdural
hematoma

Laminectomy

Heparin, then
warfarin
sodium, 10 d

Prothrombin
Cerebral
time, 31 s
hemorrhage
(control 10-13 si.
Partial thromboplastin time
61 s (control
2540 s)

Drug, duration
Bishydroxycoumarin,
18 d
Heparin
several days

Hemorrhagic
complication
Pituitary
apoplexy
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Treatment
Craniotomy

Craniotomy

Died 2 d postop
of severe bila
teral bronchopneumonia
Residual spastic
paresis at 6
mo
Initial recovery
from deficit. Died
3 mo postop
of multiple
metastases
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Perforation of a M eckel's Diverticulum
by a Foreign Body
Perforation of a Meckel's diverticulum by
a sharp object often presents with subtle
nonspecific abdominal findings. A
53-year-old man had features resembling
acute appendicitis and right ureteral
obstruction. At laparotomy a wooden
toothpick was found perforating a
Meckel's diverticulum.
The diagnosis of complicated Meckel's
diverticulum should be considered when
there is typical right lower quadrant pain
or the patient is known to have ingested
a sharp foreign body. The mortality
resulting from perforation is low. The
authors discuss other complications of
Meckel's diverticulum.
La perforation d'un diverticule de Meckel
par un objet pointu presente souvent a
I'examen, des signes abdominaux non
specifiques discrets. Un homme age de
53 ans montrait un tableau clinique res
semblant a celui d'une appendicite aigue
et d'une obstruction de I'uretere droite.
On a decouvert a la laparotomie un curedent de bois perforant un diverticule de
Meckel.
Devant une douleur atypique au qua
drant inferieur droit ou lorsqu'on sait
qu'un patient a ingere un corps etranger
pointu, on doit envisager le diagnostic
d'une complication du diverticule de
Meckel. La mortalite dans ces cas est
faible. Les auteurs examinent les autres
complications du diverticule de Meckel.

Meckel’s diverticulum occurs in approx
imately 2% of the population and, in
most individuals, remains asymptomatic.
It may produce complications at any age.
In the pediatric years, its prime presen
tation is rectal bleeding while in
ad u lth o o d , it is m ore com m only
associated with obstruction and inflam
mation. Probably the most common
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disease with which it may be confused is
acute appendicitis. Perforation, usually
following penetration by a sharp object,
often presents subtly; the associated mor
tality is low.
In this paper we report a case of per
forated Meckel’s diverticulum and discuss
various aspects of Meckel’s diverticulum.
Case Report
A previously healthy 53-year-old man was
seen in the emergency department with a
24-hour history of intermittent pain in the right
lower quadrant radiating to the suprapubic and
right groin regions, d e - h ad -bo a s sociated
gastrointestinal or genitourinary symptoms.
Four days earlier he had eaten hors-d’oeuvre
fastened with toothpicks.
He felt moderately uncomfortable. His ab
domen was soft and not distended. It was mild
ly tender over McBurney’s point. Bowel sounds
were present and findings on rectal examina
tion were normal. His hemoglobin value was
17.1 g/dl and the leukocyte count was 10.3 x
109/1; when repeated, the leukocyte count was
13.3 x 109/ 1. Three roentgenographic views
of the abdomen suggested the presence of free
air under the right diaphragm. After an in
travenous pyelogram was found to be normal,
a repeat upright abdominal film confirmed the
presence of free air (Fig. 1). Perforated acute
appendicitis was diagnosed. At laparotomy
purulent peritoneal fluid was seen and, 50 cm
proximal to the ileocecal junction, there was
an inflamed Meckel’s diverticulum, measuring
1.5 x 2 cm, which was perforated by a
toothpick (Fig. 2). A 5-cm resection of small
bowel to include the perforation was carried
out and an end-to-end anastomosis perform
ed. Recovery was smooth.

Discussion
Meckel’s diverticulum is found in ap
proximately 2% of the population,1-2
though various autopsy series suggest in
cidences ranging from 0.3% to 4%. The
sex ratio is 1:1, but complications are
three times more common in males.3
Meckel’s diverticulum, being a segment
of small bowel, is subject to the same pro
blems as any other area of small bowel.
In the largest review to date of Meckel’s
diverticular disease, the condition was
noted to be associated with obstruction
in 31%, bleeding in 25%, inflammation
in 24%, perforation in 12.4%, herniation

in 7.4% and tumour formation in
0.5%.4 Patients with problems related to
Meckel’s diverticulum usually have
nonspecific sym ptom s with no
pathognomonic features. In a 51-year
review of Meckel’s diverticular disease
from the Mayo Clinic, the 51 symp
tomatic patients had vague complaints
which were, in order of frequency, ab
dominal pain, gastrointestinal bleeding
and abdominal tenderness.5 Often the
problems relating to Meckel’s diver
ticulum are influenced by age. The usual
presentation in adults is intestinal obstruc
tion while in children it is painless
gastrointestinal bleeding.6 The bleeding
is usually a result of ulceration of the ec
topic gastric epithelium lining the diver-

FIG. 1—Upright abdominal film shows free
air (between arrows) under medial aspect of
dome of right diaphragm.

FIG. 2— Resected small bowel with
toothpick perforating Meckel’s diverticulum.
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ticulum. Intussusception caused by
Meckel’s diverticulum, although occurr
ing at any age, is far more common in
male infants less than 2 years of age.2
Probably the most common preoperative
diagnosis made in patients with Meckel’s
diverticulum is acute appendicitis. A
review of 50 cases of Meckel’s diver
ticulum showed a preoperative diagnosis
of acute appendicitis in 40%.7 In an at
tempt to improve diagnostic accuracy,
O ’Sullivan8 suggested the following
criteria: (a) a history of ingestion of a
sharp-edged foreign body, (b) sudden
rather than gradual onset of pain, (c)
maxim al tenderness m edial to
McBurney’s point and (d) unexplained in
testinal obstruction in a child or young
adult.
In cases of gastrointestinal bleeding
suggestive of Meckel’s diverticulum, it
has been proposed that technetium scan
ning can aid in the diagnosis. However,
up to one third of these scans may give
false-negative results.4
Our patient, like many with Meckel’s
diverticulum, was referred to hospital
with a diagnosis of acute appendicitis, but
he had no anorexia, nausea or perium
bilical pain which are characteristic of ap
pendicitis. The pain radiated into the
suprapubic and right groin areas; this is
unusual for appendicitis. The pain, when
present, prompted the patient to move
about rather than to lie still. These last
two features suggested renal colic, so in
travenous pyelography was carried out.
The clinical features typical of bowel
perforation were lacking. The patient had
minimal localized pain and tenderness,
and no convincing peritoneal signs. Bowel
sounds were alternately normal or slightly
diminished rather than absent.
As in other cases,3 rather than present
ing with severe and sudden abdominal
symptoms, the patient presented with
mild ones. Rosswick3 postulated that the
mildness of symptoms is related to the
fineness of the perforating foreign body.
In this case, the toothpick had partially
sealed the perforation, possibly reducing
the degree of reaction.
In Rosswick’s review' o f all
documented foreign-body perforations of
Meckel’s diverticula, fishbones caused
56% (28/50) and wood splinters 12%
(6/50). There were only two documented
deaths resulting from perforation of a
Meckel’s diverticulum and the majority
of patients did well. Meckel’s diver
ticulum produces illness in a small percen
tage of patients over 40 years of age,4
but a 6% to 7% mortality when there
are complications relating to the diverti
culum.

although it most often remains asymp
tomatic, it may produce complications at
any age. Contrary to Charles M ayo’s
comment" in 1933, “ Meckel’s diver
ticulum is frequently suspected, often
looked for, and seldom found” , the
diagnosis in this patient was not
suspected.
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N O T IC E
Postgraduate Course
in General Surgery
From May 5-7, 1983 a postgraduate
course in general surgery will be held at
the Fairmont Hotel in San Francisco.
Presented by the department o f surgery
and the Howard C. Naffziger Surgical
Society of the University of California
School of Medicine in San Francisco, this
clinically oriented program offers general
surgeons an intensive overview of prob
lems encountered in daily practice. This
year’s symposium will focus on colon and
rectal disease, surgery of the biliary tract,
esophagus and liver and on wound man
agement.
The program is sponsored by Extended
Programs in Medical Education of the
University of California School of
Medicine in San Francisco. It will meet
the criteria for 15 ACCM E/AM A /C M A
category 1 credit hours.
For further information write or call:
Extended Programs in Medical Educa
tion, Room 569U, University o f Cali
fornia, San Francisco, Calif. 94143;
telephone (415) 666-4251.
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Meckel’s diverticulum occurs in ap
proximately 2% of the population and
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Coronary Artery Bypass in Patients over 65 Years of Age
At the Vancouver General Hospital 235
consecutive patients (172 men, 63
women) aged 65 years or older under
went aortocoronary bypass grafting be
tween January 1974 and December
1979; 168 were 65 to 69 years of age
and 67 were 70 years or older. Con
comitant cardiac procedures were carried
out in 6 5 (valve surgery in 53, resection of
ventricular aneurysm in 10, repair of ven
tricular septal defect in 1, excision of left
atrial tumour in 1). A mean of 2.6
vessels per patient were grafted.
Early mortality was 7.7%. For patients
who underwent bypass grafting alone,
the mortality for those 65 to 69 years
was 5 . 1 % and for those 70 years or
older it w as 5.9%. For patients who
underwent bypass grafting and a con
comitant procedure, the mortality for
those 65 to 69 years of age was 3 .1 %
and for those 70 years or older 24.2% .
At follow-up (mean 30 months) there
were 23 late deaths. The 5-year survival
(life-table method) for the whole group
w as 7 7 % including early deaths and
8 3 % excluding early deaths. Late sur
vival in those aged 70 years or older
w as similar to that in patients aged 65
to 69 years. Improvement in function
w as good; 9 2 % of patients were in New
York Heart Association functional class I
or II at follow-up, where 9 4 % had been
in class III or IV before operation.
Acceptable operative mortality with
good long-term survival and lessening of
symptoms support the use of aor
tocoronary bypass grafting in patients
over 65 years of age. Complex pro
cedures in those 70 years of age or older
carry a high risk.
Au Vancouver General Hospital, entre
janvier 197 4 et decembre 1979, 235
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patients consecutifs (172 hommes et 63
femmes) ages de 65 ans et plus ont subi
un pontage aorto-coronarien; 168 etaient
ages de 65 a 69 ans et 67 avaient 70
ans ou plus. Une intervention cardiaque
concomitante dut pratiquee chez 65 de
ces patients (53 chirurgies valvulaires, 10
resections d'anevrismes ventriculaires, 1
reparation de communication interventriculaire et 1 excision de tumeur de I'oreillette gauche). Le nombre moyen de pon
tages par patient etait de 2.6.
La mortality precoce etait de 7.7%.
Pour les patients de 65 a 69 ans qui
n'ont eu que I'operation de pontage elle
etait de 5 .1 % alors que pour ceux de 70
ans et plus elle etait de 5.9%. Pour les
patients qui ont subi un pontage et une
intervention concomitante, la mortality
etait de 3 . 1 % chez les 65 a 69 ans, et
de 2 4 .2 % chez les 70 ans et plus.
La surveillance post-therapeutique (30
mois en moyenne) revele 23 deces
tardifs. Pour I'ensemble du groupe, la
survie a 5 ans (methode des tables
actuarielles), incluant les deces precoces,
etait de 7 7 % et de 8 3 % en excluant les
morts precoces. La survie tardive chez
les patients de 70 ans et plus 6tait
semblable a celle des 65 a 69 ans. On a
constate une bonne amelioration de la
fonction cardiaque; aux examens de
controle, 9 2 % des patients etaient dans
les categories I et II de la classification
de la New York Heart Association, alors
que 9 4 % appartenaient aux classes III et
IV avant I'operation.
Une mortality operatoire acceptable,
une bonne survie a long terme et une
amelioration des symptomes sont autant
delements qui plaident en faveur du
pontage aorto-coronarien chez les
patients de 65 ans et plus. Les
interventions complexes chez ceux de 70
ans et plus component un risque eleve.
C o ro n a ry bypass surgery a ffo rd s
dramatic relief o f angina, with marked
improvement in life-style, and data show
ing increased longevity for selected groups
continue to accum ulate. A s im 
provements in surgical technique have
lowered the mortality for cardiac surgery
o f various kinds, including coronary

artery surgery, so increasing numbers o f
elderly and other “ high-risk” patients are
considered for coronary bypass surgery.
Early experience in several centres1'3
showed an increased operative mortality
for patients over 65 years o f age, so the
present study was undertaken to deter
mine the operative risks, to identify fac
tors contributing to operative mortality
and morbidity and to determine long
term survival and quality o f life.

Patients and Methods
Between Jan. 1, 1974 and Dec. 31,
1979, 235 patients (172 men, 63 women)
aged 65 years or over underwent aor
tocoronary bypass grafting at the Van
couver General Hospital. The patients
ranged in age up to 84 years; 168 were 65
to 69 years o f age, 48 were 70 to 74 years
and 19 were 75 years or older. Fig. 1
shows the number o f operations perform
ed in each year o f this study.
Sixty-five patients underwent a con
com itant cardiac procedure. Valve
replacement or repair was performed in
53, resection o f a left ventricular
aneurysm in 10, repair o f a ventricular
septal defect in 1 and excision o f a left
atrial tumour in 1. One coronary artery
was bypassed in 43 patients, two in 66,
three in 79, four in 41 and five in 6 pa
tients, for a mean o f 2.6 grafts placed per
patient. Endarterectomy was performed
on 112 vessels in 74 patients — the right
coronary artery in 47 and the left in 65.
Ventricular function was assessed from
the ventriculogram obtained in the right
anterior oblique projection. Function was
normal in 36% o f patients, impairment

FIG. 1— Number of operations by year.
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was mild to moderate in 46% and severe
in 18%.
Patients or the attending family doc
tor were contacted for follow-up by mail
or by telephone, and 216 of the 217 who
survived operation were reached (99.5%).
The period of follow-up ranged from 12
to 88 months (mean 30.0 months).
Results

Early Deatns and Complications
Early mortality (within 30 days) for the
whole group was 7.7% (18/235) (Table
I). For patients who underwent bypass
grafting only, the figure was 5.3%, but
for those who had a concomitant pro
cedure, the early mortality was 13.8%
(9/65). A concomitant procedure in pa
tients aged 70 years or older was
associated with a much higher mortality
— 24.2% (8/33). Overall, the early mor
tality for all patients aged 65 to 69 years
was 4.8% and for all patients aged 70
years or older 14.9%. The most frequent
cause of early death was low cardiac out
put (Table II). The mortality for each year
of the study is shown in Table III. The
improvement in mortality with time is
notable, particularly since 1976, when
cold potassium cardioplegia was intro
duced to our unit. Early mortality was
higher in those with poor ventricular
function: 6.6% in those with mild to
moderate impairment of ventricular func
tion and 16% in those with severe impair
ment, compared with 3.8% in patients
with normal function.
There were 43 nonfatal early complica
tions, a morbidity rate of 20% (Table IV).
They included stroke, reoperation for
bleeding or tamponade, perioperative

Mortality,
no./total no. (%)

A C B G o n ly
A g e 6 5 -6 9

7 /1 3 6 15.11

A ge > 7 0

2 /3 4

(5.91

A ge 6 5 -6 9

1 /3 2

13.11

A ge > 7 0

8 /3 3

124.21

and 5% in class II; at follow-up, 92%
were in class I or II and 8% in class III.
D iscussion

Late Deaths and Complications
There were 23 late deaths (mean follow
up of 30 months)) Five-year survival for
the whole group by the life-table method,
including operative mortality, was 77%,
and for those who survived the operation
83% (Fig. 2). The 65 patients who under
went bypass grafting plus a concomitant
procedure had a poorer survival than the
170 who had bypass grafting alone. When
long-term survival was compared by age
groups 70 years and older and 65 to 69
years (Fig. 3), the long-term survival was
similar apart from the higher initial
operative mortality in the older patients.
The cause of death was cardiac in 17 of
the 23 late deaths (myocardial infarction
or sudden death in 9 and congesive heart
failure in 8). One patient died o f stroke,
two of sepsis, two of carcinoma and one
of aspiration pneumonia. Late complica
tions included 17 admissions to hospital
for cardiac causes, including 2 for
myocardial infarction, 5 for congestive
failure, 2 for pericarditis, 2 for heart
block and 6 for other cardiac problems.
Two patients required removal of sternal
sutures for persistent drainage. In addi
tion, three patients suffered a stroke and
one patient had peripheral arterial em
bolus from a valve prosthesis. Functional
improvement according to the New York
Heart Association (NYHA) classification
is shown in Fig. 4. Preoperatively, 94%
of patients were in NYHA class III or IV

Before 1976 a high operative m ortali
ty was reported for coronary artery
bypass in patients over 65 years of age,
ranging from 8% to 22% .13 As ex
perience was gained, particularly when
cold cardioplegia was introduced,
operative mortality fell.
Our operative mortality of 5.3% for
aortocoronary bypass grafting alone in
patients over 65 years of age is higher than
in younger patients in our unit, but is
lower than in earlier reports and continues
to improve with experience. Recent
reports4’5 confirm this trend. The lowest
operative mortality reported to date, by
Knapp and associates,4 was only 1.6%.

FIG. 2—Survival (life-table method) for all
patients, aortocoronary bypass grafting alone
(ACBG) and bypass grafting plus a concomi
tant procedure (ACBG + ).
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Table III-Deaths by
Year of Operation
24

Deaths,
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Table l-Early Mortality after
Aortocoronary Bypass Grafting (ACBG)
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myocardial infarction and wound com
plication. There were 20 cases of confu
sion or psychosis.
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FIG. 3—Survival (life-table method) for 168
patients aged 65 to 69 years and 67 patients
aged 70 years and over.
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FIG. 4—Symptom status, New York Heart
Association classification (NYHC).
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In the multicentre experience of the Col
laborative Study in Coronary Artery
Surgery (CASS) study,6 an operative
mortality of 7.9% was noted for patients
aged 70 and over. When other procedures
are performed concomitantly with cor
onary bypass, we experienced no increase
in risk for patients aged 65 to 69 years,
but a definite increase for those 70 and
over (24%). Impaired ventricular func
tion was also an important risk factor in
our experience.
Postoperative complications were fre
quent, with a morbidity of 20%. Of
greatest concern were the eight strokes,
two o f which produced a m ajor
neurologic deficit. We anticipate a lower
frequency o f this complication now that
we have abandoned femoral cannulation
for cardiopulmonary bypass.7 Wound
complications remain a common pro

blem. Confusion was frequent (9%), but
was self-limited.
Follow -up revealed a gratifying
response to surgery. For those who sur
vived the initial operation, actuarial sur
vival was 89% at 4 years and 83% at 5
years. Improvement in the severity of
symptoms was good. There were few late
complications.
We conclude that coronary artery
bypass can be offered to patients over 65
years of age with a reasonably low
operative risk and the expectation of a
good long-term result. Patients should
not be denied this surgery on the basis of
age alone. Complex procedures in pa
tients over age 70 carry a high operative
risk.
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Coronary Artery Bypass in Patients under 40 Years of Age
Coronary artery bypass surgery was per
formed in 92 patients, ranging in age
from 20 to 40 years. The male-to-female
ratio was 5:1. The operative mortality
was 3.3 % . Sixty-two patients were
followed up for a mean of 3.5 years.
Complete relief of angina was reported
by 79% of patients and an additional
10% experienced some improvement.
The survival rate at 3.5 years was 97%.
The results favour myocardial
revascularization in young adults.
Des pontages aorto-coronariens ont ete
pratiques chez 92 patients dont Page
allait de 2 0 a 40 ans. Le rapport
hommes-femmes etait de 5:1. La
mortalite operatoire fut de 3.3.% .
Soixante-deux patients ont fait I'objet
d'examens de controle pendant une
moyenne de 3.5 annees. Soixante-dixneuf pourcent des patients ont rapporte
un soulagement complet de I'angine et
un autre 10% beneficia d'un certain
degre d'amelioration. Le taux de survie
apres 3 .5 ans etait de 97 % . Ces resultats sont en faveur d'une revascularisa
tion myocardique chez le jeune adulte.
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Coronary artery disease is relatively com
mon in young adults.1-5 Since the disease
is progressive, the prognosis in young pa
tients with angina, treated medically, is
generally poor. Myocardial revasculariza
tion, therefore, seems to be justified. Un
fortunately, information on the long-term
results of coronary artery bypass grafting
in patients 40 years of age and younger
is scanty.6’7 This report presents a
10-year experience and follow-up of 92
young adults who underwent coronary
artery bypass grafting at the University
of Alberta Hospital in Edmonton.
Patients
During the period from Jan. 1, 1970 to
Aug. 31, 1980, 92 patients (78 men, 14
women), ranging in age from 20 to 40
years, underwent coronary artery bypass
grafting at the University of Alberta
Hospital. The average age of the men was
36.5 years and that of the women was 35
years.
All patients had disabling angina pec
toris that was being treated with nitrates
and either propranolol or other beta
blocking agent at the time of referral.
Some were also taking hypolipidemic
drugs (clofibrate) and antithrombotic
drugs (sulfinpyrazone). Fifty-three pa
tients had a history of myocardial infarc
tion and 9 of them had had two or more
infarctions. The functional capacity of
the cardiovascular system was severely

compromised in the majority of patients,
resulting in the mean functional class of
III (New York H eart Association
[NYHA] classification).
Risk Factors
Most patients presented with two or
more risk factors. Eighty-five patients
(92%) were smokers and one third of
them smoked more than one package dai
ly. Twenty-two patients had abnormal
blood glucose levels but frank diabetes
mellitus with significant glucosuria was
present only in 10. Serum cholesterol
greater than 240 mg/dl (6.2 mmol/1) was
recorded in 41 patients. Twenty-six pa
tients were overweight. Diastolic blood
pressure greater than 90 mm Hg or
systolic blood pressure greater than 140
mm Hg, or both, was found in 14 pa
tients. A family history of heart attack,
hypertension, stroke or diabetes was
reported by 56 patients. The association
of risk factors in our patients was quite
similar to that found by others6-7 except
for a surprisingly low incidence of
hypertension.
Coronary Stenosis and
Ventricular Dysfunction
All patients underwent selective cor
onary arterio g rap h y with ven
triculography. Stenosis was considered
significant if the luminal diameter was
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reduced by more than 70%. The majori
ty of patients had stenosis of more than
one vessel: 35 patients had stenosis of two
vessels, 25 patients three vessels and 3 pa
tients had stenosis of four vessels.
Stenosis of a single vessel was seen in 29
patients; however, no left main coronary
artery was involved.
A left ventriculogram demonstrated
some degree of ventricular dysfunction in
38 patients and a large akinetic or
paradoxically pulsating area indicative of
aneurysm in 2. Two patients had an ejec
tion fraction less than 35%.
Results of Bypass
All 92 patients underwent coronary
artery bypass surgery with insertion of
reversed saphenous vein grafts under mild
to m oderate h y p o th erm ia. Cold
potassium cardioplegia was used in 41 pa
tients operated upon between 1975 and
1980. A single graft was placed in 20 pa
tients, two grafts in 30 patients, three in
33 patients, four in 8 patients and five
grafts were placed in 1 patient. One of the
92 patients died at operation and two died
in the early postoperative period, for a
surgical mortality of 3.3%. The patient
who died during operation could not be
weaned from cardiopulmonary bypass.
One patient who died within the first 24
hours had a massive myocardial infarc
tion. Another patient who died 6 days
after the operation developed bron
chopneumonia and cardiopulmonary in
sufficiency that could not be controlled
because of a long-standing dysfunction of
three endocrine organs (adrenal cortex,
pancreas and thyroid gland).
Immediate complications, which occur
red in 23 of the 89 survivors, included
fever in four patients, persistent sinus
tachycardia in four, myocardial infarc
tion in three, ischemic changes in two,
bleeding from the chest tube in two,
premature ventricular contractions in
two, atrial fibrillation in one, incomplete
right bundle branch block in one, ven
tricular fibrillation in one, pulmonary em
bolism in one, partial collapse of the
lower lobe of the right lung in one and
transient bilateral loss of temporal visual
fields in one patient.
Only 62 patients have been followed up
by means of outpatient visits, question
naires and telephone interviews. Twentyseven patients had moved out of the pro
vince and could not be traced. The
follow-up period ranged from 6 months
to 9 years (mean 3.5 years). Thirty-three
patients were followed up for 3.5 or more
years while 29 were followed up for less
than 3.5 years. One patient died 3 years
after the operation from an unknown
cause. Another patient died 4 years after
the operation from refractory heart
failure following multiple myocardial in
farctions. The 3.5 year survival was 97%.

Forty-nine (79%) of the 62 patients
reported complete relief of angina and
were able to do more physical work than
preoperatively. Most of them returned to
full-time or part-time work. Only five pa
tients whose symptoms were relieved did
not return to work after operation. Thir
teen patients still suffered chest pain but
only in 7 (11%) was the pain severe or fre
quent, or both, while in the other 6 it was
mild, atypical and rare. Three patients
had to be reoperated on at 2, 7 and 14
months respectively because of graft oc
clusion. They were discharged in satisfac
tory condition.
Only 28 patients (45%) stopped smok
ing or otherwise changed their life-style
in an attempt to control risk factors.
The majority of patients reported no
substantial changes in mood, sexual ac
tivity or family relations. Twenty-three
(37%) however, claimed to have ex
perienced reduced anxiety, improved
mood and a more active sex life. Only
four (6%) complained of depression and
decreased sexual activity. It appears that
in young patients heart surgery has a less
traumatic impact on the emotional state
than in older patients. However, to con
firm this conclusion, a detailed psychiatric
assessment is required.
Discussion
Myocardial revascularization is being
increasingly used for the treatment of cor
onary artery disease refractory to medical
therapy. Excellent results of coronary
bypass grafting with operative mortality
rates of 1% to 3% and 5-year survival
rates of 90% to 95% have been
reported.810 These reports are based
predominantly on older patients while
surgical experience with coronary artery
bypass grafting in young adults is limited.
Myocardial revascularization in young
adults is especially challenging because of
the very low mortality in the general
population at this age. The results of drug
therapy alone for young adults with
disabling angina pectoris are poor. In one
retrospective study" of 116 patients, 40
years or younger, with angina treated
medically, the 5-year survival was only
66%. In another study of 266 patients
unselected by age who had angina man
aged with drugs alone, the 5-year survival
was 75% .12
Because medical therapy in young
adults with disabling angina is unsatisfac
tory, myocardial revascularization pro
vides a promising alternative. Our results
with a 3.3% operative mortality and a 3%
attrition rate at 3.5 years seem to justify
coronary artery bypass grafting. During
the period from January 1970 to August
1980, 1846 patients underwent coronary
bypass surgery at the University of Alber
ta Hospital; there were 83 operative

deaths (4.5%). It should be pointed out,
however, that the operative mortality dur
ing the period from 1970 to 1975 (before
the introduction o f cardioplegia) was
7.5%; after that time it fell to 2.8%.
Our study also revealed that the most
commonly encountered risk factors were
cigarette smoking, genetic predisposition
and hypercholesterolemia, while diabetes,
obesity and hypertension were not as
common as in older subjects.
The extent of atherosclerosis of the cor
onary arteries was somewhat smaller than
in older patients. Moreover, associated
conditions requiring operation were en
countered in a very small proportion of
patients. None of our patients needed
valve replacement and only six had resec
tion of an aneurysm.
Our study shows that coronary bypass
grafting in young patients with disabling
angina substantially improves the short
term prognosis. However, to assess the ef
fect of coronary artery bypass grafting on
long-term survival in this group of pa
tients, a follow-up of at least 10 years is
needed. Since the candidates for coronary
bypass
o p e ra tio n s
have
less
atherosclerosis of the coronary arteries
and relatively good ventricular function
compared with older subjects, it is
reasonable to assume that coronary
bypass grafting in young adults with
disabling angina should also improve the
long-term prognosis.
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A tradition o f innovation.

R onald F. P a ce , m d ;* M ichael J. C ham berlain , m d ,
R onald B. P assi, m d , frcsic ], fa c s *

fr c p , frcpic ];!

Diagnosing Papillary Stenosis by
Technetium-99m HIDA Scanning
The diagnosis of papillary stenosis, occa
sionally seen after cholecystectomy, is
confirmed by endoscopic retrograde
cholangiopancreatography (ERCP), which
demonstrates delayed emptying of con
trast material into the duodenum for
more than 45 minutes. The authors
assessed 2,6-dimethyl phenyl carbamoyl
methyl iminodiacetic acid labelled with
technetium-99m ( " mTc HIDA) as a less
invasive procedure in these cir
cumstances by comparing it with the
findings from ERCP.
Twenty-six patients who had pain
after cholecystectomy were studied by
continuous 1-hour scintigraphy after in
jection of " mTc HIDA. Biliary flow was
estimated by measuring uptake and
clearance of the entire liver and common
bile duct. Volunteers who had no pain
after cholecystectomy served as
controls.
Of the 26 study patients, all " mTc
HIDA scan findings were within the con
trol range in 11. Of these, 10 had nor
mal biliary drainage confirmed by ERCP.
The one patient with delayed drainage
did not improve after endoscopic sphinc
terotomy. Tw o patients demonstrated
pooling of " mTc HIDA in cystic dilata
tions of the biliary tree, while the other
13 patients had obstruction of the distal
common bile duct and impaired flow
demonstrated on the " mTc HIDA scan.
All 13 of these patients had papillary
stenosis proven by ERCP.
The authors conclude that " mTc HIDA
scanning is a valuable, minimally invasive
method of diagnosing papillary stenosis.
On confirme le diagnostic de stenose
papillaire. observee occasionnellement
apres une cholecystectomie, par cholan-
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giopancreatographie endoscopique retro
grade (CPER); celle-ci met en evidence
un retard de vidange de plus de 45
minutes de la substance de contraste
dans le duodenum. Les auteurs ont evalue dans ces circonstances I'utilisation de
I'acide 2,6-dim ethyl phenyl carbamoyl
methyl iminodiacetique marque au
technetium-99m ( A H I D " mTc) comme
moyen moins envahissant, en la comparant a la CPER.
Vingt-six patients qui avaient des douleurs apres une operation de cholecys
tectomie ont ete etudies par scintigraphie
continue d'une heure apres I'injection
d'A H ID -99mTc. L'ecoulement biliaire a 6te
evalue en mesurant sa captation et sa
clairance dans le foie entier et le choledoque. Des volontaires non souffrants
apres cholecystectomie ont servi de
temoins.
Onze des 26 patients etudies presentaient des scintigraphies a I'AHID 99mTc
qui se situaient a I'interieur de i'ecart
retrouve chez les temoins. Parmi ceux-ci,
10 avaient un drainage biliaire normal
confirme par CPER. Le patient presentant
un retard de vidange n'a pas ete ameliore par une sphincterotomie en
doscopique. Deux patients montraient
une accumulation de l 'A H I D " mT c dans
des dilatations kystiques de I'arbre
biliaire alors que les 13 autres patients
avaient une obstruction de la partie dis
tale du choiedoque et une diminution de
l'ecoulement biliaire demontree par la
scintigraphie a I'AHID 99mTc. Tous les 13
souffraient de stenose papillaire demon
tree a la CPER.
Les auteurs concluent que la scinti
graphie a l 'A H I D " mTc est une methode
diagnostique de grande valeur, encourant
un traumatisme minimal pour le patient,
dans les cas de stenose papillaire.

diagnosed when ERCP demonstrates
dilated biliary ducts with stenosis of the
distal ampullary segment of the common
duct and delayed drainage of contrast
material into the duodenum in excess of
45 minutes.2 Because ERCP is not
universally available, is expensive and is
potentially hazardous, there is a need for
an alternative, less invasive method to
identify patients with papillary stenosis
from other patients who suffer from
postcholecystectomy pain. We assessed
technetium-99m 2,6-dimethyl phenyl car
bamoyl methyl iminodiacetic acid (99mTc
HIDA) scanning as a minimally invasive
method for identifying biliary obstruction
due to papillary stenosis in patients with
pain after cholecystectomy.
99mTc HIDA Imaging
HIDA is labelled with technetium-99m
to form a radiopharmaceutical with a
half-life of 6 hours. Intravenous injection
of 99mTc HIDA is followed by rapid con
centration of the isotope in the liver, then
excretion into the bile. Continuous scin
tigraphy over the liver for 1 hour follow
ing injection yields sequential images of
" mTc HIDA excretion as it passes along
the biliary tree to the duodenum (Fig. 1).
These images are stored and analysed by
two separate but complementary
methods.
A moving picture is constructed from
the images taken over the duration of the
study, permitting bile flow to be assess
ed qualitatively and the anatomy of the
biliary system to be defined.
A time-activity curve is constructed by
encircling a region of interest which com
bines the liver and biliary tree outlines.
A computer totals the counts within the
boundary for each frame of the study and
plots the corresponding activity against
time (Fig. 2a). The resulting curve depicts
initial uptake and concentration of "raTc
HIDA followed by its excretion from the
biliary tree as it passes into the
duodenum. After correction for
radioisotope decay, the time-activity
curve is quantified; the time required to
reach maximum activity (Tmax) and the
excretory half-life (Te05) can then be
measured.
Hepatic cellular function is assessed by

Papillary stenosis is an infrequent cause
of postcholecystectomy pain. Regarded
with skepticism in the past, it has gained
validity with the recent advent of en
doscopic retrograde cholangiopan
creatography (ERCP).1
In a patient with a history of recurrent
biliary tract pain after cholecystectomy
and with liver function test findings sug
gesting cholestasis, papillary stenosis is
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similar analysis of a thin slice of the liver
periphery for Tmax and Te0 5 (Fig. 2b). In
this way, patients with primary or secon
dary hepatic parenchymal disease can be
identified. If liver cell function is normal,
it is assumed that delayed uptake and ex
cretion from the combined liver and
biliary tree outline are due to an obstruc
tion to bile flow.
Patients
Ten asymptomatic postcholecystec
tomy patients with normal liver function
and normal operative cholangiograms
volunteered to undergo 99mTc HIDA
scanning to obtain control values.
Twenty-six anicteric patients with
postcholecystectomy pain were studied by
99mTc HIDA scanning and analysis of
the time-activity curve, and the results
were compared with the findings of
ERCP.

demonstrated not only delayed biliary ex
cretion but also abnormal hepatic cell
function (Table I, group 3b). Endoscopic
retrograde cholangiopancreatography not
only confirmed papillary stenosis in these
patients but indicated more severe abnor
malities than in the other nine (Fig. 4).
We believe that in this group of patients,
high-grade biliary obstruction produced
secondary hepatic damage which im
paired the parenchymal phase of 99mTc
HIDA excretion.
Discussion
Scanning with 99mTc HIDA is safe,
minimally invasive and easily performed.
Analysis of the time-activity curve permits
quantification of biliary flow, which com
pares favourably to measurements of
biliary drainage made at the time of
ERCP.

Before ERCP was introduced, the
diagnosis of papillary stenosis could be
verified only by operative calibration of
the ampulla of Vater. If a no. 3 Bakes’
dilator would not pass through the papilla
without undue force at the time the com
mon bile duct was explored, the diagnosis
of papillary stenosis was confirmed and
the appropriate surgical procedure could
then be perform ed.3 Intravenous
cholangiography was used by some to
identify papillary stenosis,4 but it was
not until ERCP became available that the
diagnosis could reliably be made preoperatively.
In areas where ERCP is not available,
or if cannulation of the common bile duct
has not been successful, we believe that
99mTc HIDA scanning may be used to
assess bile flow along the common duct
and to help determine the need for fur
ther diagnostic or therapeutic procedures.

Results
Control Group
Scan analysis gave a mean ( ± standard
deviation) parenchymal value for Tmax of
12.8 ± 2.8 min and for Teo s of 44.1 ±
7.6 min. Combined liver and biliary tree
values for Tmax were 15.0 ± 3.3 min and
for Te0 5 were 45.9 ± 7.7 min (Table I).
The control mean plus two standard
deviations was used as the upper limit of
normal to identify any abnormal scans in
the study group.
Study Group
Three different categories of patients
were identified. In group 1, 11 patients
had parenchym al and com bined
hepatobiliary function values similar to
the control group (Table I). Ten
demonstrated normal biliary drainage by
ERCP. The one patient in whom ERCP
demonstrated impaired drainage of con
trast material from the common duct did
not improve symptomatically after en
doscopic sphincterotomy.
On " mTc HIDA scanning, two pa
tients (group 2) showed retention of
99tnTc HIDA in the liver hilus suggesting
that there was bile stasis high in the com
mon bile duct; ERCP identified a
choledochal cyst in one patient and
Caroli’s disease with multiple intrahepatic
dilatations in the other.
The " T c HIDA scans of the remain
ing 13 patients (group 3) all demonstrated
distal obstruction of the common bile
duct.
Analysis of the time-activity curve in
dicated that in 9 of these 13 patients
biliary excretion was substantially delayed
but hepatic cell functions remained nor
mal (Table I, group 3a); ERCP confirm
ed papillary stenosis in all 9 patients (Fig.
3). T he four rem aining p atien ts
192

FIG. 1—Sequential images obtained during continuous 1-hour scintigraphy after injection
of 99mTc HIDA show hepatic concentration of radionuclide followed by biliary excretion.

Fig. 2b
FIG. 2—Time-activity curves for (a) combined hepatic and biliary tree, to assess bile flow,
and (b) peripheral portion of liver distant from large bile ducts, to assess hepatic parenchymal
function.
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Table 1 -M e a n (+ Standard D eviation) Values Obtained from T im e-A ctivity Curve Analysis in the
Control and S tudy Groups Correlated w ith the Findings o f Endoscopic Retrograde
(ERCP)_________________________________
Parenchym a, min

Combined liver
and biliary tre e . min

Group

No.

Tm«

To0j

Control
1
2

10
11
2

12.8 + 2.8
12.3 + 3.5
16.9 ± 1.6

44.1 + 7.6
36.7 + 6.6
59.5 ± 1.2

15.0 + 3.3
15.7 + 3.7
29.6 + 5.1

9
4

13.2 + 3.8
22.1 ± 2.4

45.9 + 5.8
77.1 + 31.8

26.0 + 8.6
32.9 + 8.9

3a
3b

T™

Conclusions
from ERCP

T e 0.5

45.9 + 7.7 Normal
40.0 + 6.4 Normal biliary drainage
129.2 + 90.4 Stagnation of dye at hilum;
Caroli's disease,
choledochal cyst
118.5 + 62.0 Papillary stenosis
175.1 + 76.2 Severe papillary stenosis
with secondary hepatic
damage

Moreover, this technique may be a
valuable adjunct to ERCP in the follow
up of patients after definitive therapy. In
this setting, a persistent or recurrent ab
normality of bile flow detected by 99mTc
HIDA scanning would select those pa
tients who require an extension of their
sphincterotomy from those with normal
bile flow.
Previous reports indicate that 99mTc
HIDA scanning is a useful aid in diagnos
ing acute cholecystitis. In a patient with
acute abdominal pain, visualization of the
gallbladder proves patency of the cystic
duct and indicates that the pain does not
originate in the tract.5 The technique can
also be used to confirm congenital biliary
atresia in neonates6 and is useful in
visualizing bile leaks and assessing the
patency of biliary-enteric anastomosis
postoperatively.7 It is useful in assessing
bile flow in postcholecystectomy patients
as our results indicate and biliary obstruc
tion evident by this method correlates
closely with the findings from ERCP.
Conclusions

Of the 26 patients studied by 99mTc
HIDA scanning and analysis of the timeactivity curve, 25 patients were accurate
ly identified as having either normal or
impaired biliary drainage. The results of
99mTc HIDA scanning and ERCP dif
fered in one patient, and the lack of
symptomatic improvement after en
doscopic sphincterotomy suggested that
the ERCP findings were erroneous.
Scanning with 99mTc HIDA with
analysis of the time-activity curve is easi
ly performed and is without risk. It can
differentiate between normal and
obstructed bile flow and is a suitable test
not only to screen patients who present
with pain after cholecystectomy, but can
also be used to assess the results of
definitive therapy at follow-up.
We believe that " mTc HIDA scanning
with time-activity curve analysis is a
valuable, minimally invasive method to
aid in diagnosing biliary obstruction due
to papillary stenosis in patients who pre
sent with pain after cholecystectomy.
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Fig. 3b
FIG. 3—(a) Immediate and (b) delayed (45
minutes) films at endoscopic retrograde
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are characteristic of papillary stenosis.

Fig. 4b
FIG. 4—(a) Immediate and (b) delayed (55
minutes) films at ERCP in patient with abnor
malities of hepatic cell function and biliary flow
on WmTc HIDA scan. Findings indicate severe
papillary stenosis with extremely poor biliary
drainage.
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ANATOMY FOR SURGEONS: VOLUME 3.
The Back and Limbs. 3rd ed. W. Henry
Hollinshead. 878 pp. Illust. Harper & Row.
Publishers, Philadelphia; J.B. Lippincott
Company of Canada Ltd., Toronto, 1982.
Price not stated. ISBN 0-06-141266-X (v.
3).

This edition of Hollinshead’s classic text has
maintained the high standards that it attained
in the past.
Volume 3 of the third edition has maintain
ed the general plan of organization found in
the second edition, published in 1969. Several
new figures have been added where indicated,
to reinforce the text. Unfortunately, the col
ouring in Fig. 5-17 was omitted and this is in
consistent with the legend for the figure, but
this is not a serious error.
The section on the back, chapter 2, should
have been revised to represent the current
thinking in scoliosis.
In chapter 5, Fig. 41A does not do justice
to the normal 15° of volar tilt of the distal ar
ticular surface of the radius. For the surgeon
reading the text, this is important.
The quotation of James on page 127 that on
ly 2 of 31 of his cases with curves between 70°
and 99° required correction and fusion is not
consistent with present-day thinking on
scoliosis. Although this is not a textbook of
orthopedics, such a statement should be remov
ed or modified.

The description of anatomy in the section
on tennis elbow is inadequate, considering the
confusion of the present-day state of the art
of therapy. This requires improvement.
Electromyographic studies of the vertebral
column are assessed and the pertinent findings
described clearly, with benefit to the reader.
The nerve entrapment syndromes are
covered in many areas and offer a clear
understanding of the associated anatomy,
knowledge of which is required in exploring the
various sites.
This volume is still a classic in anatomy for
suegeons. Volume 3 is strongly recommended
for all involved in treatment o f the back and
limbs.

Leon Heller , md , frcsic], facs
Department o f orthopedic surgery,
Sir Mortimer B. Davis-Jewish
General Hospital,
Montreal, PQ
BONE IN CLINICAL ORTHOPAEDICS. A
Study in Comparative Osteology. Edited by
G. Sumner-Smith. 435 pp. Illust. W.B.
Saunders Company Canada Ltd., Toron
to, 1982. $63.70. ISBN 0-7216-8638-9.

This book is intended to fill a gap between the
literature destined for students in orthopedics
and publications of interest to those who want
to study bone in depth. The editor has succeed

ed in securing the contributions of experts. The
collaboration o f veterinarians interested in
morphology and physiology of bones and of
orthopedic surgeons makes this book par
ticularly interesting for those involved in ex
perimental surgery.
Although most of the basic aspects of bone
are well outlined, physiologic bone remodell
ing, mechanism of mineralization and electrical
phenomena of bone could have received more
attention. To make the book even more attrac
tive to clinically oriented orthopedic surgeons,
the inclusion of more clinical data would have
been advantageous.
The book gives a good overall review and
discussion of the matter. It will prove most
useful to veterinarians and medical doctors
with special interest in bone physiology.

H ans K. U hthoff , md , frcsic]
Chairman and professor,
Division of orthopedic surgery,
Ottawa General Hospital,
Ottawa, Ont.

COLONOSCOPY. Diagnosis and Treatment
of Colonic Diseases. Hiromi Shinya. 233
pp. Illust. Igaku-Shoin Medical Publishers,
Inc., New York; J.B. Lippincott Company
of Canada Ltd., Toronto, 1982. Price not
stated. ISBN 0-89640-065-4.

SESAP IV Question
SESAP IV became available in October 1982. The SESAP item appearing in each issue o f the Journal will henceforth .
come from SESAP IV.

322. A 24-year-old woman has melanoma verified by biopsy on the right cheek (0.5 cm in diameter), 3 cm beneath the
lateral canthus of the right eye. The lesion in invasive to Level IV and is 2.5 mm thick. The most appropriate treatment is

(A) wide local excision
(B) wide local excision plus orbital exenteration
(C) wide local excision, superficial parotidectomy, and ipsilateral cervical lymphadenectomy
(D) wide local excision plus ipsilateral cervical lymphadenectomy
(E) wide local excision including orbital exenteration, superficial parotidectomy,
and ipsilateral cervical lymphadenectomy
For the incomplete statement above select the one answer that is best of the five given. For the critique of Item 322 see
page 196.
(Reproduced by permission from SESAP IV Syllabus: Surgical Education and Self-Assessment Program No. 4. For enrol
ment in the Surgical Education and Self-Assessment Program No. 4, please apply to the American College of Surgeons,
55 East Erie St., Chicago, IL 60611.)
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The introduction of colonoscopy launched a
new era in the management of patients with
colon and rectal disease. Performed either for
diagnosis or therapy, it is of considerable
benefit to the patient. When the radiologic
findings are equivocal or symptoms are
suspicious and persistent, colonoscopic evalua
tion may afford peace of mind to both the pa
tient and the treating physician. Since this pro
cedure requires considerable expertise, it is im
portant that physicians acquire the necessary
skills to perform colonoscopy safely. This book
provides straightforward, useful information
and guidelines to accomplish this goal.
The text comprises 19 chapters, covering all
aspects of colonoscopy methodically. The con
struction and the method of cleansing the in
struments are explained. Proposed re
quirements for equipment and an endoscopy
suite are described, but this ideal is only a pipe
dream for most of us. Indications and con
traindications are clearly listed. Conduct of the
colonoscopic examination is well detailed.

PROTECTION OF THE ISCHEMIC
MYOCARDIUM: CARDIOPLEGIA.
David J. Hearse, Mark V. Braimbridge and Per Jynge. 420 pp. Illust.
Raven Press Books, Ltd., New York,
1981. $42.00. ISBN 0-89004-423-6.

A long-sought goal in cardiac surgery has
been to achieve, with safety, a motion
less and bloodless operative field that
facilitates rapid and accurate surgical
procedures.
The history of modern cardiac surgery
in the last 25 years is filled with efforts
to arrest the myocardium electively and
to resuscitate it subsequently. All meth
ods have limitations, the most serious
being inadequate myocardial protection
during arrest with subsequent death from
low cardiac output. However, since 1975
the application of cold potassium cardio
plegia has almost achieved the optimal
cardiac surgical field and has added
enormously to patient survival by pro
A highlight of the text is the description of
viding adequate myocardial protection
techniques for inserting the colonoscope. A
during long periods of arrest. Cold car
host of maneuvers and tricks to aid the en
dioplegia. in its present form, is a result
doscopist in successfully advancing the scope
of intense experimental and clinical in
expeditiously with least discomfort to the pa
vestigation in Europe and North Amer
tient are outlined. The various trouble spots
ica.
The background work is detailed
and problem areas are delineated, and methods
of handling them are offered by this master en extensively in the opening chapters that
review 28 years of continuous effort.
doscopist. These aids are of value to both the
There are two excellent chapters on
novice and the colonoscopist with modest ex
perience. A magnificent catalogue of en the pathophysiology of myocardial in
doscopic photographs of colonic disease is jury secondary to operative ischemia,
anoxia and hypoxia that results from
presented, ranging from the common
inadequate myocardial protection during
neoplastic processes and inflammatory bowel
cardioplegia.
diseases to uncommon entities such as
For clinical and basic science inves
Pneumocystis cystoides intestinalis and colonic
endometriosis. Snaring techniques are superbly tigators, the chapter dealing with assess
ment of ischemic myocardial damage
illustrated. The author describes complications
outlines models for in-vitro experiments
encountered, with particular attention to
using heart muscle fragments; the value
prevention and management. He suggests a
of in-vivo and ex-vivo preparations are
regimen of follow-up examinations. Special
diagnostic and therapeutic applications of col considered. The latter has many physio
logical logistic advantages when usgd in
onoscopy such as retrieval of foreign bodies
prolonged laboratory cardiopulmonary
and reduction of volvulus are presented with
perfusion experiments. This chapter ' is
the aim of reducing or eliminating the need for
exploratory surgery.
an excellent review and possibly the
source of new ideas for investigation in
In the chapter on neoplastic polypoid lesions,
the field of myocardial preservation.
the author stresses the importance of differen
Cardiac surgeons have developed many
tiating superficial carcinoma (a term that 1
techniques for myocardial protection.
abhor and by which he means carcinoma in
The authors analyse the technical and
situ) from invasive carcinoma. Quoting from
physiologic problems of the common
the work of Fenoglio, he writes that “ . . . there
est arrest techniques and the various
are no lymphatics in the colonic mucosa, only
methods of cardioplegia such as con
in the muscularis mucosa” . In fact, the
tinuous versus intermittent perfusion,
muscularis mucosae is part of the mucosa, but
single versus multiple infusions, aqueous
the lymphatic plexuses are associated with the
solution versus blood cardioplegia and
muscularis mucosae.
normothermic versus cold solutions.
Apart from this small but important point,
Two chapters discuss the chemical
the book is easy reading and is complemented
composition and the clinical results of
by high-quality colour illustrations. It deserves
various cardioplegic solutions such as
to be read by any aspiring or practising en those of Bretschneider, Kirsch and Tyers
doscopist. Any physician interested in perform and the St. Thomas’s solution. The prin
ing colonoscopy will profit from it, especially
ciples of formulation and administration
from the chapters on techniques of insertion
of cold cardioplegia are well presented
and disease processes encountered.
and cardiac surgeons should compare
their cardioplegic solutions with the ones
presented. The reasons for using each
P hilip H. Gordon , md, frcsic], facs
component in the solutions is well dis
cussed and merits careful study. It is clear
Department of surgery,
that the contributions of the three basic
Sir Mortimer B. Davis-Jewish
General Hospital,
principles of cardioplegia, namely clinical
Montreal, PQ
cardiac arrest, hypothermia and the use

of protective additives, all interact and
reinforce one another.
The book concludes on a practical
note by assessing the clinical results of
cardioplegia in cardiac surgery. Low
cardiac output, postperfusion infarction,
dysrhythmias and the incidence of cytochemical evidence of myocardial damage
are presented. The book is well illus
trated with tables, graphs and electron
miscroscopy photographs of injured myo
cardium. In addition, numerous refer
ences follow each chapter.
The book is a thoughtful presentation
of all aspects of cardioplegia and is
simultaneously a textbook and a refer
ence book. It is essential reading for
everyone closely associated with a car
diac surgical team, be they surgeon, an
esthetist, resident-in-training or perfu
sionist.
P eter A l l e n ,

m d , fr c s [c ]

600 Fairmont Medical Bldg.,
750 West Broadway,
Vancouver, BC
SURGERY OF THE GALL BLADDER AND
BILE DUCTS. 2nd ed. Edited by Lord
Smith of Marlow and Dame Sheila
Sherlock. 495 pp. Illust. Butterworth & Co
(Canada) Ltd., Scarborough, O nt., 1981.
$79.95. ISBN 0-407-00118-2.

The editors had ample material for the longoverdue updating of the first edition of this
text. The book reads easily and the type is clear
on good-quality glossy paper. Most chapters
are well illustrated. The noninvasive and in
vasive radiologic techniques that have radically
altered biliary tract surgery are well described.
These benefits are offset, however, by a lack
of balance and organization. As a result, some
important areas are covered in a sketchy
fashion in one chapter without reference to the
more complete coverage that can be found in
another chapter, thus leading , in many cases,
to redundancy.
The chapter on anatomy of the liver and
biliary tract is generally good, but lacks good
diagrams on liver anatomy, required for
hepatic resection. This defect is made up par
tially in the chapter on carcinoma of the
gallbladder and common hepatic duct. The
ultrastructure of the liver and biliary apparatus
is well described and thorough, as are the sec
tions on physiology and anomalies. The
chapter on anomalies has good, descriptive
diagrams. There is extensive coverage of biliary
atresia, which the average surgeon is unlikely
to see, but only a minor reference to
choledochal cysts, which the general surgeon
may find a major problem. The chapter on
radiology of the biliary system is sketchy, but
the following chapter by the same author on
transhepatic cholangiography is very complete.
Dame Sherlock’s chapter on jaundice con
tains a pot-pourri of material that would have
enhanced some of the other chapters and
reduced the amount of repetition. For exam
ple, bilirubin metabolism should have been in
cluded in the chapter on physiology, hepatic
scintiscanning belonged in radiology, acute
cholecystitis should have been left for the
chapter on cholecystitis and the discussions on
endoscopic retrograde cholangiopancreato-
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graphy and laparotomy were both sketchy and
should have been included in other chapters.
Infection and anesthesia are covered complete
ly and are well presented. The chapter on
gallstones and cholecystitis is incomplete; it
should have been combined with that on
cholecystectomy and cholecystostomy. Every
surgeon should know about cholecystostomy,
but this procedure does not deserve a chapter
of its own which, again, has led to repetition.
The problem of common duct stones and the
technique of common-bile-duct exploration are
well covered but in my opinion there is an
overemphasis on the use of metallic in-

struments in the duct, which, in many cases,
can be avoided by copious flushing and careful
use of a Fogarty catheter.
This text can be of considerable help to the
surgeon-in-training and is of interest to the
practising surgeon if it is read in its entirety.
But used as a reference text, the reader will find
considerable gaps in coverage.
H arvey H . S igman ,

md , frcs[C]

Department of surgery,
Sir Mortimer B. Davis-Jewish
General Hospital,
Montreal, PQ
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Treatment of cutaneous melanoma in the head and neck region is often dif
ficult because wide local resection (5 to 6 cm) cannot be performed without
significant functional and aesthetic deformity. Furthermore, although the le
sion in this young woman is close to the eye, lymphatic pathways draining the
primary usually would go not superiorly to the eye, but rather inferiorly to
the lymph nodes of the parotid gland and the ipsilateral cervical region. Because
the lesion is invasive to Level IV and 2.5 mm thick, this patient’s prognosis
would be improved by superficial parotidectomy and cervical lymphadenectomy combined with local excision.
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As a further service to its readers the Canadian Journal of Surgery is pleased
to accept suitable classified advertisements. The deadline is 1 month before
issue date. Regular classified rates (for each insertion): $31.00 for the first
40 words or less, additional words 30C each, to maximum of 150 words
(additional $12.00 for frame). Special Display under 75 words, 2V4" X2",
$75.00. $5.00 charge (first insertion only) for CJS box numbers. Display
rates available on request.
Copy should be mailed to the Canadian Journal of Surgery, PO Box
8650, Ottawa, Ontario K1G 0G8.
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UPDATE IN COLON AND RECTAL SURGERY —

The Division of General Surgery at the Toronto
General Hospital w ill present a Clinical Day for
Surgeons on Friday. June 17, 1983. The program
w ill be entitled. "A n Update in Colon and
Rectal Surgery". The guest speakers w ill be Dr.
Malcolm Veidenheimer, Chairman of Depart
ment of Colon and Rectal Surgery, Lahey Clinic
and Mr. Peter Hawley, Consultant Surgeon at St.
Mark’s Hospital for Diseases of the Colon and
Rectum. London, England. Contact: Ms. Toni
D'Agostino, Eaton Building, 9th Floor, Room 211,
Toronto General Hospital, 101 College St., Toronto,
Ont. M5G 1L7 — or — tel: (416) 595-3846.

—S83-001

Upjohn Company of Canada, The
Dalacin C
Solu-Medrol

196
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RESEARCH FELLOW — For 1 to 2 years, com
mencing July 1, 1983 for research work in
Intestinal Transplantation. Please send curriculum
vitae to: Dr. Zane Cohen, c /o The Toronto General
I Hospital, 101 College

St., Eaton Building, 9th

Floor, Room 211, Toronto, Ont. M5G 1L7, (416)
595-3846.
—S83-006
CLINICAL FELLOWSHIP — Ewart Angus Sur
gical Intensive Care Unit, Wellesley Hospital,
Toronto. Available July 1, 1983 for 1 year, in a
multidisciplinary acute surgical unit with 650
admissions per year. Duties include clinical
research in a strong academic unit, and
teaching. Reply to: Dr. D.P. Jones, Director,
Surgical ICU, Suite 219, ' E.K. Jones Building,
160 W ellesley St. E., Toronto, Ont. M4Y 1J3.
(416) 966-6656.
—S83-003
GENERAL SURGEON: ONT. — Six-physician
clinic in town of 7000, service area 15 000, re
quires certified general surgeon. Fully accredited
65-bed hospital: good anesthetic back-up: shared
call. Eligible for under serviced area grant.
Contact: Dr. J. Dove, 56 King St., Dryden, Ont
P8N 1B6. Tel: (807) 223-2258.
-S83-007
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• Both handle and trigger serrated to improve control
• Visible staple counter
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• Can release pressure on trigger without premature staple release
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• Staple is released with a smooth, comfortable forward motion
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